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NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET 
DET MEDISINSKE FAKULTET 
Uracil in DNA - et viktig mellomprodukt for adaptiv immunitet og mutagen skade 
 Uracil er en av fire nukleobaser i RNA, men små mengder kan også befinne seg i 
DNA. Det er to kilder til genomisk uracil: misinkorporering av deoksyuridin trifosfat (dUTP) 
i steden for deoksytymidin trifosfat (dTTP) under DNA replikasjon, og deaminering av 
cytosin. dUTP misinkorporering danner uracil:adenin (U:A) par uten konsekvenser for 
genetisk informasjon. Cytosin deaminering resulterer derimot i uracil:guanin (U:G) par med 
mutagent potensiale. U:G par har derfor lenge blitt ansett som DNA skade, men i 
begynnelsen av 2000 tallet ble det etterhvert også klart at activation induced deaminase 
(AID) drevet cytosin deamineringer startpunktet for antistoffsmodningsprosessene somatisk 
hypermutasjon (SHM) og klasseskift rekombinajon (CSR). Til tross for sin rolle i det 
antistoffmodning har sekvensringsekperimenter av kreftgenomer vist at andre cytosin 
deaminaser (APOBECer) er ansvarlige for mutasjonssignaturer i mange ulike krefttyper. 
 Vårt arbeid har fokusert på uracils tilknytning til kreft og adaptiv immunitet. Mange  
uracil-relaterte observasjoner kommer fra musemodeller. I artikkel I undersøkte vi derfor 
aktivitetsnivå og mengde av tre uracilreparerende enzymer UNG2, SMUG1 og TDG i ulike 
cellelinjer fra menneske og mus. Vi fant at den totale uracilfjerningskapasiteten fra U:A og 
U:G substrater var større i humane celler enn for museceller, hovedsakelig fordi UNG-nivået 
var høyere. I museceller stod SMUG1 for 50 % av uracil-fjerningskapasitet fra U:G substrat, 
men bare 1 % i humane celler. Slike forskjeller er viktige å ta i betraktning når man bruker 
musemodeller i forskning rettet mot genomisk uracil. Vi stimulerte videre primære B-celler 
fra mus til å gjennomgå CSR. UNG og SMUG1 aktivitet i de stimulerte B-cellene var på 
samme nivå som i de øvrige musecellelinjene, hvilket indikerer at både UNG og SMUG1 er 
uttrykt og kan fjerne U:G fra deaminert cytosiner i aktiverte B-celler. 
 Flere forskningsgrupper har forsøkt å måle genomiske uracilnivåer, men resultatene 
deres varierte med nesten tre størrelsesordener. De store forskjellene i målte uracilnivåer kan 
forklares med biologiske ulikheter i prøvene til de ulike gruppene, men vi foreslår at det 
stammer fra tekniske svakheter i målemetodene. I artikkel II identifiserte vi og løste 
problemer ved DNA preparasjon som bidro til overvurderingen av uracilnivåer, hovedsakelig 
fra med-isolert dUMP og in vitro-generert uracil fra cytosindeaminering. Vi presenter en 
metode for absolutt kvantifisering av genomisk uracil hvor DNA hydrolyseres med enzymer 
til nucleosider, deoksycytidin fjernes ved væskekromatografi-fraksjonering, og deoxyuridin 
måles gjennom væskekromatografi-massespektrometri (LC/MS/MS). Vi testet metoden i en 
relevant biologiske sammenheng ved måling av genomisk uracilnivåer i mus embryonale 
fibroblaster (MEFer) og humane lymfoblastoide cellelinjer som ikke utrykker UNG. Vi fant 
at de UNG-manglene cellene inneholdte fem- til elve ganger mer genomisk uracil. Videre 
observerte vi at UNG-kompetente celler inneholdt 400 til 600 uraciler per genom. Våre 
uracilmålinger er lavere enn tidligere rapporterte genomisk uracil verdier. Dette indikerer at 
det basale uracil nivået har blitt overvurdert og at vår metode gir den mest nøyaktige uracil 
kvantifiseringen.  
 UNG2 er ansett som den viktigste glycosylasen i reparasjon av genomisk uracil, mens 
SMUG1 fungerer som støtte. I artikkel III studerte vi rollene til de to glycosylasene ved bruk 
av Ung-/-Smug1-/- mus. Vi observerte at SMUG1i hovedsak står for genomisk 5-
hydroxymethyluracil (5-hmU) fjerningsaktivitet i musevev og MEFer, og at Smug1-/- mus 
akkumulerte 5-hmU. I motsetning til dette hadde SMUG1-status ingen effekt på genomiske 
uracil nivåer og nesten ingen effekt på uracil fjerningsaktivitet. Fjerningsaktivteten ble kun 
funnet lavere i Smug1+/- og Smug1-/- hjerneprøver. UNG-mangel reduserte uracil 
fjerningsaktiviteten i alle vevsprøver bortsett fra hjerne, og Ung-/- mus hadde to- til tre-gang 
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høyere genomiske uracilnivåer enn villtype mus. Vi fant imidlertid en mye større økning, 3- 
til 20-ganger, av genomiske uracilnivåer i Ung-/-Smug1-/- mus, i tillegg til en komplett 
ablasjon av uracil fjerningsaktiviteten. Vi forutsetter derfor at UNG er i hovedsak ansvarlig 
for uracil-fjerningsaktivitet i alle testete vev bortsett fra hjerne med SMUG1 som støtte, og at 
enten UNG eller SMUG1 er tilstrekkelig for å opprettholde basale nivåer av genomisk uracil. 
 Selv om det er mange bevis for at AID og APOBEC mutasjonssignaturer i kreft 
stammer fra enzymatisk cytosin deaminering har uracilnivåer ikke ble testet i sammenheng 
med AID og APOBEC uttrykk. I artikkel IV målte og korrelerte vi derfor genomisk uracil- og 
AID-nivåer i en rekke ulike B-celle lymfomcellelinjer. Vi fant tydelig korrelasjon mellom 
genomisk uracil og AID uttrykk i lymfomcellelinjer, og ingen korrelasjon i ikke-
lymfomcellelinjer. I tillegg økte eller reduserte vi AID nivåer ved AID-overuttrykk, B-celle 
stimulering og shRNA mediert AID ekspresjonshemming.  Vi observerte at AID økning førte 
til mer genomisk uracil mens AID senking reduserte mengden genomisk uracil. Vi korrelerte 
genomisk uracil med uracil-DNA glykosylasenivåer, men fant kun svakere korrelasjoner enn 
med AID uttrykk og kun i ikke-lymfomcellelinjer. Ved repetisjon av sekvenseringsanalysene 
rettet mot APOBEC mutasjonssignaturer fant vi en AID-spesifikke mutasjonssignatur i B-
celle lymfomer og kronisk lymfatisk leukemi. Vi har dermed påvist at høye AID uttrykk 
følges av genomisk uracil akkumulering og at dette er assosiert med kreft in vivo. 
 
 I sum har dette arbeidet bidratt til bedre forståelse av de biologiske egenskapene til 
genomisk uracil og de proteinene som kontrollerer dets nivåer. Dette har gitt ny innsikt i 
hvordan uracil prosesseres og hva konsekvensene er ved feilregulering. 
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1. INTRODUCTION 
 Genomic uracil is both a lesion and a necessary intermediate for adaptive immunity in 
mammalian cells. In this sense, both an abundance and a shortage of DNA uracil through 
either genetic abnormalities or exogenous perturbations can lead to pathological phenotypes. 
In this thesis, I will first provide an overview of the possible sources of genomic uracil 
(section 2). Then, I will describe the main and alternative pathways for its removal from 
DNA (sections 3 and 4). Next, I will delve more deeply into endogenous DNA uracilation 
and explain how genomic uracil is used as an intermediate in antibody maturation and as a 
tool to restrict the replication of exogenous viral genomes (sections 5 and 6). Finally, I will 
provide an overview of how both an abundance and a shortage of genomic uracil can lead to 
human disease (section 7). 
 Before continuing onwards, I encourage the reader to familiarize him- or herself with 
the abbreviations section on the previous page. I will generally list an unabbreviated name 
before using the abbreviation, but a section or more may sometimes stand between the 
original unabbreviated name of a molecule, idea, or process and its subsequent abbreviated 
use, leading to confusion. Furthermore, I will not expand on the abbreviations between the 
five canonical DNA and RNA bases, nucleosides, and nucleotides. The general nomenclature 
in this case is as follows, using adenine as an example: the free base is A or Ade, the RNA 
nucleoside is rA or rAdo, the DNA nucleoside is dA or dAdo, and the nucleotides are 
(d)AMP, ADP, and ATP for mono-, di, and triphosphorylated forms, respectively. 
2. Sources of Genomic Uracil 
 Uracil is a canonical RNA base that can be found in DNA in very low quantities. In 
this section, I will describe the three mechanisms by which uracil is introduced into DNA: 
dUTP misincorporation during DNA replication instead of dTTP (section 2.1), non-
enzymatic, spontaneous or chemical-induced cytosine deamination to uracil (section 2.2), and 
enzymatic cytosine deamination to uracil by DNA cytidine deaminases (section 2.3). There is 
no overt deleterious effect of dUTP misincorporation into DNA instead of dTTP because the 
resulting U:A pairs identically to the original T:A pair, although the uracil may be recognized 
and improperly processed to yield a mutation. Cytosine deamination to uracil is mutagenic 
and yields a C:G to T:A transition mutation after replication.  
2.1 dUTP misincorporation during DNA replication 
 Mammalian DNA polymerases cannot differentiate between dUTP and dTTP [1], so 
the extent of dUTP misincorporation depends on the dUTP/dTTP ratio in the vicinity of the 
polymerase during DNA synthesis (figure 1) [2,3]. Thus, a cell must maintain a low 
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dUTP/dTTP ratio to avoid excessive DNA uracilation. The normal intracellular ratio is 
estimated at well below 1% [4]. 
 dUTP is an intermediate in normal pyrimidine metabolism (reviewed in [3]). Low 
dUTP levels are maintained by deoxyuridine 5ƍ-triphosphate nucleotidohydrolase (dUTPase), 
which dephosphorylates dUTP to dUMP [5]. The dUMP is converted to dTMP by 
thymidylate synthase (TS) using N5,N10-methylene-tetrahydrofolate (MTHF) as a methyl 
donor. dTTP is eventually generated from the dTMP by thymidylate kinase (DTYMK) and 
nucleoside diphosphate kinase (NDK) and used in replication [3,6–8]. The main factors 
controlling the dUTP/dTTP pool are dUTPase and TS activities, and it has been estimated 
that one dUTP per 104 dTTPs is incorporated per cell per day [2,9]. This amounts to ~80,000 
misincorporated uracils per genome (~27 dUrd per 106 dN), assuming a 46.1% GC content 
and that G = C and A = T (Chargaff’s rule) [10,11].  
 A significant reduction of either dUTPase or TS activity leads to a phenomenon called 
“thymineless death,” which is thought to be primarily a result of dTTP pool depletion instead 
of dUTP misincorporation [12,13]. It has been proposed that thymineless cells accumulate 
single-stranded DNA (ssDNA) gaps that are converted into double-stranded DNA (dsDNA) 
breaks (DSBs) behind the replication fork. The released dTMP can be converted to dTTP and 
used for new polymerase initiations, but further disintegration of small replication bubbles 
causes replication origin destruction [14]. Thymineless death seems to be independent of 
dUTP incorporation [15,16]. More subtle attenuation of genomic uracil misincorporation by 
TS inhibition will be discussed in section 7.2.4.  
 
Figure 1: dUTPase and TS activities regulate the amount of dUTP in the cell. dUTP is 
degraded to dUMP by dUTPase and converted to dTMP by TS. The dTMP is subsequently 
converted to dTTP by DTYMK and DNK. The dUTP misincorporation rate is a factor of the 
dUTP/dTTP ratio. 
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2.2 Non-enzymatic cytosine deamination to uracil 
 Cytosine is spontaneously deaminated to uracil in DNA. The spontaneous 
deamination rate of ssDNA is 2x10-10 deaminations per second and the rate of dsDNA is 200 
to 300 times slower [17,18]. The deamination rate was measured in vitro by heat-inducing 
deamination at 95 °C and extrapolating to 37 °C. The actual in cellulo deamination rate may 
be attuned by e.g. different solution conditions, protein binding, and DNA supercoiling. The 
spontaneous deamination rate has been estimated to be 100 to 500 cytosines per cell per day 
(0.033 to 0.17 dUrd per 106 dN) if 0.1% of the genome is single-stranded [19].  
 Nitrous anhydride (N2O2) can also induce cytosine deamination (called nitrosative 
deamination) [20,21]. N2O2 is an intermediate in nitric oxide (NO•) production. NO• is 
produced as a physiological response to infection, a regulator of immune functions, or a 
chemical messenger for neurons (reviewed in [22]). Inflammation and cancer have been 
linked to the generation of high NO• levels, and an estimated 20% of cancers are caused by 
inflammation and chronic infection [22,23]; however, deamination only occurs at toxic N2O2 
levels [24,25]. Thus, nitrosative deamination is not likely to be a significant contributor to the 
genomic uracil load.  
2.3 Enzymatic cytosine deamination to uracil 
 Enzymatic cytosine deamination is primarily performed by the apolipoprotein B 
mRNA editing enzyme, catalytic polypeptide-like (APOBEC) enzyme family. APOBECs 
have one or two zinc (II)-binding catalytic domains that catalyze cytosine deamination in 
DNA or RNA (reviewed in [26–28]). There are eleven known APOBECs in humans: 
activation induced deaminase (AID), APOBEC1, APOBEC2, APOBEC3A through 
APOBEC3G, and APOBEC4 (A1, A2, A3A through A3G, and A4, respectively). A1, A2, 
and A4 have not been shown to have verifiable DNA cytosine deamination activity or 
contribution to the genomic uracil load, so I will describe them only briefly and focus on AID 
and A3. 
 A1 is primarily an mRNA editing deaminase present in the gastrointestinal tract that 
participates in lipid metabolism [29]. Briefly, A1 deaminates apolipoprotein B (APOB) pre-
mRNA to change a glutamine codon to a stop codon, shortening the subsequent APOB 
protein [30,31]. APOB is the primary lipoprotein in chylomicrons. The shortened protein has 
an accelerated plasma turnover relative to the full length protein, so the editing activity of 
APOBEC1 is crucial for maintaining physiological concentrations of APOB-containing 
lipoproteins in plasma [28]. A2 has no known physiological substrate, is expressed only in 
heart and skeletal muscles, and is thought to promote muscle fiber differentiation [32–34]. Its 
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function remains largely unelucidated, but it has been shown to deaminate methylated 
cytosines, which may indicate a role in epigenetic regulation [28,35]. Finally, A4 also has no 
known substrate. It is found in the testis and has been suggested as a possible mRNA editing 
enzyme in spermatogenesis, though this has not been researched and no detectable mutagenic 
activity in bacterial or yeast assays has been detected [36,37]. 
 A3 enzymes have been shown to deaminate ssDNA and their primary role seems to be 
acting against exogenous viruses and endogenous retroelements [38–41]. Section 6 contains a 
brief overview of the role of A3 enzymes in innate immunity. A3D, A3F, and A3G are 
cytoplasmic, A3B is nuclear, and A3A, A3C, and A3H are both cytoplasmic and nuclear 
[39,42–44]. Moreover, A3 enzymes deaminate at specific target sequences [45–48]. In 
general, A3 enzymes are found in T-cell, B-cells and phagocytic cells, although they are not 
confined to immune cells and can be expressed in e.g. the ovaries and testes and embryonic 
stem cells [49,50]. There is no clear agreement as to relative abundance of A3 in different 
tissues because of technical limitations in their measurement, but the general consensus 
suggests a broad and constitutive expression profile in humans [28]. Given their prevalence, 
nuclear localization, and mutagenicity, it is unsurprising that recent evidence indicates that 
A3 enzymes play a large role in the development of many cancers. The pathological 
consequences of A3 mutagenicity will be discussed in section 7.2.5.  
 AID also deaminates ssDNA and is essential for immunoglobulin (Ig) gene 
diversification in activated mature B-cells [51–54]. Normally, AID expression is restricted to 
germinal center (GC) B-cells, although there is evidence of AID expression in other cell 
types as a result of hepatitis C or  H. pylori infection as well as pro-inflammatory cytokines  
[55–57]. AID targets the sequence WRCY (W=A/T, R=A/G, Y=T/A). The role of AID in 
antibody maturation is discussed in sections 5.3 and 5.4 and the consequences of AID 
deamination outside the Ig loci is discussed in section 7.2.5. 
 Cytosines can also be deaminated by methyltransferases. Methylation of cytosines at 
CpG islands by methyltransferases is fundamental to epigenetic gene silencing. DNA 
(cytosine-5)-methyltransferases (DNMTs) convert cytosines to 5-methylcytosines (5-mC) 
using S-adenosylmethionine (SAM) as a methyl donor [58]. This reaction includes a 
dihydropurine intermediate that can spontaneously deaminate to uracil prior to methyl 
transfer from SAM. Thus, either dysfunctional DNMTs or low SAM levels result in DNMT1 
cytosine deamination [59,60]. Several prokaryotic methyltransferases as well as the catalytic 
domain of DNMT3a have been shown to deaminate cytosine [59,61,62]. Not all DNMTs 
exhibit this activity and their contribution to the genomic uracil load remains unstudied [63]. 
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3. Repair of Genomic Uracil by the Base Excision Repair Pathway 
 Repair of genomic uracil is usually performed by the base excision repair (BER) 
pathway, in which uracil-DNA glycosylases initiate the repair process by recognizing and 
excising uracil (figure 2). BER also repairs nucleobase oxidations, alkylations, and 
deaminations, as well as misincorporated nucleotides, abasic (AP) sites, and ssDNA breaks 
(SSBs), the specificity of which depends on the initiating DNA glycosylase (reviewed in 
[64,65]). BER can proceed via short- or long-patch (SP or LP, respectively) repair pathways 
or DNA polymerase ȕ (POLȕ) dependent two nucleotide insertion [66–68]. In this section, I 
will provide a step-by-step overview of SP- and LP-BER pathways and then provide a more 
detailed examination of the known uracil-DNA glycosylases. 
3.1 General base excision repair pathway 
 The exact mechanism by which glycosylases scan DNA for their respective lesions is 
not fully elucidated. For non-recruited DNA scanning, i.e. if the glycosylase is not recruited 
to the vicinity of the replication fork for scanning during replication, a glycosylase requires a 
balance of  specialized thermodynamics and kinetics for its interaction with both specific and 
non-specific DNA sequences [69]. Should the enzyme bind too tightly to non-specific 
sequences, it may not have the opportunity to scan the entire genome before further 
replication. Conversely, if the enzyme binds too weakly, some lesions may be overlooked 
[70,71]. The general consensus in the field is that most DNA glycosylases scan DNA in two 
ways (reviewed in [72]). The first scanning mode is referred to as “DNA sliding” and 
involves tracking along the DNA using a loosely-associated enzyme state, and the second 
mode is referred to as “DNA hopping” and involves intermittent dissociation and re-
association with the DNA [73–75]. Due to their complexity, studies on glycosylase DNA 
scanning have been performed with simplified in vitro systems, so the effects of glycosylase 
recruitment to e.g. the replication fork, post-translational modifications (PTMs), and 
glycosylase-protein binding have not been studied. 
 The common initiation step for all glycosylases upon lesion recognition is the 
“flipping” of the aberrant base out of the DNA helix and into the enzyme’s substrate 
recognition pocket in which the N-glycosidic bond between the C1 on the deoxyribose (dR) 
and the nucleobase is cleaved, leaving an AP site (reviewed in [76]). Most organisms have 
several DNA glycosylases for the removal of various damages, which has traditionally been 
thought to indicate a level of redundancy by the BER glycosylases [76]. After base removal, 
apurinic/apyrimidinic endonuclease 1 (APE1) nicks the phosphodiester bond 5ƍ to the AP 
site, leaving a 3ƍ-OH and a 5ƍ-deoxyribose phosphate (dRP) moiety [76,77]. Some 
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glycosylases (called bifunctional glycosylases) also have AP-lyase activity that allows them 
to nick the phosphodiester bond 3ƍ of the AP site by ȕ-elimination or both 3ƍ and 5ƍ of the AP 
site by ȕ/į-elimination. The AP-lyase-derived nick leaves a fragmented sugar derivative 3ƍ of 
the strand break and is therefore blocks DNA polymerases, so APE1 or polynucleotide kinase 
3ƍ-phosphate (PNKP) must process the nick before subsequent DNA synthesis [78]. 
 DNA synthesis can then proceed via SP- or LP-BER, which insert one or two to 
twelve nucleotides, respectively. The choice of SP/LP-BER is likely determined by relative 
protein concentrations and specific interactions between repair and scaffolding proteins at the 
lesion, as well as lesion type, stress response, cell type, and cell cycle [66–68,79–84]. Most 
glycosylases responsible for oxidatively damaged base excision are bifunctional and tend to 
follow SP-BER while monofunctional glycosylases follow either SP- or LP-BER [85]. It has 
therefore been proposed that since oxidatively damaged bases often occur in clusters, closely-
spaced LP-BER could lead to strand breakage, so SP-BER is a more sensible choice for 
oxidatively damaged bases [85]. Despite these insights, the exact mechanisms determining 
SP- versus LP-BER remain unknown. 
 In SP-BER, one nucleotide is usually inserted by POLȕ or (less frequently) POLȜ and 
the nick is ligated by DNA ligase I (LIG1) or LIG3Į in complex with scaffolding protein X-
ray repair cross-complementing protein 1 (XRCC1) [65,86–88]. Several other polymerases 
(POLȖ, POLș, POLȚ, and POLȜ) have also been proposed to be involved in BER [89–92]. 
LIG3 is stabilized by but can function independently of XRCC1 and is essential in 
mitochondrial BER, but apparently dispensable in nuclear BER [93–95]. In LP-BER, two to 
twelve nucleotides are inserted by POLȕ or POLį and POLİ in complex with proliferating 
cell nuclear antigen (PCNA) and replication factor C (RFC). The nucleotide insertion 
displaces the nucleotides 3ƍ of the AP site, leaving a ssDNA “flap.” The flap is removed by 
flap endonuclease 1 (FEN1) and ligation is performed by LIG1 [96]. 
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Figure 2: The SP- and LP-BER pathways. The base is recognized and excised by a 
monofunctional glycosylase that levels an AP-site or bifunctional glycosylase also nick the 
strand. The AP-site is nicked by APE1 and the nicked strand processed by APE1 or PNKP, 
resulting in a SSB with a 3ƍ-OH and 5ƍ-phosphate. In SP-BER, POLȕ fills in the nucleotide 
and LIG1 or LIG3 ligate the nick. In LP-BER, POLȕ, POLį, or POLİ fill in two to twelve 
nucleotides, FEN1 removes the flap, and LIG1 ligates the nick. Modified from [97]. 
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3.2 Uracil recognition and excision by uracil-DNA glycosylases 
 There are five known uracil-excising DNA glycosylases: uracil-DNA glycosylase 1 
and 2 (UNG1/2), single-strand selective monofunctional uracil DNA glycosylase 1 
(SMUG1), G/T mismatch-specific thymine DNA glycosylase (TDG), and methyl-CpG-
binding domain protein 4 (MBD4) (table 1). Their activities depend on sequence context, 
DNA strandedness (i.e. ssDNA or dsDNA), the base opposite the uracil (U:A or U:G), cell 
cycle, PTMs, interaction partners, and their location in the genome [97,98]. Several of these 
parameters were studied in Articles I and III of this thesis. 
3.2.1 UNG1 and UNG2 
 UNG is the major uracil glycosylase in mammalian cells [99,100]. The UNG gene 
encodes two isoforms with identical catalytic domains and unique N-termini that determine 
protein localization [101]. UNG1 expression is controlled by the PB promoter in the UNG 
gene and localizes to mitochondria, and UNG2 is controlled by the PA promoter and localizes 
to the nucleus [101]. UNG1 mRNA is expressed in all tissues, but UNG2 mRNA is mainly 
found in proliferative tissue like the testis, colon mucosa, small intestine, and the thymus 
[102]. UNG mRNA and protein levels are cell cycle-dependent: UNG2 is up-regulated in late 
G1- and early S-phase and UNG1 is constitutive expressed with a less pronounced up-
regulation in early S-phase [102]. UNG2 also preferentially excises uracil from ssDNA 
contexts than from dsDNA, and U:G over U:A [100,103]. Furthermore, sequence context 
specificity (i.e. the flanking nucleotides) trumps U:G over U:A preference [98,104,105]. In 
addition to uracil, UNG2 has been shown to less efficiently excise uracil analogues with 
minor 5ƍ modifications like 5-fluorouracil (5-FU), 5-hydroxyuracil (5-hU), alloxan, and 
isodialuric acid [77,100,105,106]. 
 It makes biological sense that the UNG2 is the main uracil-excising enzyme coupled 
to DNA replication because many more uracils probably arise from dUTP minsincorporation 
during replication than from spontaneous cytosine deamination. UNG2 has a much higher 
catalytic turnover rate compared to other uracil-DNA glycosylases, so it is well suited for fast 
uracil excision in the replication fork where dUTP misincorporation takes place and the 
spontaneous deamination rate increased [17,100]. Furthermore, UNG2 is phosphorylated at 
Ser23 in late G1- and early S-phase, which increases its association with the DNA binding 
protein replication protein A (RPA) catalytic turnover rate on ssDNA [107]. Conversely, 
UNG2 Ser64 and Thr60 phosphorylations throughout the S-phase reduce RPA binding and 
facilitate ubiquitinylation and proteosomal degradation in G2 [107]. Co-immunoprecipitation 
experiments have also shown that BER complexes contain UNG as the only uracil-DNA 
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glycosylase, APE1, POLĮ, POLȕ, POLį, POLİ, DNA protein kinase (DNA-PK), XRCC1, 
PCNA, LIG1, DNA replication licensing factor MCM7 (MCM7, also referred to as mini-
chromosome maintenance protein 7), and cyclin A, supporting replication-associated repair 
[108,109]. Finally, UNG2 co-localizes with RPA and PCNA in replication foci [110,111].  
 UNG2’s role in the mutagenic processing of genomic uracil in antibody maturation 
will be discussed in sections 5.3 and 5.4, and the consequences of UNG2 deficiency will be 
discussed in sections 7.2.1 and 7.2.2. 
3.2.2 SMUG1 
 Like UNG2, SMUG1 excises uracil, 5-hU, 5-FU, alloxan, and it also excises 5-
hydroxymethyluracil (5-hmU), 5-carboxyluracil (5-caU) and 5-formyluracil (5-fU) [100,112–
114]. Unlike UNG2, SMUG1 is constitutively expressed throughout the cell cycle and is 
thought to be the primary backup for UNG2 in the repair of U:A and U:G, although it cannot 
compensate for UNG2 deficiency in human B-cells [100,115]. While UNG2 is responsible 
for rapid repair of both U:A and U:G during replication, SMUG1 is thought to be more 
important for U:G repair in non-replicative chromatin [116]. 
 SMUG1 has been suggested as a reader of epigenetic markers like 5-hmU in addition 
to its role as a repair glycosylase [117]. Up-regulation in ten eleven translocation (TET) 
enzymes, which are linked to DNA demethylation, induced 5-hmU accumulation [118,119]. 
Furthermore, 5-hmU was recently shown to be introduced by enzymatic oxidation of thymine 
by TET enzymes in mouse embryonic stem cells (mESC) independently of 5-
hydroxymethylcytosine (5-hmC) or ROS-mediated thymine oxidation [120]. Smug1-/- mouse 
embryonic fibroblasts lack 5-hmU excision activity and resist normally toxic concentrations 
of 5-hmdUrd treatment [121]. It had been speculated that a glycosylase excising 5-hmU in 
DNA could be involved in the demethylation of 5-mC [122]. The theory has gained 
credibility in light of evidence showing that 5-hmC is a natural DNA component [123–125]. 
5-mC could thus be demethylated by 5-mC hydroxylation to 5-hmC, deamination to 5-hmU 
by AID/APOBECs, excision by SMUG1, and BER insertion of C [118,119,126]. This 
mechanism has been called into question since the discovery that AID/APOBECS do not 
deaminate 5-hmC and deaminate 5-mC ten-fold slower than the unmodified base [127,128]; 
however, both 5-hmU and SMUG1 may yet have undiscovered epigenetic roles.  
 There is also evidence for a role of SMUG1 in ribosomal RNA (rRNA) regulation. 
SMUG1 has broad nuclear localization and is slightly enriched in the nucleoli, where rRNA 
synthesis and metabolism takes place [100,129]. SMUG1 depletion in mice leads to 5-hmU 
accumulation in RNA and SMUG1 interacts with pseudouridine synthetase dyskerin (DKC1), 
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indicating a role for SMUG1 in rRNA quality control in that 5-hmU-modified RNA may be 
degraded by the exosome in its absence [130].  
3.2.3 TDG 
 TDG excises U:G (not U:A) and T:G that presumably originate from C or 5-mC 
deamination, respectively, with a preference towards U:G [131,132]. TDG has a very low 
turnover compared to UNG2 because it tightly binds to the AP site generated by uracil 
excision [133,134]. C-terminal TDG SUMOylation at Lys350 reduces AP site binding 
affinity and increases U:G turnover while decreasing T:G activity [134,135]. So although 
TDG does not seem like a viable backup for UNG2 and SMUG1, its SUMOylated form plays 
a role in uracil repair. In addition to uracil and thymine, TDG can excise 5-hU, 5-hmC, 5-FU, 
the lipid peroxidation product 3,N4-ethenocytosine (İC), and the 5-mC oxidation products 5-
formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) [136–139].  
 TDG is important in epigenetic regulation during embryonic development. Knockout 
or catalytic inactivation of TDG leads to embryonic lethality in mice [126,126]. The TDG-
deficient embryos showed a decrease in developmental transcription factors (e.g. Hox) by 
perturbed methylation at their regulatory domains. In addition, TDG knockdown led to 5-caC 
accumulation in embryonic stem cells and simultaneous TET and TDG overexpression led to 
5-caC and 5-fC depletion in HEK293 cells [127,138]. The fact that TDG has been shown to 
excise TET-oxidized 5-fC and 5-caC combined with their accumulation in TDG knockdown 
cells is a clear indicator of TDGs role in the demethylation of 5-mC after TET oxidation 
[140]. This represents the first validation of a pathway for active DNA demethylation. 
3.2.4 MBD4 
 MBD4 has similar substrate preference to TDG, but preferentially binds to 5-
mCG:TG and excises neither 5-fC nor 5-caC [141–143]. In addition, MBD4 has been shown 
to excise the peroxidase-mediated inflammation products 5-chlorouracil (5-CU) and 5-
bromouracil (5-BU), the chemotherapy products 5-FU and 5-iodouracil, and İC  [144–148]. 
There is evidence for direct DNA demethylation by MBD4 5-mC excision using growth 
arrest and DNA damage-inducible protein GADD45 (GADD45) as a scaffold [35,149]. 
Protein kinase C (PKC) phosphorylation of MBD4 has also been shown to potentiate its 5-
mC glycosylase activity following parathyroid hormone stimulation, leading to demethylation 
within the cytochrome P450 27B1 (CYP27B1) promoter [150] . This indicates that MBD4 
may have a role in the epigenetic de-repression of hormone regulated genes [143]. 
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Table 1: Uracil-DNA glycosylases (modified from [65]). 
 
4. Repair of Genomic Uracil by the Mismatch Repair Pathway 
 The primary role of the mismatch repair (MMR) pathway is the repair of base-base 
mismatches and insertion/deletion loops (IDLs) (reviewed in [151]). Although MMR has not 
been shown to be employed in the removal of genomic uracil under normal circumstances, it 
is crucial for mutagenic uracil processing in antibody maturation. In this section, I will give a 
general overview of the MMR pathway. I will also briefly mention uracil repair by MMR to 
provide a framework for better understanding the section on antibody maturation (section 5). 
4.1 General mismatch repair pathway 
 The key proteins in MMR are the MutS and MutL protein families (reviewed in 
[152]). The MutSĮ dimer is composed of the MSH (MutS homolog) 2 and MSH6 
heterodimer and the MutSȕ dimer is composed of the MSH2 and MSH3 heterodimer. MutSĮ 
recognizes base-base mismatches and IDLs and MutSȕ recognizes longer IDLs and is thought 
to be unable to repair base-base mismatches [153,154]. The MutLĮ dimer is composed of 
MutL homolog (MLH) 1 and mismatch repair endonuclease PMS2 (PMS2) and interacts with 
MutS dimers to recruit downstream repair proteins by signaling the mismatch recognition  
[155]. This can alternatively be performed by MutLȕ (MLH1 and PMS1) or MutLȖ (MLH1 
and MLH3), which may be involved in repairing IDLs and in meiotic recombination 
[156,157].  
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 Exonuclease 1 (EXO1) is also recruited to coordinate downstream proteins to finalize 
repair. EXO1 starts 5ƍ-directed mismatch excision in the presence of MutSĮ or MutSȕ and 
RPA [158,159]. Alternatively, EXO1 can introduce a 3ƍ nick directed excision with MutLĮ, 
which is activated by PCNA and RFC [160,161]. MutLĮ endonuclease also incises 5ƍ to the 
mismatch after recognition of the 3ƍ nick and mismatch. Then, EXO1 excises 5ƍ to 3ƍ from the 
MutLĮ incision site through and beyond the reach of the mismatch [160]. Although sterile 
because of meiotic effects, EXO1-deficient mice do not accumulate many mutations, so it is 
possible that other exonucleases are involved [162]. Moreover, EXO1-deficiency in mice 
increases lymphoma susceptibility and decreases survival compared to wild-type animals, but 
they have a higher survival than MSH2-deficient mice [162]. After the error is removed, 
POLį synthesizes a new strand and LIG1 ligates the nick [152,163]. 
 There are two moving models for the events following mismatch recognition. In the 
“stationary” model, MMR proteins induce DNA bending or looping that brings two distant 
sites together [164,165]. MutSĮ and MutSȕ remain bound at the mismatch, and MutSĮ 
ATPase activity acts in a proofreading role to verify mismatch binding before proceeding 
with downstream excision. In the “moving” model, MutSĮ/ȕ-MutLĮ complexes load at a 
mismatch site and then search for the strand break where exonucleases can be recruited to 
initiate excision [166–170]. 
 To preserve genome integrity, MMR should only occur on the newly-synthesized 
strand with the mispaired nucleotide. Strand discrimination is strand-specific, but the source 
of the nicking activity is not fully understood [171]. Bound PCNA determines the orientation 
of the MutLĮ incision on the leading strand and enhances its endonuclease activity [172]. In 
the lagging strand, the 5ƍ ends of the Okazaki fragments are used for strand discrimination 
[173]. 
 There is very little evidence of uracil repair by the MMR pathway outside of antibody 
maturation. Human MutSĮ has been shown to bind to U:G substrate in vitro [174]. MutSĮ 
also preferentially recognizes U:G or UU:GG relative to UU:AA homoduplexes, as well as 
uracil photoproducts [175–177]. Finally, U:G pairs have been shown to activate MutSĮ 
ATPase activity [178]. 
5. A Necessary Intermediate in Antibody Maturation: Genomic Uracil in Somatic 
Hypermutation and Class Switch Recombination 
 Uracil is enzymatically introduced into DNA for the antibody maturation processes 
somatic hypermutation (SHM) and class switch recombination (CSR). In this section, I will 
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first provide a brief overview on innate and acquired immunity and general B-cell maturation. 
I will then explain SHM and CSR, focusing on the role of genomic uracil. 
5.1 Innate versus acquired immunity 
 The body is constantly exposed to many dangers from pathogenic microorganisms. To 
this end, the innate immune system works as a first-line defense to stop pathogens, identify 
them, and mount short and long term responses (reviewed in [179]). The innate immune 
system is composed of anatomical and physiological barriers (e.g. the skin, placenta, and 
respiratory, urinary, and gastrointestinal tracts), anti-microbial toxins or molecules (e.g. ȕ-
defensins, lysozymes, and APOBECs), and phagocytosis and the inflammatory response (by 
e.g. phagocytes, the complement system, and the activation of the adaptive immune system). 
The inflammatory response is initiated by the activation of non-self-recognizing receptors 
e.g. toll-like receptors (TLRs). TLRs recognize pathogen-associated molecular patterns like 
bacterial lipopolysaccharide (LPS, an endotoxin in bacterial cell walls), bacterial flagellin, 
and dsRNA and unmethylated CpG islands from viruses. 
 The acquired (or adaptive) immune system is activated by the innate immune system 
and mounts a targeted, long-term response with memory. The acquired immune system’s 
response to infection can be broadly split into the cell-mediated or humoral responses, for 
which T-cells or B-cells are mainly responsible, respectively. The cell-mediated response is 
composed of T-helper cells, which help coordinate the activity of the immune system through 
macrophage antigen presentation and subsequent cytokine secretion and activation of B-cells 
and cytotoxic T-cells. The cell-mediated response also involves cytotoxic T-cells that can 
recognize antigens and kill other cells, and memory T-cells that retain antigen recognition 
over a long time frame. The humoral response is mediated by activated B-cells, which 
undergo affinity maturation and mature into antibody-secreting plasma cells or memory B-
cells. Here, I will only focus on antibody production in B-cells. 
5.2 B-cell maturation 
 B-cells develop from hematopoietic stem cells in the bone marrow (reviewed in [179]. 
In the bone marrow, stromal cells secrete growth factors for hematopoietic stem cell 
differentiation and antigen-independent V(D)J recombination takes place in immature B-
cells. V(D)J recombination is the initial antigen-independent rearrangement of 
immunoglobulin genes necessary to produce a high number of unique antibodies from limited 
genetic material (reviewed in [180]). Briefly, the variable (V), diversity (D), and joining (J) 
segments of immunoglobulin genes are rearranged through the introduction of site-specific 
DNA DSBs. The recombination activating proteins recombination activating gene (RAG) 1 
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and RAG2 assemble a pair of dissimilar recombinational signal sequences (RSSs) into a 
synaptic complex and cleave the DNA strands. The resulting strands are reorganized and 
repaired by the non-homologous end-joining (NHEJ) pathway, and further genetic diversity 
may be achieved by random nucleotide insertions and template-independent DNA fill-in 
synthesis by POL and POLȜ. Mature, naïve B-cells that express membrane bound IgM are 
then released from the bone marrow. 
 Upon infection, B-cells bind to antigens and are activated by T-cells in secondary 
lymphoid organs (spleen, lymph nodes, tonsils, and Peyer’s patches) and are selected for 
immunoglobulin antigen binding affinity, which requires B-cell receptor- (BCR, membrane 
bound Ig), CD40 ligand- (CD40L) and growth-factor (e.g. B-cell activating factor, BAFF) 
stimulation [181–183]. A fraction of B-cells differentiate into centroblasts in the primary 
follicles of the lymphoid organs to form GCs [184,185]. Further B-cell differentiation occurs 
in GCs through SHM and CSR. SHM introduces mutations of the V regions of the 
immunoglobulin heavy (IgH) and constant (IgC) genes, thereby introducing another level of 
diversity to immunoglobulins (reviewed in [186,187]).  
 B-cells are selected for maturation into plasma cell and memory B-cell based on the 
specificity of their immunoglobulin binding to antigen. This is achieved through pro-
proliferative and pro-apoptotic properties of GCs. Centroblasts lack expression of anti-
apoptotic factors, allowing rapid apoptosis by default or in response to exogenous signals 
[188–190]. Indeed, isolated GC B-cells quickly undergo apoptosis in vitro unless rescued by 
anti-apoptotic cytokines [191–193]. Clonal selection of BCR-expressing cells then leads to 
the selection of B-cells expressing high-affinity antibodies for differentiation into antibody-
secreting plasma cells or memory B-cells [194–196]. Together, SHM and V(D)J 
recombination are estimated to produce  more than 109 different antibodies [197]. Some 
animals (e.g. cattle, pigs, sheep, and chickens) also employ a process called gene conversion, 
in which parts of “pseudo” V regions are transferred to rearranged V regions, but this will not 
be discussed in the thesis [198,199]. 
 The constant (C) region of the IgG chain can be recombined by CSR from IgM or IgD 
to IgA, IgE, or IgG to have differing effector functions (reviewed in [200,201]). CSR occurs 
in switch (S) regions of the IgH gene, which are located upstream of each C region and 
recombine DNA to replace C or Cį regions with a downstream C region, thereby bringing 
the functional V(D)J region close to the downstream C region (reviewed in [202,203]). The 
altered C regions produce antibodies of different isotypes with different effector functions 
without altering antibody specificity [204,205]. 
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 B-cell differentiation into antigen-secreting plasma cells or memory B-cells occurs 
after successful response to antigen in the GC (reviewed in [206]). Plasma cells secrete 
soluble antibodies and memory B-cells are long-lived and can proliferate into antigen-
secreting cells upon re-encountering an antigen. B-cell differentiation is determined by BCR 
signaling upon antigen stimulation and will not be further explained in the thesis [207–209]. 
The resulting antibodies from B-cells have three main functions: neutralizing pathogens by 
forming a coat around them, opsonizing pathogens (i.e. labeling them for phagocytocis), and 
activating the complement system. 
5.3 Somatic hypermutation 
 In SHM, mutations are introduced into the V region of the Ig gene, leading to protein-
level mutations and subsequent selection for proliferation based on Ig antigen binding affinity 
(figure 3). AID initiates SHM by deaminating cytosines, creating U:G mismatches [210–
212]. Normal BER can be employed and a CTP re-inserted, leaving no mutation. C:G to T:A 
transition mutations can be generated by normal replication across U by POLį or POLİ 
[213,214]. Ung-/- mice exclusively develop these transitions in Ig V regions [215]. 
Alternatively, the U can be excised by UNG2, creating an AP site that can be processed in 
several ways. The AP site can be replicated over by the error-prone translesion synthesis 
(TLS) polymerase DNA protein REV1 (REV1) [216–220]. REV1 has been demonstrated to 
bypass polymerase-stalling AP sites and induce C:G to G:C transversion mutations 
[217,218,221]. In the absence of REV1, POLȘ can generate C:G to G:C transversions as well 
[222–224]. Finally, C:G to A:T transversions also require UNG2-induced AP sites, but the 
responsible TLS polymerase or polymerases are unknown [215,225]. APE2 also likely plays 
a large role in SHM. APE1 is down-regulated and APE2 up-regulated in GC B-cells [226]. 
APE2 has a functional PCNA-interacting domain and monoubiquitinylated PCNA at Lys164 
has been shown to recruit POLȘ and REV1 [227,228]. 
 Alternatively, U:G mismatches can be recognized by MutSĮ, activating EXO1 to 
create a ssDNA gap. The gaps are filled in by error-prone TLS polymerases POLȘ or POLȗ 
[229–233]. These mutations are associated with A:T pairs 5ƍ of the U:G mismatch and POLȘ, 
MSH2/6, and EXO1-deficient cells have been shown to lack 90 % of A:T mutations found in 
WT cells [234–237]. 
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Figure 3: Somatic hypermutation. AID deaminates C to U. Normal replication yields a C:G 
to A:T mutation. U can be recognized by the MMR pathway, resulting in end-resection and 
fill-in by TLS POLȘ or POLȗ and A:T to G:C or tandem mutations. UNG2 can excise U, 
leaving an AP-site that can be replicated over by TLS REV1 to yield a C:G to G:C mutation. 
The AP-site can also be faithfully repaired or replicated by TLS POLȘ to yield a A:T to G:C 
mutation 5ƍ of the U. Modified from [238]. 
5.4 Class switch recombination 
 CSR is the intrachromosomal rearrangement between S regions of IgH genes leading 
to the replacement of the C locus with CȖ, Cİ, or CĮ loci and thus antibody isotype 
switching (figure 4) (reviewed in [203,239]). S regions are located upstream of all C genes 
except for Cį and are 1-10 kbp in length [240]. Recombination occurs between DSBs 
introduced in the donor  S region (S) and a downstream acceptor region, though 
recombination can also occur with regions farther downstream [240,241]. S regions are G-
rich and have a frequency of the preferred AID target motif WGCW (W=A/T) [242–244]. 
Like with SHM, CSR is induced by AID-mediated DNA deamination of cytosines in the S 
regions of Ig gene V regions [52,53,212,245–247]. CSR occurs in G1 phase during cell 
division and is linked to RNA transcription [248,249]: AID is regulated by cell division and 
deaminates ssDNA, and interaction with RNA polymerase II-associated exosome complex 
enhances AID recruitment to DNA [245,250,251].  
 AID-generated uracils are excised by UNG2. CSR is reduced by 95% in UNG-
deficient mouse splenocytes and in humans with dysfunctional UNG, indicating that it is the 
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major glycosylase in CSR U excision [212,215,238,252–254]. SMUG1 can function as a 
weak backup and it has been shown that SMUG1 overexpression can partially rescue CSR in 
UNG-deficient mouse splenocytes and UNG/SMUG1 deficient splenocytes are devoid of any 
residual CSR activity [253,255]. Interestingly, SMUG1 overexpression in the presence of WT 
UNG decreases CSR, suggesting either a role for UNG in the recruitment of error-prone 
repair components or SMUG1 in the recruitment of error-free BER [255].  
 After uracil excision, APE1 and/or APE2 nick the DNA at the AP site. If the two 
nicks are in close enough proximity, a DSB is produced, which requires APE1 and APE2 
[256]. S region DSBs are greatly reduced in Apex1+/-Apex2-/- mouse splenocytes but only 
slightly reduced in Apex1+/- or Ape2-/-, suggesting redundant roles for APE1 and APE2 in 
CSR [256]. Contrarily, another study showed that APE1-deficiency in a mouse B-cell 
lymphoma cell line (CH12F3) caused an 80% reduction in CSR while APE2-deficiency did 
not affect CSR [257,258]; however, CH12F3 cells have a demonstrably abnormal uracil 
profile in response to CSR stimulation compared to ex vivo-stimulated B-cells, so a 
fundamental difference in the biology of the cell line may explain this discrepancy [259]. 
Indeed, an interaction between APE2 and PCNA may promote error-prone repair and APE2’s 
3ƍ to 5ƍ exonuclease processivity is enhanced by PCNA [226,260].  
 If no DSBs are initially produced, POLȕ replaces the nucleotide and the nick is 
ligated by LIGIII in complex with XRCC1. POLȕ inhibits S region DSBs and CSR, 
suggesting that it may compete with DSB formation but is overcome by the amount of AID-
induced SSBs [226,261]. Alternatively, the MMR pathway can convert a SSB into a DSB. 
MutSĮ binds to U:G mismatches in dsDNA and recruits MutLĮ and EXO1, which then 
initiates resection of the SSB 5ƍ to the mismatch [262,263]. PMS2 (part of MutLĮ dimer) also 
exhibits exonuclease activity and can create additional SSBs to provide more entry sites for 
EXO1 [160,264]. Combined with the SSB from UNG2 excision of U and APE1/2 nicking of 
the DNA strand, MMR therefore creates a DSB with a long ssDNA tail that results in a blunt 
DSB upon polymerization of the ssDNA with a DNA polymerase [226,239]. 
 The blunt DSBs are joined by the NHEJ or alternative end-joining (A-EJ) pathways. 
NHEJ is initiated by the XRCC5/6 dimer (also known as Ku80/Ku70, respectively), which 
binds to DSBs and recruits the Artemis/DNA-PK catalytic subunit (DNA-PKcs) complex and 
other NHEJ proteins [265,266]. The two DNA ends bound to DNA-PKcs are joined together 
and processed by Artemis/DNA-PKcs to make them compatible for joining [267,268]. POL 
and POLȜ bind to the XRCC5/6/DNA complex and fill in nucleotides at the strand breaks 
[269]. Finally, the XRCC4-like-factor (XLF)/XRCC4/LIGIV complex ligates across the 
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DNA ends [270–272]. A-EJ works as a backup DSB repair mechanism in the absence of 
NHEJ proteins and it has been shown that NHEJ-deficient cells retain significant CSR 
activity [273–278]. Moreover, A-EJ probably does not compete with NHEJ and the choice 
between the two is likely determined by the density of DNA lesions [279]. A-EJ involves 
larger microhomologies between the DSB junctions than NHEJ, but the pathway is not well 
understood and may even represent several pathways [280,281]. The consensus initiation step 
for A-EJ is 5ƍ to 3ƍ resection at the DSB to expose ssDNA for annealing to a homologous 
sequence [282]. DNA endonuclease RBBP8 (RBBP8, also called C-terminal-interacting 
protein, CtIP) is used for the DNA end-resection step [276,283]. Base-pairing then occurs at 
regions with complementary microhomology and the ends are joined by an undetermined 
ligase [281].  
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Figure 4: Class switch recombination. AID deaminates C to U in C loci of Ig S regions. The 
Us are excised by UNG2 and the AP-site nicked by APE1 or APE2, which may result in a 
DSB if two adjacent nicks occur in opposite strands. The MMR pathway can also process an 
AP-site and U in the strand opposite the APE1/2 nick, creating a blunt DSB. The DSBs are 
joined to other C loci by NHEJ or A-EJ. Modified from [223,238]. 
6. Host Defense by Uracilation of Exogenous Genomes: Genomic Uracil in Innate 
Immunity 
 APOBEC3A-G (A3A-A3G) constitute an innate barrier to retroviruses, endogenous 
retro-elements, and DNA viruses (reviewed in [284,285]). The biological function of 
APOBECs in this sense is the uracilation of exogenous DNA instead of cellular genomic 
DNA, so this section will only give a brief overview of A3 proteins in antiviral defense. 
 The restriction of human immunodeficiency virus (HIV) by A3G is well-
characterized. A3G is incorporated into incoming virus particles in the cell through 
interaction with the nucleocapsid domain of the group specific antigen (Gag) protein in an 
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RNA-independent manner [286–292]. Then, A3G deaminates cytosines in the cDNA created 
by reverse transcription of viral RNA, the frequency of which can exceed 10 % of all 
cytosines, resulting in a staggering loss of genetic information and subsequent formation of 
defective virions during the subsequent replication cycle [48,293]. Most lentiviruses 
(including HIV) counteract A3G by expressing viral infectivity factor (Vif), which hijacks 
the E3 ubiquitin ligase Cullin-5 (CUL5) to target A3G for ubiquitinylation and proteosomal 
degradation [294–301]. The actual restriction of viral cDNA could be performed by UNG2 
and APE1 processing of the uracils, but APOBEC-mediated viral restriction has also been 
shown to occur in the absence of UNG2 and SMUG1, so whether this actually occurs or to 
what extent remains in question [27,302–305]. 
 Although not as well characterized as with HIV, A3 enzymes have been shown to 
restrict several other viruses. Human T-cell lymphotropic virus (HTLV) does not encode any 
Vif-like protein and cannot degrade A3 in vitro [306,307]. Despite this, there was no 
hypermutation in viral cDNA from HTLV-infected patients [306]. Two possibilities have 
been suggested to explain this discrepancy. First, the infrequent replication by reverse 
transcription in HTLV reduces the opportunities for A3 deamination to occur [308–311]. 
Second, elements in the C-terminus of the HTLV-1 nucleocapsid inhibit A3G packaging to 
the virus particle [312]. Hepatitis B virus (HBV) may also be susceptible to APOBEC 
deamination by A1, AID, and all A3 enzymes except A3D and A3E [313–319]. A3G 
restriction of HBV has been reported with a reduction of ~30-fold viral DNA in the presence 
of A3G [316,318,320]. Hepatitis C virus (HCV) replication can be inhibited by A3G in vitro, 
but no hypermutated sequences have been found, possibly because HCV is RNA-based 
during all phases of replication (i.e. no cDNA is produced) [321]. Nevertheless exogenous 
Vif-1 decreased A3G levels and increased the HCV replication rate in vitro [322]. Human 
papillomavirus has been shown to be susceptible to A3A, A3C, and A3H editing [323]. 
Finally, human herpesviruses (HHV) can be restricted by APOBECs with the identification 
of hypermutated viral DNA, and A3C overexpression has been shown to reduce viral load 
[314,324]. Although much work remains to be done in the characterization of A3 enzymes’ 
(as well as other APOBECs’) roles in viral restriction, it is clear that they are potent DNA 
damagers and therefore also potentially dangerous for the host genome. 
7. Pathology of an Abundance or Shortage of Genomic Uracil 
 Given that work during the decade has clearly illustrated the role of genomic uracil as 
a necessary intermediate in immunity and a mutagenic DNA lesion, it is unsurprising that 
perturbations in the “uracilome” have pathological consequences (figure 5). In this section, I 
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will describe how a shortage of genomic uracil by AID deficiency leads to immunodeficiency 
and even autoimmunity. Then, I will discuss how an abundance of genomic uracil by uracil-
DNA glycosylase deficiency, perturbations in pyrimidine biosynthesis, or dysfunctional 
enzymatic cytosine deamination can lead to both immunodeficiency and cancer. 
 
Figure 5: Overview of uracil-DNA glycosylase AID/APOBEC dysregulation, their impacts 
on genomic uracil levels, and their resulting pathogenicities.  
7.1 Shortage of genomic uracil from AID deficiency 
 A shortage of genomic uracil by AID deficiency leads to immunodeficiency. Hyper-
immunoglobulin M (HIGM) syndromes are a heterogeneous group of genetic disorders that 
result in defective CSR with or without defective SHM (reviewed in [325]). HIGM syndrome 
leads to bacterial infections of the respiratory and digestive tracts and lymphoid hyperplasia 
[325–328]. HIGM syndrome patients may also suffer from autoimmune disorders [328]. The 
most common forms of HIGM syndrome are a result of CD40 or CD40 ligand deficiencies 
[329], the lack of which precludes B-cell stimulation for CSR and SHM upon antigen 
recognition. Although very rare, AID deficiency results in HIGM with both defective CSR 
and SHM, usually in an autosomal recessive manner [52,53]. C-terminal mutations in AID 
have been reported to be autosomal dominant and impair CSR but not SHM [330,331]. AID 
contains a nuclear export signal (NES) in its C-terminus, so the autosomal dominance of 
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HIGM in patients with C-terminal mutated AID may suggest that either the inactivation of the 
NES leads to an accumulation of the mutant allele in the nucleus or AID acts in a 
multimerization or complex formation with not yet defined partners crucial for CSR [332–
334]. Thus, in CD40(L)- or AID-deficient HIGH syndromes, a shortage of genomic uracil 
causes immune dysfunction resulting from a lack of high affinity antibodies. 
7.2 Abundance of genomic uracil from deficient uracil repair or increased uracilation 
 An increased uracil burden is pathogenic. In this section, I will describe how UNG2 
deficiency can lead to both HIGM and lymphomagenesis (7.2.1 and 7.2.2). Next, I will list 
the evidence linking the other uracil-DNA glycosylases to increased mutagenicity (7.2.3). 
Then, I will briefly explore how the alteration of the pyrimidine biosynthesis pathway by 
folate deficiency can lead to both an increased and reduced risk of cancer (7.2.4). Finally, I 
will outline recent advances showing how enzymatic deamination by AID/APOBECs has 
been clearly linked to a variety of cancers (7.2.5). 
7.2.1 UNG2 deficiency: Hyper Immunoglobulin M Syndrome 
 A deficiency in DNA uracil repair by UNG can lead to both dysfunctional CSR and 
oncogenesis. Like those lacking AID, persons lacking functional UNG suffer from HIGM 
syndrome [327]. Imai et al. studied a small group of HIGM syndrome patients with mutations 
in the UNG  gene and found them to have strongly impaired CSR and SHM skewed SHM 
with no quantitative deficiency [254]. The SHM-induced base insertion in these patients was 
skewed towards G-C instead of A-T, likely due to the absence of UNG, forcing replication 
over unrepaired U:G. Although this work only included three patients, the biological 
conclusions from the study fit data from studies performed on transgenic mice. Ung-/- mice 
have been shown to have greatly reduced CSR but competent SHM [215,335]. The little CSR 
activity remaining in these mice is attributed to uracil processing by SMUG1and MutSĮ; 
however, SMUG1 overexpression does not rescue CSR in Ung-/- mice, although it does 
increase CSR levels in Ung-/-Msh2-/- mice to Ung-/- levels [210,336]. Furthermore, SMUG1 
overexpression in UNG-competent mice leads to diminished CSR, suggesting that SMUG1 
preferentially initiates the traditional error-free BER pathway, while UNG2 uracil excision 
leads to error-prone repair [255]. Thus, either an abundance of unrepaired uracil or its repair 
in an error-free manner are both deleterious to competent CSR and the immune response. 
7.2.2 UNG2 deficiency: increased lymphomagenesis 
 UNG2 deficiency can also increase the global uracil load and lead to hyperplasia and 
lymphoma. Ung-/- mice show a 22-fold increase in B-cell lymphoma development over wild-
type mice [337], which is linked to early-age lymphoid hyperplasia in splenic B-cells and 
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possibly an immunological imbalance characterized by differential interferon (IFN) Ȗ, 
interleukin (IL) 6, and IL-2 levels [338]. Gene-specific mutation analysis in mice showed a 
1.4-1.8 increase in the AID deamination targets and oncogenes B-cell lymphoma 6 protein 
(Bcl-6) and Myc proto-oncogene protein (Myc) [339]. Moreover, a high-AID-expressing 
lymph node tumor analyzed showed 3-fold increased mutation levels in both Bcl-6 and c-Myc 
loci, but not the tumor suppressor gene p53 that is not targeted by AID [339]. The C:G to T:A 
transition mutation frequency in Ung-/- mice was increased as well, which is consistent with 
the aberrant SHM caused by UNG-deficiency.  
7.2.3 SMUG1, TDG, or MBD4 deficiencies: increased mutagenesis 
 Although considered a backup for UNG2 uracil excision in BER, SMUG1’s role in 
uracil repair is not necessarily redundant. siRNA-mediated silencing of Smug1 in mouse 
embryonic fibroblasts (MEFs) revealed a 2.4-fold increase in mutation frequency over wild-
type MEFs, suggesting that UNG2 and SMUG1 are not fully complementary [340]. 
Furthermore, although Ung-/-Smug1-/- mice will breed normally and remain healthy beyond 1 
year of age, Ung-/-Smug1-/-Msh2-/- mice have greatly increased cancer predisposition and 
shortened lifespans, indicating when both base excision and mismatch repair pathways are 
defective, the mutagenic effects of  spontaneous cytosine deamination are sufficient to 
increase cancer incidence without precluding  mouse development [121].  
 MBD4 is important for mutation suppression. MBD4-deficient mice are fertile, 
develop normally, and have no increase in tumorigenesis, but show a two- to three-fold 
increase in C:G to T:A transition mutations at CpG sites in the small intestines [341,342]. 
Cancer-susceptible mice heterozygous for the Min allele in adenomatous polyposis coli 
(Apcmin) gene crossed with Mbd4-/- mice also showed an accelerated tumor formation with 
predominant CpG to TpG transition mutations as the Apc gene [341]. Furthermore, MBD4 is 
mutated in 26-43 % of gastric, colorectal, endometrial, and pancreatic cancers that exhibit 
microsatellite instability, and the presence of an MBD4 mutant that binds 5-mCpG sites but 
lacks glycosylase activity has been shown to more than double the mutation frequency in 
colon cancer cells [343–347]. Thus, MBD4 repair of cytosine deamination at CpG sites is 
crucial to avoid mutagenesis and possibly cancer, although as with TDG it is unclear whether 
an abundance of uracil is the main cause. 
 Several studies have linked single nucleotide polymorphisms (SNPs) in uracil-DNA 
glycosylase genes with elevated uracil levels or increased cancer predisposition. Germline 
variations in TDG and UNG genes were linked to colon cancer predisposition, though their 
rarity is indicative of a limited role [348]. Furthermore, SNPs in TDG and SMUG1 have been 
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associated with esophageal squamous cell carcinoma (ESCC), and several SMUG1 SNPs 
modestly increase breast, bladder, and colon cancer risk [349–353]. Two SNPs in SMUG1and 
one in UNG were also shown to increase genomic blood uracil levels [354]. Finally, several 
SNPs in MBD4 have been associated with increased risk of ESCC and lung, colon, and 
cervical cancers [355–360]. There are several conflicting reports regarding the risk of the 
uracil-DNA glycosylase SNPs and their associations, so I provided a more complete list 
thereof in Table 3. It is therefore likely that dysfunctional glycosylase activity plays at least a 
small role in oncogenesis, though the interplay between uracil repair-related genomic 
instability and other oncogenic factors is unclear. 
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Table 3: SNPs associated with uracil-DNA glycosylases [349–377]. 
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7.2.4 Folate deficiency: contradicting evidence for oncogenesis 
 Whether an increased uracil load by thymidylate synthase inhibition or dysfunction 
contributes to cancer risk is under contention. Folate is a necessary co-factor for TS activity 
and folic acid deficiency or folate antagonists such as methotrexate impair its activity 
[378,379]. TS inhibition is cytotoxic to some cancers, and one hypothesis for TS inhibitor-
induced cytotoxicity is that futile cycles of glycosylase uracil excision, BER, and further 
dUTP misincorporation induce DNA fragmentation [13,380]. Were this the case, TS inhibitor 
sensitivity would increase with increased UNG expression, but this is not the case: cancer 
subtypes resistant to the TS inhibitor pemetrexed exhibit higher UNG expression than 
pemetrexed-sensitive subtypes, and UNG overexpression has been ineffective at sensitizing 
cells to other TS inhibitors [381,382]. Instead, UNG loss has been shown to enhance DSBs in 
colon cancer cell lines upon pemetrexed treatment, so it has been suggested that pemetrexed-
induced uracil misincorporation is genotoxic by uracil accumulation near replication origins, 
replication fork stalling, fork collapse, DSB break formation, and cell death [383]. 
 However, the clinical picture is less straightforward. Although folate depletion 
(leading to lowered TS activity) appears to increase carcinogenesis [384,385], supplemental 
folate intake and high folic acid levels have also been shown to increase cancer risk [386–
388]. Another study showed that a low-folate diet did not increase tumor development in 
Ung-/- mice [389]. Finally, it was shown that increasing dietary folate both increased and 
decreased genomic uracil in mice colon and livers, respectively [390]. Thus, it remains 
unclear whether and to what extent genomic uracil is modulated by thymidylate synthase. 
7.2.5 Enzymatic cytosine deamination: increased widespread carcinogenesis 
 DNA uracil abundance by enzymatic DNA cytosine deamination can also lead to 
oncogenesis. A general hallmark of many B-cell lymphomas is a translocation between the 
Ig-loci and a proto-oncogene, such as the BCL1/Ig translocation in Mantle zone lymphoma, 
BCL2/Ig translocation in follicular lymphoma, and MYC/Ig translocation in Burkitt’s 
lymphoma [391,392]. The role of AID in these translocations has been well established: 
removal of AID has been shown to decrease the frequency of MYC/IgH translocations [393]. 
These translocations occur most frequently at transcription start sites, which is consistent 
with the accepted model of transcription-coupled deamination of single stranded DNA [394]. 
AID also shifts the incidence from pre-B-cell to more mature B-cell lymphomas in MYC-
overexpressing mice and shifts the preference from Mantle cell lymphoma to diffuse large B-
cell lymphoma in BCL6-overexpressing mice [395,396]. Furthermore, ablation of AID 
activity by knock-out in mice results in the accumulation of significantly fewer mutations 
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linked to B-cell lymophomagenesis [397]. These data suggest that AID deamination is 
lymphomagenic. In addition, AID is highly expressed in several lymphomas, so deamination 
may be important for therapy resistance and disease progression [398–400]. High AID levels 
have also been correlated with high genomic uracil levels in lymphoma cell lines and primary 
B-cell leukemia and lymphoma cells [259]. 
 Enzymatic DNA cytosine deamination has also been linked to non-B-cell cancers. A 
2012 study by Nik-Zainal et al. sequenced the genomes of 21 breast cancer tumor samples 
and discovered unique mutational signatures in clusters called “kataegis” (Greek for shower 
or thunderstorm) [401]. The kataegis clusters were attributed to APOBEC cytosine 
deamination and subsequent work showed that the mutational signatures observed were 
indeed consistent with the action of these enzymes [402]. Another study found that A3B was 
up-regulated in the majority of breast cancer tumor samples and cell lines analyzed and the 
tumors and cell lines with high A3B levels contained twice as many somatic hypermutations 
as those with low A3B levels [403]. The same study also showed that genomic uracil levels 
were decreased in a high-A3B-expressing cell line upon small hairpin RNA (shRNA) knock-
down of A3B. Subsequent work has shown that: increased AID/APOBEC expression levels 
increase mutational frequency and kataegis in yeast in an UNG-dependent fashion [404]; 
APOBEC mutational signatures and kataegis are present in most cancers, including breast 
pancreas, lung, and liver cancer, medulloblastomas, chronic lymphocytic leukemia, B-cell 
lymphomas, and acute lymphocytic leukemia [405]; and kataegis clusters are present in 
multiple myeloma, ovarian cancer, osteosarcoma, and renal cell carcinoma [406–409]. Thus, 
an increase in enzymatic DNA uracilation has a clear link to cancer. 
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8. AIMS OF THE THESIS 
 The overarching goal of the articles presented in this thesis and my doctoral studies in 
general was to better understand the link between genomic uracil’s role in cancer and 
adaptive immunity. Thus, we explored the following topics: 
1. How does uracil repair differ between man and mouse? An overwhelming amount 
of mechanistic insights are gained from both in vitro and in vivo mouse studies, so 
it was crucial to identify what drawbacks a mouse model may have. 
2. We aimed to establish a method to measure absolute global genomic uracil levels. 
A wide variety of methods have been employed to measure genomic uracil, but 
they have yielded an equally broad distribution of results, suggesting possible 
technical shortcomings in the methods. A method to accurately determine uracil 
levels was therefore crucial to make conclusions regarding its regulation. 
3. What are the relative contributions of UNG and SMUG1 to general uracil repair in 
various tissues? Together, the two enzymes supposedly maintain a low genomic 
uracil burden, so understanding their relative contributions to uracil excision 
would help clarify their respective roles. 
4. Do AID/APOBEC expression levels correlate with genomic uracil levels? Given 
the recent discovery of APOBEC mutational signatures in cancers, it was 
important to determine whether the global uracil burden was substantially 
increased with high AID/APOBEC expression or whether the uracils were 
transient, i.e. they were repaired too soon after introduction to measure.  
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9. SUMMARY OF RESULTS 
9.1. Article I - Uracil-DNA glycosylase in base excision repair and adaptive immunity: 
species differences between man and mouse. 
May 2011, Journal of Biological Chemistry 
Doseth B, Visnes T, Wallenius A, Ericsson I, Sarno A, Pettersen HS, Flatberg A, Catterall T, 
Slupphaug G, Krokan HE, Kavli B 
 Mouse models are very commonly used in molecular biology, including for the 
elucidation of BER and SHM and CSR. In this article, we examined the species differences in 
the initiation of uracil repair between mouse and man to better understand the applicability of 
results derived from mouse models. 
 We measured the uracil excision activity using a standard oligonucleotide-based 
nicking assay in which a 19-mer oligonucleotide containing one uracil is removed by the 
uracil-DNA glycosylases in sample cell extracts and the strand cleaved. We used a variety of 
normal, embryonic, and cancer human and mouse cell lines and found that the mean human 
cell line uracil excision activity was nine to ten-fold higher than mouse using substrates with 
both U:A and U:G. Then, we measured complete BER in the cell lines using covalently 
closed circular DNA (cccDNA) substrates with a single U:A or U:G incubated with cell 
extracts and radiolabelled nucleotides that can be used to estimate repair. Human extracts 
showed higher U:A repair efficiency than mouse extracts, but there was no species difference 
in U:G repair. This suggests distinct U:A versus U:G BER mechanisms in man and mouse. 
 Next, we examined the relative contributions of UNG and SMUG1 in man and mouse 
by selectively inhibiting each enzyme. UNG was inhibited using the irreversible inhibitor 
uracil-DNA glycosylase inhibitor (Ugi) from a B. subtilis bacteriophage, and SMUG1 was 
inhibited with a neutralizing SMUG1 IgG [410]. U:G lesions had previously been reported to 
be mostly repaired by UNG2 in humans and SMUG1 in mice [100,411]. Inhibiting both UNG 
and SMUG1 completely abolished measurable uracil excision activity in all samples, 
suggesting a minor role for TDG and MBD4 in uracil repair; however, the enzymes should 
not be ruled out because the reaction conditions may have disfavored them and did not 
include APE1, which increases the turnover of the enzymes by releasing them from the AP 
site. UNG showed a six-fold higher uracil excision activity in human extracts than in mouse. 
Interestingly, SMUG1 neutralization increased U:G activity in the samples, which could be 
explained by SMUG1 having a high affinity for U:G but a relatively lower turnover than 
UNG. Therefore, SMUG1 can compete with UNG for the limited U:G substrate when 
uninhibited. Contrastingly, SMUG1 exhibited an 8-fold higher uracil excision activity in 
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mouse than in man. Furthermore, about 50 % of the total excision activity in mouse samples 
could be attributed to SMUG1, compared to only 1 % in human samples. Thus, UNG and 
SMUG1 have similar relative contributions in mouse and human cells, but UNG is clearly the 
predominant glycosylase in human cells. 
 We then quantified the relative abundances of UNG, SMUG1, and TDG in the cell 
lines to determine whether protein levels could explain the relative contributions of the 
enzymes to uracil excision activity. Due to their low abundance, all proteins except for 
human UNG required immunoprecipitation prior to western blot analysis. UNG was ~20-fold 
higher in human than in mouse cell lines, indicating that the higher relative UNG activity was 
a result of a higher abundance of the enzyme and not necessarily a more active enzyme. The 
large difference may be explained by alternative transcriptional regulation of UNG in mouse 
and man. Indeed, there is limited homology between human and mouse UNG promoter 
sequences, although many key transcription factor binding sites are conserved [412]. Also, 
human UNG2 is regulated by stepwise phosphorylations, but one phosphorylation site is not 
conserved in mouse UNG2, suggesting a less stringent regulation of the protein in mouse 
cells [107]. There was no significant difference in SMUG1 levels between human and mouse 
cell lines, and TDG was 3.4-fold higher in mouse cells. Thus, the reliance on SMUG1 in 
mouse cell lines was most likely a result of a lower UNG abundance. 
 Finally, we measured the contributions of UNG and SMUG1 to uracil excision in 
CSR. To this end, we stimulated ex vivo wild type and Ung-/- splenic B-cells from mice with 
LPS and IL-4 to induce in vitro CSR. As expected, there was no UNG activity in the Ung-/- 
B-cells, as well as no change in SMUG1 activity with UNG-deficiency. All excision activity 
was again abolished when inhibiting both UNG and SMUG1, suggesting that TDG and 
MBD4 are unlikely to play a role in CSR uracil excision. In contrast to a previous report, 
SMUG1 activity was not down-regulated upon stimulation, but rather it was increased by 40 
% [255]; however, SMUG1 activity does decrease with stimulation if normalized to total 
protein in the extract instead of to the number of cells used. Normalization to total protein can 
be disadvantageous because cell morphology changes after stimulation, a difference in 
cytoplasmic proteins that can skew normalization. Thus, SMUG1 may also play a role in 
backup uracil excision during CSR, although it may recruit error-free BER proteins that 
inhibit CSR in vivo. 
 CSR is completely abolished in humans lacking functional UNG, but only 95 % 
reduced in mice. MMR plays a role in CSR, but it also depends on uracil processing by a 
glycosylase and is therefore unlikely the reason for why UNG deficiency has a more 
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pronounced effect in mice. SMUG1 overexpression partially rescues CSR in Ung-/- mice and 
Ung-/-Smug1-/- mice are completely devoid of CSR [253,255]. Additionally, uracil in ssDNA 
at AID hotspots is 200-fold more favored by human UNG2 than human SMUG1 and SMUG1 
prefers U:G in a dsDNA context. Finally, SMUG1 activity represented a larger portion of the 
uracil excision capacity in mouse cell lines and human cells expressed much more UNG than 
mouse cells, so mouse cells may rely more heavily on SMUG1 than on UNG2. Thus, 
SMUG1 functions as a backup for UNG2 in mouse CSR, but may not do so to the same 
extent in human cells. 
 In conclusion, we identified key differences between human and mouse cells 
suggesting that though UNG2 is the major uracil-DNA glycosylase in both organisms, 
SMUG1 likely plays a larger role in mouse cells. Care should therefore be taken before using 
conclusions derived using mouse models to elucidate human biology. 
9.2. Article II - A robust, sensitive assay for genomic uracil determination by 
LC/MS/MS reveals lower levels than previously reported. 
September 2013, DNA Repair 
Galashevskaya A*, Sarno A*, Vågbø CB, Aas PA, Hagen L, Slupphaug G, Krokan HE 
*(shared first authorship) 
 Uracil’s roles in adaptive immunity and possible carcinogenicity underscore the need 
for a reliable assay to quantify it. Several groups have employed a variety of methods to 
assay whole-genome uracil, but the resulting broad variation in their results suggest that the 
methods contained technical shortcomings despite the heterogeneity of the samples 
measured. In this article, we set out to both identify and ameliorate any potential 
shortcomings in LC/MS-based uracil quantification. 
 We decided to measure dUrd by enzymatic hydrolysis of DNA to dNs instead of Ura 
by UNG excision for several reasons. First, dUrd contains a labile N-glycosylic bond between 
Ura and the deoxyribose moiety that requires substantially less energy to fragment than the 
heterocyclic Ura bonds, and less collision energy often tends to give lower background 
signals. Thus, measurement of dUrd by multiple reaction monitoring (MRM) on a triple-
quadrupole mass spectrometer yielded a lower background than Ura. Second, the extent of 
Ura excision by UNG cannot easily be confirmed. One group found that restriction digestion 
of genomic DNA was essential to ensure complete Ura excision, presumably because the 
enzyme could more easily scan the shorter DNA fragments [413]. Conversely, the extent to 
which DNA is hydrolyzed can be easily measured by measuring dAdo/Cyd/Guo/Thd. 
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 Naturally occurring 13C-dCyd is isobaric with and yields an identical mass transition 
to dUrd, so they are indistinguishable by MRM. Given that dCyd is five to six orders of 
magnitude more abundant than dUrd, the small percentage of 13C-dCyd presented completely 
obfuscated the dUrd peak using a normal reverse phase chromatography column, despite 
good chromatographic separation between the two nucleosides. We avoided this problem by 
using a reverse phase column with embedded weak ion-pairing groups (PrimeSep200) with 
which dUrd elutes before dCyd, avoiding obfuscation. We could not directly measure dUrd 
from hydrolyzed DNA using HPLC with a PrimeSep200 column directly coupled a MS/MS 
because dUrd elutes too near the void volume of the column, where ion suppression interferes 
with the signal. So, we set up a precursory HPLC step to separate dUrd from both dCyd and 
ion-suppressing contaminants. This had the added advantage of allowing direct quantification 
of total dNs by HPLC-UV. We found that measuring dUrd in this way gave a mean accuracy 
of 94.3%, intra- and inter-day CV values of 9.7 % and 10%, respectively, and a lower limit of 
quantification of 5 fmol dUrd. 
 We found that dUrd can be largely overestimated by co-purification of dUMP with 
DNA. Co-purified dUMP would then be dephosphorylated to dUrd during DNA hydrolysis. 
Alternatively, dCMP could be co-purified and deaminated. Note that this drawback is not 
present when measuring UNG-excised Ura. To eliminate co-purified dUMP, we pre-treated 
DNA samples with phosphatase to dephosphorylate dUMP and then precipitated the DNA. 
We hypothesized that dUrd would not carry over after the precipitation. Indeed, we found 
that up to 98% of the dUrd measured was removed after phosphatase treatment, confirming 
that dUMP (or dCMP) had been co-purified with DNA. 
 The rate of dCyd deamination is determined by temperature, pH, and DNA 
strandedness [17,19]. Thus, we wanted to avoid in vitro dCyd deamination by avoiding high 
heat and basic or acidic pH. Our final hydrolysis reaction was performed at 37 °C for 50 min 
and lay within pH 6 to 7.6. Other methods denature DNA by heating to 95 °C before a 3 h to 
6 h DNA hydrolysis [24,25,414]. We found that heating DNA to 95 °C for 5 min resulted in a 
1.7-fold increase in genomic dUrd. Furthermore, the hydrolysis step introduced 4.805 x 10-3 
dUrd per 106 bp per min. We therefore included a control sample in our assay that has been 
deuracilated with UNG to measure the amount of in vitro generated dUrd. Subtracting the 
deuracilated control from the actual samples yields an accurate estimation of the actual 
genomic dUrd content in a sample. 
 Next, we aimed to validate the assay. We first compared dUrd content from DNA 
isolated using a spin column kit and phenol:chloroform:isoamyl alcohol, and found no 
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difference between the isolation methods. Next, we compared our assay to LC/MS/MS 
analysis of UNG-excised Ura (similar to [415]) and found a significant lack of reproducibility 
with the Ura excision method. Finally, we compared DNA from UNG2 proficient and 
deficient lymphoblastoid cell lines as well as Ung+/+ and Ung-/- MEFs and found that UNG 
deficiency leads to a clear increase in genomic uracil levels. 
 From these results, we proposed that our method addresses the major sources of error 
in genomic uracil measurement. 
9.3. Article III - UNG and SMUG1 efficiently complement each other in removing 
genomic uracil from mouse organs. 
Manuscript 
Sarno A*, Alsøe L*, Galashevskaya A, Tekin NB, Jobert L, SenGupta T, Carracedo S, 
Krokan HE, Nilsen H *(shared first authorship) 
 It is widely accepted that UNG2 is the primary uracil-DNA glycosylase with SMUG1 
acting as its immediate backup. In paper I, we confirmed that this is indeed the case, although 
SMUG1 likely plays a larger role in mouse cells. In this article, we aimed to further clarify 
the respective roles of the two glycosylases, focusing on their effect on the genomic uracil 
load. Thus, we used Ung-/-Smug1-/- mice to elucidate the relative roles of UNG and SMUG1. 
 First, we generated Smug1-/- mice and characterized them. The homozygous knockout 
mice showed no residual SMUG1 expression in the spleen by mRNA or western blot and the 
heterozygous mice had 50 % SMUG1 compared to wild type mice. Moreover, the mice were 
fertile and the Smug1 knock-out gene was inherited at Mendelian ratios. SMUG1-deficiency 
led to no obvious pathological abnormalities in appearance or organ lesions. Blood cell count 
was also normal in these mice, but they exhibited a 20 % reduction in lymphocytes. We then 
crossed the Smug-/- mice with a previously-established Ung-/- strain, which also had no gross 
abnormalities except for CSR deficiency and a high incidence of lymphoma late in life 
[215,337]. The Ung-/-Smug1-/- mice also showed no gross morphological abnormalities. Thus, 
we concluded that combined UNG/SMUG1 deficiency is well-tolerated in mice, at least in 
the time period examined here. 
 To confirm that SMUG1 is the major enzyme responsible for 5-hmU repair, we 
measured 5-hmU levels by LC/MS/MS and 5-hmU excision activity using the oligo nicking 
assay described in article I. Expectedly, there was no 5-hmU excision activity in Smug-/- 
MEFs. The wild type MEF and organ extracts showed a preference towards 5-hmU:G over 5-
hmU:A and no activity on single-stranded 5-hmU substrate. The 5-hmU excision activities 
were almost identical to the uracil excision activities, indicating that SMUG1 excises the two 
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nucleosides at the same rate. 5-hmU levels were lowest in wild type organs and MEFs and 
increased in Smug1+/- and further in Smug1-/- organs, suggesting that a single copy of the 
Smug1 gene (and subsequent 50 % expression relative to wild type) is not sufficient to 
maintain basal levels of 5-hmU. We measured 1.4- to 3.8-fold increases in 5-hmU over wild 
type in SMUG1-deficient organs. Furthermore, there was a slight increase in 5-hmU in MEFs 
after 22 passages, but it was independent of SMUG1 status. Lastly, there was no significant 
correlation between 5-hmU excision activity and 5-hmU levels. 
 We then explored the effect of SMUG1-deficiency on genomic uracil levels and uracil 
excision activity. There was a higher variation in uracil excision activity between tissue types 
than there was with 5hmU excision, possibly because of the contribution from UNG. The 
spleen and heart displayed the highest activities with U:G and ssU substrates, which also had 
similar activity profiles between organs. The only organ extract that had a different relative 
activity between U:G and ssU was the brain, the uracil excision activity of which was 
reduced using both U:G and U:A substrates. The reduction of uracil excision activity with 
SMUG1 deficiency in the brain combined with the low excision activity observed with ssU 
substrate regardless of SMUG1 status strongly suggests that SMUG1 is the major uracil-
DNA glycosylase in the brain.  
 Finally, we measured the effect on uracil excision activity and genomic uracil 
accumulation on Ung-/- and Ung-/-Smug1-/- mice. For the activity assays, we used wild type 
organ extracts pre-incubated with Ugi to simulate Ung-/- mice and found that uracil excision 
was completely abolished in all organ extracts with the ssU substrate and substantially 
reduced in all extracts save the brain with U:A and U:G substrates. The lack of any effect on 
uracil excision activity by UNG deficiency further indicates that SMUG1 is the major uracil-
DNA glycosylase in the brain. Expectedly, there was no appreciable activity in any extract 
from Ung-/-Smug1-/- mice, regardless of substrate. Unlike SMUG1, UNG-deficiency resulted 
in a two- to three-fold increase in genomic uracil levels over wild type in mouse organs, 
although they did not correlate with uracil excision activity. Strikingly, the Ung-/-Smug1-/- 
exhibited a three- to 20-fold increase in genomic uracil levels over wild type. The heart, 
skeletal muscle, kidney, and lung samples showed an increase of 20- to 30-fold in genomic 
uracil over wild type and the liver a greater than 80-fold increase. The spleen and brain only 
exhibited three- and four-fold increases in genomic uracil, respectively. The synergistic 
increase in genomic uracil levels in Ung-/-Smug1-/- mice demonstrates that SMUG1 can 
maintain genomic uracil at near wild type levels in the absence of UNG. 
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 The spleen’s relatively modest increase in genomic uracil was especially interesting 
given its high proliferative capacity. dUTP misincorporation has the potential to be a much 
more substantial source of genomic uracil compared to cytosine deamination, so more highly 
proliferative cells should accumulate more uracil than organs with lower proliferation. We 
did not observe such a clear correlation, although we only tested DNA isolated from organs, 
which have a heterogeneous cell composition. Although tempting to ascribe the large 
increase in genomic uracil to either dUTP misincorporation or cytosine deamination, more 
work needs to be performed to elucidate the relative contributions of the two mechanisms. In 
addition to proliferation rates, dUTP/dTTP ratios may vary between tissue and cell types, 
which would impact the dUTP misincorporation rate. Furthermore, ion levels and pH that can 
alter the spontaneous deamination rate are also likely to be tissue-dependent. TDG and 
MBD4 may also have contributed to uracil repair, despite the fact that no uracil excision 
activity was observed in Ung-/-Smug1-/- organ extracts. The activity assay itself may not have 
been optimized for TDG and MBD4, as discussed in article I.  
 Thus, the main conclusion from this article is that while UNG is indeed the major 
glycosylase responsible for uracil repair in mice, SMUG1 alone can maintain genomic uracil 
at physiologically normal levels and is responsible for the majority of uracil excision in the 
brain. The relative contributions of dUTP misincorporation versus cytosine deamination 
remains to be explored, as well as to what extent SMUG1 can compensate for UNG in 
humans. 
9.4. Article IV - AID expression in B-cell lymphomas causes accumulation of genomic 
uracil and a distinct AID mutational signature. 
November 2014, DNA Repair 
Pettersen HS, Galashevskaya A, Doseth B, Sousa MML, Sarno A,  Visnes T, Aas PA, 
Liabakk NB, Slupphaug G, Sætrom P, Kavli B,  Krokan HE 
 AID and APOBECs are associated with several mutational signatures in kataegis 
hotspots found in a wide variety of cancers (section 7.2.5). Although the presence of these 
mutational signatures implies at least the transient presence of genomic uracil, only one study 
had measured genomic uracil levels in APOBEC-expressing cells and they only did so to 
demonstrate the effect of shRNA knock-down of A3B [416]. In this article, we aimed to test 
whether there was a correlation between AID, APOBEC, and uracil-DNA glycosylase levels 
and genomic uracil. Note that an article containing very similar experiments and results was 
published the week we submitted our manuscript [259]. 
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 To find a correlation between AIC/APOBEC levels and genomic uracil, we measured 
genomic uracil by LC/MS/MS and AID/APOBEC expression by qPCR in 17 cancer cell lines 
for. There was a staggering 72-fold variation in genomic uracil levels between the cell lines, 
and we observed that uracil levels were higher in lymphoma cell lines (4.4- and 18-fold 
higher in lymphoma cell lines than in non-lymphoma cell lines and primary B-cells from 
healthy donors, respectively). Of all the DNA cytosine deaminases, AID showed the best 
correlation with genomic uracil (R2 = 0.70). We confirmed the correlation with AID levels 
measured by western blot (R2 = 0.95) and mass spectrometry (R2 = 0.65). 
 Next, we tested whether AID attenuation by CSR stimulation, exogenous AID 
expression, or shRNA knockdown could alter the genomic uracil load in B-cell lines. AID 
overexpression in the mouse B-cell lymphoma cell line CH12F3 increased genomic uracil 
six-fold. Stimulation of the CH12F3 line to undergo CSR induced AID expression and 
increased genomic uracil four-fold 48 h after stimulation. The increase in genomic uracil 
post-stimulation was probably not due to an increase in dUTP misincorporation because 
CH12F3 cells proliferate more slowly upon stimulation. Thus, unless there was a large 
attenuation in the dUTP/dTTP ratio, the slower proliferation of the unstimulated cells would 
decrease their dUTP misincorporation relative to the stimulated cells. We also knocked down 
AID by shRNA in a cell line with high constitutive AID expression, reducing AID expression 
by 60 % and correspondingly reducing genomic uracil levels by 38 %. Thus, we showed that 
endogenous and exogenous AID expression increase genomic uracil levels in cellulo. 
 We explored uracil repair to determine to what extent it is responsible for the high 
genomic uracil levels in AID-expressing cell lines. Uracil excision activity assays (mean of 
U:G and U:A) had a statistically significant but weak inverse correlation (R2 = 0.52) with 
genomic uracil. We further measured the four uracil-DNA glycosylases by mass spectrometry 
and found weak inverse correlations between UNG and SMUG1 levels and genomic uracil 
(R2 = 0.42 and 0.28, respectively). These inverse correlations suggest that UNG and SMUG1 
play a minor but significant role in the accumulation of AID-induced genomic uracil. The 
correlations were likely not higher because genomic uracil represents a balance of uracil 
introduction and repair. Uracilation in these cells seems to mostly be a product of AID 
deamination, whereas uracil repair regulated by a variety of factors including but not limited 
to uracil-DNA glycosylases, some of which are likely dysfunctional in cancer cell lines. 
 A method to distinguish between genomic uracil in U:A versus U:G contexts would 
be the best way to exclude dUTP misincorporation as a source of uracil in these cell lines, but 
no such method yet exists. As an alternative, we correlated cell doubling time with genomic 
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uracil and found that the lymphoma cell lines showed no correlation and the non-lymphoma 
cell lines had an inverse correlation between genomic uracil and cell doubling time. This 
suggests that dUTP minsincorporation may affect the genomic uracil load in cells with low 
AID expression, but has little to no impact in cells with high AID expression. In addition, we 
measured in vitro U:G BER activity on synchronized HeLa cells. We found that UNG was 
the major contributor to BER G1/S and G2/G1, though to a lesser extent and only 1.5-fold 
more than TDG. SMUG1 exhibited a small contribution to BER during all cell cycle phases. 
Thus, TDG and SMUG1 may have roles in BER of U:G mismatches in G1- and to a lesser 
extent in S. The relative roles of the glycosylases is likely similar in other cell lines, although 
this has not been demonstrated. 
 Alexandrov et al. analyzed sequencing data in from 7,042 cancers and found A3 
kataegis-localized mutational signatures in acute lymphoblastic leukemia (ALL), lung 
adenocarcinomas, and breast, pancreas, and liver cancers [405]. We hypothesized that there 
may be different kataegis mutational signatures in B-cell lymphomas and chronic 
lymphocytic leukemia (CLL), so we re-analyzed the data accordingly. We found that B-cell 
lymphomas and CLL have an AID-specific mutational signature in kataegis regions (AGCT 
instead of TCA/T for other cancer types with kataegis clusters). This finding strongly links 
AID with genomic instabilities in B-cell malignancies. 
 In this article, we demonstrated a clear link between AID expression and genomic 
uracil as well as identified an AID mutational signature in CLL and B-cell lymphomas. The 
work we presented provides a strong piece of evidence to the theory that enzymatic DNA 
cytosine deamination is a major contributor to genomic instability in cancer. 
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10. DISCUSSION 
10.1 SMUG1 plays a larger role in uracil repair in mice than in humans 
There are significant differences in uracil processing between mouse and man that 
should be recognized before any conclusions are made using mouse models. Nevertheless, 
the overall uracil excision mechanisms between the two species seem to be similar enough 
for significant insight to be gained by using mouse models. The major difference between 
man and mouse seems to be the extent to which SMUG1 serves as a backup uracil-DNA 
glycosylase in mouse. UNG2 levels are lower in mice in general, so SMUG1 may act more as 
a partner with a large degree of overlapping function than a backup in mice. This is in part 
evidenced by the residual CSR activity in Ung-/- mice (5 % of wild type) that is much less 
pronounced in UNG-deficient humans [215]. Furthermore, we showed in article III that 
SMUG1 alone is sufficient to maintain physiologically low genomic uracil levels in mice. 
Thus, UNG deficiency, dysfunction, or deregulation may play a larger role in humans by 
inducing a more pronounced increase in the genomic uracil burden and therefore increasing 
overall genomic instability. 
We showed in article III that either UNG or SMUG1 are sufficient to maintain 
genomic uracil at near wild type levels, but this has not been shown in humans. Given that 
UNG2 seems to play a larger role in human cells, its inactivation may predispose cells to 
uracilation more than in UNG-deficient mouse cells. Unlike Ung-/- mice, UNG-deficient 
humans likely still express some form of the enzyme, albeit mutated. Thus, it may be 
incorrect to assume that UNG2 dysfunction in humans could be mitigated by SMUG1 in the 
same way that it is in Ung-/- mice because mutated UNG2 may still outcompete SMUG1 in 
uracil binding, thereby negating its effects as a backup glycosylase. Such a situation may not 
be well reflected in vitro because of the relatively high abundance of uracil in most assays.  
10.2 AID deamination causes uracil accumulation in B-cell malignancies 
AID can be a major contributor to the genomic uracil load in B-cells. We (in article 
IV) and Shalhout et al. showed that AID and genomic uracil levels correlated well in 
lymphoma cell lines [259]. Moreover, genomic uracil levels could be attenuated by 
attenuating AID levels, i.e. exogenous AID overexpression or endogenous AID induction by 
cytokine stimulation increased genomic uracil levels, while AID knockdown decreased uracil 
levels. Uracil-DNA glycosylase expression and uracil excision activity did not correlate as 
well with genomic uracil as AID expression, so it is tempting to conclude that AID 
deamination overwhelms BER in the cell lines we tested. On the contrary, the lymphoma cell 
lines exhibited lower overall uracil excision activities, indicating that uracil excision was at 
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least partly compromised. Furthermore, the article by Shalhout et al. showed that genomic 
uracil levels are not increased after cytokine stimulation in primary B-cells. Thus, genomic 
uracil levels are a function of both uracil introduction (in this case by enzymatic deamination) 
and repair. 
Enzymatic cytosine deamination also increases the genomic uracil burden in patients. 
The torrent of publications since 2012 showing mutational signatures attributed to AID and 
APOBECs in cancers provide convincing evidence that genomic uracil is involved in cancer 
development and progression [401–409,416,417]. Shalhout et al. also demonstrated that AID 
and genomic uracil levels correlate well in B-cells from CLL patients [259]. Although we did 
not directly test patient samples, we found a mutational signature specific to AID instead of 
A3 in published B-cell lymphoma and CLL sequence data, which substantiates the role AID 
in increasing genomic uracil levels in B-cell malignancies. Interestingly, Shalhout et al. also 
found that UNG2 and SMUG1 expression levels varied little between tumor samples, so AID 
deamination seems to overwhelm uracil repair in these cells. The combined evidence points 
to a role of deaminase-induced uracil in B-cell malignancies, though whether and the extent 
to which enzymatic deamination leads to cancer or is a byproduct of dysregulated DNA 
damage repair remain unknown.  
It remains unclear whether uracil repair is a targeted event. In normal CSR, AID and 
UNG2 are recruited to S regions, so uracilation is likely a transient event in which uracils are 
quickly added by AID and partially removed by UNG2 [418,419]. Thus, both an attenuation 
of UNG2 or AID levels and a dysregulation of scaffolding or recruitment proteins can alter 
the genomic uracil burden. There is no evidence that APOBECs other than AID are recruited 
to specific DNA regions or that they co-localize with and uracil-DNA glycosylase, so their 
activity likely leaves uracils scattered throughout the genome in both ssDNA and dsDNA 
contexts. UNG2 or SMUG1 must then scan the entire genome for uracils before the next 
replication cycle, which may be too high a burden for the glycosylases to remove all the 
uracil. Thus, unless uracil-DNA glycosylases are targeted to uracilation sites like UNG2 
during antibody maturation, even proficient BER may not be sufficient to remove uracils 
resulting from enzymatic deamination. The result of APOBEC or untargeted AID 
deamination could therefore be only trickle of uracils resulting from only partial repair of 
enzymatically deaminated cytosines. Furthermore, a cell may experience different levels of 
susceptibility to uracil accumulation, e.g. if glycosylase levels are low. The consequent 
genomic instability could help drive cancer development or progression. Future research 
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should therefore focus on elucidating the relative contributions of uracil introduction versus 
uracil repair in increasing the overall genomic uracil load. 
10.3 The importance of accurate absolute genomic uracil quantification 
In light of the apparent involvement of genomic uracil in cancer, it is crucial that 
groups employ standardized methods for genomic uracil measurement. Of the recent 
publications dealing with deaminase-induced kataegis, only Burns et al. measured genomic 
uracil [403]. They used UNG to excise uracil and measure it by LC/MS/MS on two breast 
cancer cell lines high in A3B expression. They found that very high A3B-expressing cell 
lines contained 15 to 20 Ura per 106 dN, whereas our results in article IV from high AID-
expressing cell lines contained up to 4 dUrd per 106 dN, which was 72-fold higher than cells 
with low AID expression. The large difference between our results could be explained 
biologically: A3B may introduce more uracils than AID and/or they may not be excised as 
efficiently in the cells we tested. On the other hand, technical variations in our two methods 
may have influenced the results. For example, it has been reported by the Ames group that 
free uracil may contaminate samples during assay preparations (e.g. during vacuum 
centrifugation) [413,420]. Such a contamination may be systematic and therefore not affect 
the conclusions derived from the assay; however, a general overestimation of genomic uracil 
by one group precludes direct comparison of their results with another group’s results. This is 
further exemplified by the article by Shalhout et al. that measured genomic uracil levels and 
AID expression in very similar samples (including some of the same cell lines) to our article 
IV [259]. They did not provide absolute uracil quantification, so although their results look 
similar to our own in that AID and genomic uracil levels correlate, albeit with a more 
pronounced difference between high and low uracil samples, we cannot directly compare our 
data. 
Perhaps more strikingly, our own uracil measurements exhibited some variation. We 
reported that wild type MEFs contained ~0.1 and ~2 dUrd per 106 dN in articles II and III, 
respectively. The main difference in the two measurements was that UNG2 deuracilated 
DNA was not used as a control in article III. Thus, some the dUrd measured was likely 
generated in vitro during sample preparation. The high uracil values in e.g. Ung-/-Smug1-/- 
organs were less affected by the overestimation because in assay uracilation is subtracted 
from (and not divided by) dUrd measurements to give the final value, but lower wild type, 
Smug1+/-, and Smug1-/- values may have been overestimated and are thus not comparable to 
the uracil values in articles II and IV.  
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It is therefore important to strive towards a universally accepted “gold standard” 
uracil assay that accurately quantifies the absolute genomic uracil levels so that values may 
be compared between different groups. Currently, no direct comparisons can be made using 
data from different groups unless within a relative context (i.e. perturbed versus unperturbed 
samples). TDG is thought to only excise U:G, so it may be employed to distinguish between 
U:A and U:G given a high enough U:G specificity. TDG’s turnover rate is much slower than 
that of UNG2, but it has been shown to increase in vitro when SUMOylated or with the 
addition of APE1, making it more suitable for uracil quantification [133–136,421]. Several 
groups have also made efforts to quantify genomic uracil within specific genes, although it is 
unclear whether their methods have the resolution to measure basal genomic uracil levels 
[422–424]. Regardless of this, it is clear that genomic uracil measurements will likely yield 
substantial insights into cancer biology, so standardizing the methods employed is crucial to 
this end. We have made substantial progress in this field, but there remains room for 
improvement. 
10.4 Final thoughts: translating genomic uracil research to the clinic 
The role of genomic uracil in cancer has potential applications in the clinic, but first 
several key questions need to be answered: at what stages of cancer is uracilation occurring, 
on what factors does it depend, and when is it pathogenic? In the short term, APOBEC, repair 
protein, and uracil levels could be compared to mutation data over time the better elucidate 
when uracil leads to mutation, as well as which factors affect its introduction and 
mutagenicity. Such a study would require large, well-stratified cohorts with multiple tumor 
samples gathered over time e.g. before and after treatment, disease progression, or even onset 
of disease. From this, it may be possible to partly elucidate what role uracilation is 
responsible for in cancer development, treatment response, or disease progression. Genomic 
uracil or factors that lead to uracilation like high APOBEC or low uracil-DNA glycosylase 
levels could then be employed as biomarkers that give prognostic insight into e.g. cancer risk, 
therapy response, or risk of disease progression. More optimistically, novel therapeutic 
strategies could target uracilation pathways to both increase or decrease genomic uracil. 
Decreasing genomic uracil in cancer or pre-cancer cells by e.g. inhibiting enzymatic 
deamination could decrease risk of disease progression by eliminating a source of genomic 
instability. Alternatively, increasing genomic uracil by e.g. TS-inhibition could target cancer 
cells already rich in uracil to overwhelm DNA damage repair and induce apoptosis.  
The exciting developments in the field of genomic uracil in the last several years have 
propelled the field into the limelight. Here I have presented data indicating that the generation 
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genomic uracil is a complex phenomenon and its consequences affect both immunity and 
cancer. Moreover, the enzymes involved in genomic uracil regulation also have important 
roles in epigenetic regulation. Future research will likely take advantage of genomic uracil in 
disease prevention, diagnosis, and treatment. 
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Considerable  progress has  been  made in  understanding  the  origins  of genomic uracil and its role  in
genome  stability and  host  defense;  however,  the main question  concerning  the basal level of  uracil in
DNA  remains  disputed.  Results from  assays  designed  to quantify  genomic uracil vary by almost three
orders of magnitude.  To  address the issues  leading to this  inconsistency,  we explored possible  short-
comings  with  existing  methods  and developed a  sensitive  LC/MS/MS-based  method  for the  absolute
quantiﬁcation  of genomic 2′-deoxyuridine  (dUrd). To  this end,  DNA was  enzymatically hydrolyzed  to
2′-deoxyribonucleosides  and dUrd  was  puriﬁed  in  a  preparative  HPLC  step  and analyzed  by LC/MS/MS.
The  standard curve was  linear over  four orders of magnitude  with  a  quantiﬁcation  limit of  5 fmol dUrd.
Control  samples demonstrated  high inter-experimental accuracy (94.3%)  and precision  (CV 9.7%). An
alternative  method that employed  UNG2 to excise uracil from  DNA for LC/MS/MS  analysis  gave  similar
results,  but  the  intra-assay variability  was  signiﬁcantly  greater. We  quantiﬁed genomic dUrd in  Ung+/+
and Ung−/− mouse embryonic ﬁbroblasts and human  lymphoblastoid cell lines carrying UNG  mutations.
DNA-dUrd  is 5-fold  higher in  Ung−/− than  in Ung+/+ ﬁbroblasts  and 11-fold  higher in  UNG2  dysfunctional
than  in  UNG2 functional  lymphoblastoid cells. We  report approximately  400–600 dUrd  per human or
murine genome in repair-proﬁcient  cells,  which is lower than results  using other methods  and suggests
that  genomic  uracil  levels may  have previously  been  overestimated.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.
1. Introduction
Deamination of  2′-deoxycytidine (dCyd) and misincorpora-
tion of  2′-deoxyuridine 5′-monophosphate (dUMP) are the major
sources of 2′-deoxyuridine (dUrd)/uracil (U) in the mammalian
genome [1]. The former creates U:G mismatches and occurs spon-
taneously, mainly via direct nucleophilic attack of the  hydroxyl ion
on the protonated base under physiological conditions, by exposure
to various chemicals, or  enzymatically by activation induced cyti-
dine deaminase (AID), APOBEC1, and possibly other members in  the
APOBEC family [2,3]. Unrepaired U:G mismatches result in C to T
transitions during replication, the most frequent type of  mutation
Abbreviations: LC/MS/MS, liquid chromatography coupled to tandem mass spec-
trometry; UNG, uracil-DNA glycosylase encoded by the UNG-gene; dCyd/dUrd/Dn,
2′-deoxycytidine/2′-deoxyuridine/2′-deoxyribonucleoside.
 This is  an open-access article distributed under the terms of the Creative Com-
mons Attribution-NonCommercial-No Derivative Works License, which permits
non-commercial use, distribution, and  reproduction in  any medium, provided the
original author and source are credited.
∗ Corresponding author. Tel.: +47 72573074; fax: +47 72576400.
E-mail address: hans.krokan@ntnu.no (H.E. Krokan).
1 Joint ﬁrst authors.
in human cancers [4]. Alternatively, dUMP misincorporation cre-
ates U:A pairs, depends on the dTTP/dUTP ratio at the  time of DNA
replication, and is governed by thymidylate synthase and dUTPase
activities [5]. U:A pairs may  be cytotoxic due to altered binding of
transcription factors and indirectly mutagenic through generation
of abasic sites [6–9].
Genomic dUrd is generally treated as a lesion that can be cor-
rected by base excision repair with  mismatch repair  as  a  likely
backup for U:G mismatches [1,10,11]. Nevertheless, dUrd is also
a  key intermediate in adaptive immunity. In  this process, dUrd
is generated by  AID-mediated dCyd deamination, which targets
variable and switch regions of  immunoglobulin genes in  B-cells
during somatic hypermutation (SHM) and class switch recombi-
nation (CSR), respectively [12].  This is  a  risky process because
off-target deamination may  cause mutations and translocations,
ultimately culminating in B-cell lymphomas [13–15]. Importantly,
the translocations occur at the  DNA damage sites [16]. Furthermore,
infection- and/or inﬂammatory cytokine-driven AID expression
may contribute to carcinogenesis in epithelial cells [17–19].
The emerging signiﬁcance of  genomic uracil thus calls for an
accurate and reliable method for its quantiﬁcation. Most  estab-
lished methods are relative, which precludes comparisons between
experimental batches and different laboratories [6,12,20–25].
1568-7864/$ – see front matter ©  2013 The Authors. Published by Elsevier B.V. All rights reserved.
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Direct quantiﬁcation of absolute levels of  genomic uracil can  be
achieved using mass spectrometry. There are two main approaches:
detection of U excised from DNA by UNG and detection of dUrd after
enzymatic hydrolysis of  DNA to  2′-deoxyribonucleosides (dNs)
[26–32]. Both strategies are seemingly straightforward, but a  wide
variation in estimates has been reported, ranging from 3  × 103 to
4 × 106 uracils per mammalian genome [31,33].  It  has been sug-
gested that the inconsistency in reported genomic uracil levels may
be due to  differences in sample type, but may also emanate from
technical shortcomings of  the employed methods [33].
Here we present an improved LC/MS/MS-based method for  the
absolute quantiﬁcation of dUrd in DNA and discuss drawbacks of
related methods. We explore the  issues that may  lead to inaccu-
rate estimation of genomic U and ameliorate them by introducing
steps for specimen clean-up and chromatographic modiﬁcations.
Additionally, we compare dUrd quantiﬁcation by DNA hydrolysis
to U quantiﬁcation by UNG excision. We lastly applied our method
to quantify genomic dUrd in  Ung+/+ and Ung−/− mouse embryonic
ﬁbroblasts, as well as  human lymphoblastoid cell lines derived
from hyper-IgM patients carrying UNG mutations. We measured
genomic uracil values lower than those previously reported, indi-
cating that previous methods may  have overestimated genomic
uracil.
2. Material and methods
2.1. Reagents
2′-Deoxyuridine, 2′-deoxycytidine, 2′-deoxyadenosine, 2′-
deoxyguanosine, thymidine, alkaline phosphatase, nuclease
P1, and BSA were  from Sigma–Aldrich (Steinheim, Germany);
DNase I was from Roche Applied Science (Mannheim, Germany);
UltraPureTM salmon sperm DNA was from Invitrogen Corpora-
tion (Carlsbad, CA, USA). Recombinant uracil-DNA glycosylase
(UNG84) was puriﬁed in-house as  previously described [34].
[2-13C;1,3-15N2]-2′-deoxyuridine was from  C/D/N Isotopes
(Pointe-Claire, Quebec, Canada).
2.2. Cell lines
Ung+/+ and Ung−/− mouse embryonic ﬁbroblast cell lines [35]
were cultured in DMEM 4500 mg/l d-glucose, supplemented
with 0.29 mg/ml  l-glutamine, 10% fetal bovine serum,  100 U/ml
penicillin, 0.1 g/ml streptomycin, and 2.5 /ml  amphotericin
B in a humidiﬁed 5% CO2 incubator at  37 ◦C. Epstein–Barr
virus immortalized human lymphoblastoid cell lines [36], a
gift from Dr. Anne Durandy (Institut National de la Santé
et de la Recherche Médicale, Paris, France), were cultured
in RPMI–1640 + GlutaMaxTM-l medium supplemented with 10%
heat-inactivated bovine serum, 100 U/ml penicillin, 0.1 mg/ml
streptomycin, and 2.5 g/ml amphotericin B.
2.3. DNA isolation and removal of intracellular
2′-deoxyribonucleotides
Cells (106/80 l) were lysed in 10 mM Tris-HCl (pH 8.0), 10 mM
NaCl,  0.5% SDS, 2.5 mM DTT, 0.25 g/l  proteinase K, 0.1 g/l
RNase A and incubated at 37 ◦C for  1  h  with shaking at  250 rpm.
Genomic DNA was extracted in phenol:chloroform:isoamyl alcohol
(25:24:1) and chloroform:isoamyl alcohol (24:1), then precipitated
by  adding 0.3 volume equivalents of 10 M ammonium acetate (pH
7.9) and one volume equivalent of 100% isopropanol, washed once
in 70% ethanol, and buffered with 100  mM  ammonium bicarbonate
(pH 7.6) and 1 mM  MgCl2. Where indicated, DNA was isolated from
cell pellets using the DNeasy® Blood and Tissue kit (Qiagen, Hilden,
Germany) according to  the manufacturer’s instructions except for
increasing the  RNase A  concentration to 0.1 g/l and decreasing
the temperature during incubation with AL buffer from 56 to
37 ◦C. Potentially co-isolated intracellular 2′-deoxyribonucleotides
were dephosphorylated by incubation with alkaline phosphatase
(pH 7.6) from Escherichia coli (0.2 U/l) in  100  mM  ammonium
bicarbonate for 30 min  and DNA precipitated with isopropanol as
described above.
2.4. DNA hydrolysis to 2′-deoxyribonucleosides
DNA was enzymatically hydrolyzed to  dNs. Prior to hydroly-
sis, a  control DNA sample was  deuracilated by treatment with
UNG to control for uracil generated in vitro during the assay.
To this end, up  to  15 g  DNA were buffered with 20 mM Tris-
HCl (pH 7.5), 60 mM  NaCl, 1 mM  DTT, 1 mg/ml  BSA in a  reaction
volume of 30 l and treated with 0.075 U UNG84  at  37 ◦C for
1 h. The DNA was isopropanol precipitated as described in 2.3
and resuspended in  30 l 100 mM  ammonium acetate (pH 6.0),
10 mM  MgCl2,  and 1 mM  CaCl2 containing 2  U DNase I and 0.2 U
nuclease P1  and  incubated for 30 min  at 37 ◦C.  As an internal
standard [2-13C;1,3-15N2]-2′-deoxyuridine was used. The sam-
ples were then buffered in ammonium bicarbonate (pH 7.6) to
a ﬁnal concentration of 100 mM,  and incubated for 20 min  at
37 ◦C with 0.1 U alkaline phosphatase from  E.  coli. To precipi-
tate contaminants that could potentially clog the HPLC column,
three volume equivalents of  ice-cold acetonitrile were added to
the samples, which were then centrifuged (16,100 ×  g, 20  min,
4 ◦C). The supernatants were transferred to  new tubes and vac-
uum centrifuged until dry at room temperature. The samples
were ﬁnally dissolved in 100 l water containing 10% acetoni-
trile.
2.5. Preparative puriﬁcation of  2′-deoxyuridine
dUrd was puriﬁed by HPLC prior to LC/MS/MS analysis. The
puriﬁcation was performed using a reverse-phase column with
weak acidic ion-pairing groups (Primesep 200, 2.1 mm × 150 mm,
5 m,  SIELC Technologies, Prospect Heights, IL), kept at 35 ◦C, on
an Agilent 1200 series HPLC system, equipped with a  G1365D
multiple wavelength detector (Agilent Technologies, Waldbronn,
Germany). Samples were maintained at 4 ◦C prior to  injection.
Each sample was injected in triplicate with an injection volume
of 30 l.  The gradient used consisted of solvent A  (water, 0.1%
formic acid) and B (methanol, 0.1% formic acid) starting at 10%
B for 0.5 min, ramping to 60% B over 6 min, holding at 60% B for
4 min, and re-equilibrating with 10% B for 10 min  at  a  ﬂow  rate
of 0.200 ml/min. dNs were quantiﬁed by measuring absorption
at  260 nm.  The fractions containing dUrd and IS  were collected
±1 min  with a Foxy R2 fraction collection system (Teledyne ISCO,
Lincoln, NE,  USA)  and vacuum centrifuged until  dry at  room tem-
perature. The samples were dissolved in  25 l  water containing 5%
methanol.
2.6. Uracil excision
Uracil was  excised from DNA for direct analysis by LC/MS/MS
to compare uracil excision with  DNA hydrolysis as  in  an alterna-
tive strategy for DNA-uracil quantiﬁcation. The uracil excision and
quantiﬁcation protocol was modiﬁed from Bulgar et al.  [26]. Up to
15 g  DNA were buffered with 20 mM Tris-HCl (pH 7.5), 10 mM
NaCl, 1  mM DTT, 1 mg/ml  BSA in a  reaction volume of 40 l  and
treated with 0.075 U UNG84 at 37 ◦C for 1 h. The NaCl concen-
tration used was  different from that used for  DNA deuracilation
described above to avoid signal loss by ion suppression during
LC/MS/MS. [2-13C,15N2]-Uracil was used as internal standard. After
incubation with UNG, 500 l ice-cold acetonitrile were added to the
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samples and they were then centrifuged (16,100 × g,  20  min, 4 ◦C).
The supernatants were transferred to  new tubes and vacuum cen-
trifuged until dry at room temperature. The samples were ﬁnally
dissolved in 40 l 10% 2 mM  ammonium formate 90% acetonitrile.
2.7. LC/MS/MS instrumentation and conditions
Both dUrd and uracil were quantiﬁed using an LC-20AD HPLC
system (Shimadzu Corporation, Kyoto, Japan) coupled to an  API
5000 triple-quadrupole mass spectrometer (Applied Biosystems,
Carlsbad, CA, USA) operated under the  multiple reaction monitor-
ing (MRM)  mode.
dUrd was quantiﬁed using a  Zorbax SB-C18 reverse phase
column at room temperature (2.1 mm × 150 mm,  3.5 m,  Agi-
lent Technologies, Santa Clara, CA, USA), protected with a  Zorbax
Reliance guard-column (4.6 mm ×  12.5 mm,  Agilent Technologies).
The injection volume was 20  l.  The gradient used contained sol-
vent A  (water, 0.1% formic acid) and B (methanol, 0.1% formic acid)
starting at 5% B for 0.5 min, ramping to 90% B over  6 min, holding at
90% B for 1.5 min and re-equilibrating with 5% B  for  5  min  at a ﬂow
rate of  0.300 ml/min. Mass spectrometry detection was performed
using positive electrospray ionization, monitoring the mass tran-
sitions 229.2 → 113.0 and 232.2 → 116.0 for  2′-deoxyuridine and
[2-13C,1,3-15N2]-2′-deoxyuridine, respectively.
For the alternative uracil-release method, uracil was  quantiﬁed
using a  hydrophobic interaction liquid chromatography column
(2.1 mm ×  100 mm,  3.5 m,  Atlantis HILIC Silica column, Waters
Corporation, Milford, MA,  USA). The injection volume was 10 l
and the HPLC was run  at 0.200 ml/min isocratically with 95%
acetonitrile and 5% 2 mM ammonium formate. Detection was  per-
formed using negative electrospray ionization, monitoring the
mass transitions 110.9 →  41.9 and 114.1 →  43.9 for  uracil and [2-
13C,1,3-15N2]-uracil, respectively.
3.  Results
3.1. Method development
3.1.1. MS/MS analysis
We used tandem mass spectrometry to validate our method’s
speciﬁcity. MS/MS  spectra revealed ions with m/z  values of  113.0
and 116.0, which correspond to the uracil and isotopically labeled
base in  the internal standard (IS), respectively. The m/z values 117.0,
99.0, and 81.1 were found in  both dUrd and IS  and correspond
to 2-deoxyribose and 2-deoxyribose without one or two water
molecules, respectively (Fig. 1A).
3.1.2. A  precursory HPLC step is essential for  sample purity
The analysis of  dUrd is complicated by naturally occurring
[13C]-2′-deoxycytidine ([13C]-dCyd), which is isobaric with dUrd.
Although dUrd and  dCyd are apparently well separated by reverse-
phase chromatography, the relative abundance of dCyd over dUrd
in DNA is so high that  the  [13C]-dCyd peak tail (∼1.1% of  all car-
bon) will obfuscate the dUrd peak, consequently interfering with
the  subsequent MS analysis. To circumvent this problem, we  used
a reverse-phase column with embedded weak acidic ion-pairing
groups (hereafter referred to by its brand name, Primesep 200),
with which dUrd elutes well before dCyd (Fig. 1B). However, dUrd
is  weakly retained in  the  column and elutes near or  with the
void volume, resulting in ion suppression from ions present in
the reaction buffer, which compete for ionization with the ana-
lyte of  interest (dUrd, data not shown). To avoid this, we  employed
a  precursory HPLC step with a  Primesep 200 column to  rid the
samples of dCyd and increase sensitivity and then analyzed the
dUrd concentration with a  reverse-phase C18 column coupled
to a  mass spectrometer. We  also tested a  standard C18 column
for the precursory HPLC step, but found that enough dCyd co-
eluted with the dUrd fraction that dCyd deamination occurred
Fig. 1. Optimized LC/MS/MS conditions ensure method speciﬁcity. (A) MS/MS spectra of 2′-deoxyuridine (m/z 229) and [2-13C,1,3-15N]-2′-deoxyuridine (m/z 232.1) showing
parent  [MH]+ to product ion  transitions. The proposed origins of key fragments are  indicated. Note  that the collision energy was  tuned to  acquire spectra with more
fragments  to demonstrate the fragmentation pattern of dUrd. The ﬁnal  settings were optimized for  the speciﬁc mass transitions analyzed. (B) Effect of precursory HPLC
step  with PrimeSep 200 and standard reverse phase C18 columns on LC/MS/MS chromatograms. Note that both chromatograms represent the same data displayed with a
different  y-axis scale. In the  lower panel, the range to 1.5 × 104 has been expanded to  visualize chromatographic tailing and  the problems related to [13C]-dCyd when using
C18  column for pre-HPLC. The dUrd peak is  obscured by the [13C]-dCyd peak tail  in  the absence of fractionation (dashed red line). Using both C18 (solid black line) and
Primesep 200 (solid blue line) columns overcome dUrd peak obfuscation by the  [13C]-dCyd peak, but the C18 column retains some dCyd, leading to a [13C]-dCyd peak in  the
LC/MS/MS step as  well as a higher dUrd peak, probably due to  dCyd deamination.
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Table  1
Summary of statistics for method validation. Deuracilated salmon sperm DNA
samples were spiked with 5,  15, and 100 fmol dUrd to determine accuracy and
intra/inter-day precision.
dUrd spike
(fmol)
Accuracy (%
theoretical value)
Intra-day
precision (CV %)
Inter-day
precision (CV %)
5 94.0 13.6 15.0
15  97.0 13.1 12.4
100  91.9 2.6 2.6
Mean 94.3 9.7 10.0
n  18 6 18
between the precursory HPLC step and the  LC/MS/MS analysis
(Fig. 1B).
An additional advantage of employing a  precursory HPLC step is
that it provides a  convenient opportunity to  quantify all dNs prior
to  LC/MS/MS analysis, thereby allowing accurate quantiﬁcation of
dUrd per dNs. We  compared the  DNA concentration measured by
spectrophotometry of  5 g salmon sperm DNA with the calculated
concentration by HPLC-UV on three separate days  and found 99.9%
recovery after hydrolysis with a CV of 8.34%.
3.1.3. Determination of range, linearity, detection limit, precision,
and accuracy
We determined the range, linearity, and detection limit for
dUrd quantiﬁcations by making standard curves in both water and
deuracilated DNA. Triplicate standard curves of dUrd in water con-
taining 5–200 fmol dUrd and 40 fmol IS were analyzed on three
different days (r2 = 1.0000), demonstrating near perfect linearity
(Supplementary Fig. 1).  Deuracilated DNA prepared by  UNG-
treatment and isopropanol precipitation of  5  g  salmon sperm DNA
was spiked with 5, 15, and 100 fmol dUrd and assayed in sets of
six replicates. The mean observed accuracy for these samples was
94.3%, and the  intra- and inter-day CV values were 9.7 and 10%,
respectively. The lower limit of quantiﬁcation was found to  be
5  fmol dUrd (CV 15% n  = 18).  The data are summarized in Table 1.
Supplementary data associated with this article can be
found, in  the online version, at http://dx.doi.org/10.1016/j.dnarep.
2013.05.002.
3.1.4. Sample contamination with intracellular
2′-deoxyribonucleotides causes overestimation of genomic dUrd
We  tested whether cellular dUMP and dCMP could possibly
interfere with dUrd analysis due to co-puriﬁcation with DNA.
Importantly, dCMP and dCyd (as well as dCyd in ssDNA) are deam-
inated more than two orders of  magnitude faster than dCyd in
dsDNA [3].  To this end, we pre-treated DNA samples with alkaline
phosphatase and then precipitated the  DNA. Our hypothesis was
that dUMP and dCMP would co-purify with DNA to a larger extent
than dUrd. Indeed, we found that up to 98% of measured dUrd in
commercially prepared DNA was removed after phosphatase treat-
ment and precipitation (Fig. 2A). DNA isolated in  our laboratory
showed similar results (data not shown).
3.1.5. Overcoming dCyd deamination during sample work-up
Three main factors have been demonstrated to  affect cytosine
deamination in  puriﬁed DNA samples: temperature, pH, and the
degree to which DNA is  denatured [3,37,38]. Taking this into con-
sideration, we made efforts to minimize dCyd deamination during
sample work-up and analysis. Several methods used by other
laboratories involve heat-denaturation of  DNA prior to enzymatic
hydrolysis [27]. We  found that DNA denaturation by heating to
95 ◦C for 5–20 min  increases the  dUrd signal approximately 1.7-
and 2.7-fold, respectively (Fig. 2B). To avoid deamination during
work-up and analyses, we optimized reaction time and buffer
conditions, concluding with enzymatic hydrolysis at  pH 6–7.6
and 37 ◦C for  50 min  using DNase I,  nuclease P1, and alkaline
phosphatase. To test the rate  at which dUrd is introduced under
these reaction conditions, we assayed the amount of dUrd gen-
erated during sample analysis over time. We  found a  constant
deamination rate of  4.805 ×  10−3 ± 5.9 ×  10−5 dUrd/106 bp/min
(R2 =  0.9964, n =  12, Fig. 2C).  This corresponds to  1.059 × 10−2
dUrd/106 dCyd/min, which is in line with previously reported
values of dCyd deamination rates of 2.6 × 10−2, 1.2 × 10−3,
and 4.8 ×  10−5 dUrd/106 dCyd/min for  deoxyribonucleosides,
single-stranded DNA, and double-stranded DNA, respectively
[3]. Subtracting the deuracilated DNA control from the normal
samples yielded a constant value regardless of the  time point (0.66
dUrd/106 bp); however, the  variation between replicate experi-
ments increased with  reaction time due to  increasing background.
Thus, we included a  deuracilated DNA control in all sample batches
to control for in vitro-generated dUrd.
It has been reported that alkaline phosphatase contained mea-
surable dCyd deaminase activity [28,29]. We  substituted dCyd for
DNA to  the equivalent of  ∼2  g  (10.5 nmol) and carried out  mock
hydrolysis with all enzymes, only alkaline phosphatase, and no
enzymes. The amount of  dUrd per dCyd in  the untreated samples
was statistically indistinguishable from  that of  the  samples con-
taining either all  enzymes or  only alkaline phosphatase (data not
shown), which strongly suggests that none of  the  enzyme prepa-
rations employed contained dCyd deaminase activity under our
reaction conditions. We therefore did not employ dCyd deaminase
inhibitors.
3.1.6. dUrd quantiﬁcation by DNA hydrolysis is more robust than
U quantiﬁcation by U excision
Several groups have employed UNG to excise uracil for GC
or LC/MS analysis [26,32]. To compare this strategy to the  dUrd
method, we  used UNG to excise U  from DNA and measured U
by a  hydrophobic interaction chromatography column coupled to
the same mass spectrometer used for dUrd quantiﬁcation. First,
we spiked U  into deuracilated DNA and determined that the  limit
of  quantiﬁcation for this assay was 5  fmol.  Then, we measured
genomic U in DNA that had been heated to  95 ◦C. The results
were similar to those obtained by DNA hydrolysis (Fig. 2B). We
also assayed genomic uracil using both  the DNA hydrolysis and U
excision on DNA isolated using either phenol:chloroform:isoamyl
alcohol isolation or a column-based kit (Supplementary Fig. 2). The
level of genomic dUrd was  similar regardless of  the DNA isolation
method when assayed using the  DNA hydrolysis method, but signif-
icantly different in UNG2 deﬁcient cells when using the U excision
method (P = 0.0275, n  = 3). This indicates that DNA hydrolysis is both
more robust and reproducible than the U excision method.
Supplementary data associated with this article can be
found, in the  online version, at  http://dx.doi.org/10.1016/j.dnarep.
2013.05.002.
3.2. Genomic uracil in human and mouse cells proﬁcient or
deﬁcient in UNG-activity
We tested the biological applicability of our method by compar-
ing the levels of genomic dUrd in mammalian cell lines. First,  we
compared two lymphoblastoid cell lines: one with UNG-deﬁciency
derived from a patient with a homozygous mutation substituting
Ser with Phe (UNG2-F251S) and one with functional UNG derived
from an individual with a  heterozygous mutation substituting Arg
with Cys (UNG2-R88C) [36].  The UNG2-R88C mutation has recently
been reported in the NCBI SNP database (rs151095402) with a
frequency of  the C/T heterozygote of  0.003 in  a cohort of  >1500 indi-
viduals in  the NHLBI Exome Sequencing Project. Furthermore, the
UNG2-R88C cell line’s overall uracil excision activity has been mea-
sured and is comparable to  that in  other UNG-WT human tissues
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Fig. 2. Sample contamination with intracellular 2′-deoxyribonucleotides and in vitro dCyd deamination leads to overestimation of genomic dUrd. (A) Alkaline phosphatase
(AP)  pretreatment of commercially prepared DNA followed by  repeated isopropanol precipitation steps prior to  DNA hydrolysis decreases the ﬁnal genomic dUrd value.
(B)  Denaturation of salmon sperm DNA by heating at  95 ◦C in water induces dCyd deamination and  increases genomic dUrd or U  content in  time-dependent manner. (C)
Prolongation  of sample work-up procedure increases the amount of measured dUrd. Salmon sperm DNA samples as well as  deuracilated controls were hydrolyzed at pH
6–7.6  and 37 ◦C for  50 min, 6  h, and 9  h. In  vitro dCyd deamination occurs at  the constant rate of 4.805 × 10−3 dUrd/106 bp/min. Results represent triplicate experiments ±SD.
and cell lines, whereas the UNG2-F251S is devoid of in vitro uracil
excision activity [39,40]. We  assayed genomic dUrd in  these human
cell lines in three separate experiments and found an  11-fold higher
level of  dUrd per base pair in  the  UNG2-F251S line (1.10 ± 0.13
dUrd/106 bp,  CV 11.6%), as compared with the  UNG2-R88 C line
(0.105 ± 0.014 dUrd/106 bp, CV 13%) (Fig. 3A).
We also quantiﬁed genomic dUrd in Ung-proﬁcient and
Ung-deﬁcient mouse embryonic ﬁbroblasts (MEFs) in  triplicate
experiments (Fig. 3B).  We  found a  5-fold higher genomic dUrd level
in the Ung−/− line (0.344 ±  0.023 dUrd/106 bp, CV 6.76%) as com-
pared with the Ung+/+ line (0.072 ± 0.006 dUrd/106 bp, CV 8.59%).
These experiments also suggest that other uracil-DNA glycosylases
(e.g. SMUG1, TDG, and MBD4 [1]) cannot compensate for the  lack
of uracil-DNA glycosylase activity in  the absence of UNG2.
4. Discussion
Although great progress has been made in  understanding the
mechanisms of base excision repair, quantitative information on
the genomic content of  the  DNA base lesions and intermedi-
ates involved has yielded highly divergent results. As  examples,
measurements of  genomic 8-oxo-7,8-dihydroguanine, uracil, and
abasic sites have given results varying by orders of magnitude for
each lesion [33,41–45].
Here, we have made efforts to  improve quantiﬁcation of
genomic uracil by mass spectrometry and ﬁnd that the  content is
lower than previously reported. Accurate quantiﬁcation of genomic
uracil is important to  understand its processing, whether present
as a  lesion or  as an essential intermediate in  antibody afﬁn-
ity maturation. The interplay between these two ﬁelds forms
the link  between adaptive immunity and oncogenesis that has
Fig. 3. Quantiﬁcation of genomic dUrd in  Ung+/+ and  Ung−/− mouse embryonic
ﬁbroblasts  and human lymphoblastoid cell lines carrying UNG mutations. (A) UNG2
dysfunctional lymphoblastoid cells (UNG2-F251S) had  11-fold higher genomic dUrd
level  than lymphoblastoid cells with functional UNG2 (UNG2-R88 C). (B) Genomic
dUrd  level was 5-fold higher in  Ung−/− than  in  Ung+/+mouse embryonic ﬁbroblasts.
Results  represent triplicate experiments ±SD.
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Fig. 4. Overview of possible errors in the methods for absolute quantiﬁcation of
genomic U/dUrd. (A) Intracellular 2′-deoxyribonucleotides can co-elute with DNA
and  be subsequently included in quantiﬁcation. (B)  Unspeciﬁc contaminants are
usually  more abundant with decreasing molecular weight of the  precursor ions.
(C)  Differential derivatization of standards versus samples may  lead to inaccuracies,
and  the efﬁciency of derivatization is  not controlled. (D) Inaccurate determination of
DNA  concentration may compromise quantiﬁcation. The extent of the uracil excision
reaction is not  monitored. (E) Denaturation of DNA by heating to 95 ◦C deaminates
dCyd  and overestimates the ﬁnal genomic dUrd measurement. (F) Deamination of
dCyd  occurs at  37 ◦C and  neutral pH. Extended incubation time during sample work-
up  may  artiﬁcially increase the amount of dUrd. (G) dCyd elutes before dUrd with
reverse-phase chromatography and may  therefore contaminate the dUrd fraction
due to peak tailing. dCyd may  then be deaminated prior to MS/MS analysis.
recently been established [13,15]. In  this sense, relative quantiﬁ-
cation of genomic uracil can be useful and in some cases preferable
to absolute quantiﬁcation. For instance, several assays are DNA
sequence-speciﬁc and can therefore shed light on speciﬁc AID
off-target effects [12,22]. Nevertheless, relative assays  hamper
comparison between data sets, and sequence-speciﬁc assays are
biased to the sequences they target. Indeed, the wide range of
reported values for genomic uracil suggests that reliable quan-
tiﬁcation of genomic uracil (as  free uracil or dUrd) is technically
problematic [31,33]. Therefore, all steps from cell lysis through
DNA isolation and analysis should be standardized and validated.
A schematic visualization of  the different approaches to genomic
uracil and dUrd analyses and steps at which errors may  arise is pre-
sented in  Fig. 4. The DNA isolation step can be a signiﬁcant error
source (Fig. 4A). We  noticed that isopropanol precipitation steps
reduced the  amount of  measured dUrd regardless of how DNA was
isolated. Adding alkaline phosphatase prior to  precipitation further
decreased the dUrd signal, presumably by removing intracellular
nucleotides (speciﬁcally dUMP and dCMP) co-purifying with  DNA.
As an alternative to DNA hydrolysis and quantiﬁcation of dUrd,
uracil can be excised using uracil-DNA glycosylase and directly ana-
lyzed by MS/MS  (Fig. 4B) [30,31].  Uracil is inherently more prone to
background signal in MS/MS  because it is a  heterocyclic molecule
that resonates between non-aromatic amide and aromatic imide
tautomers, the chemical bonds in which require more energy to
break than the N-glycosylic bond between U and the  deoxyribose
in dUrd. Consequently, the  additional collision energy required to
break up the uracil molecule results in a higher probability of mis-
taking contaminants for the analyte. In this sense, quantiﬁcation
of dUrd is advantageous to measuring U because the  abundance
of interfering components is  lower. Derivatizating U abrogates this
effect, but adds complexity because the degree to which U has  been
derivatized cannot easily be monitored. In  addition, it has proven
difﬁcult to establish robust conditions for derivatization to the
extent that different conditions have been required to derivatize
Fig. 5. Summary of improved genomic dUrd  quantiﬁcation. DNA isolation is
improved by avoiding sample heating at 56 ◦C.  A  phosphatase pre-treatment step
removes intracellular dCMP and dUMP, which otherwise co-purify with DNA. UNG2
is  used to deuracilate DNA as a control processed in  parallel to estimate whether
and how much dUrd is  generated during the analysis. DNA  hydrolysis to  dNs by
nuclease/phosphatase treatment is kept short and pH neutral. A precursory HPLC
step  efﬁciently removes dCyd from the sample. Together, it  signiﬁcantly improves
the  accuracy of the method.
biological samples and standards (Fig. 4C) [32]. Derivatization can
be circumvented by employing hydrophilic interaction chromatog-
raphy (Fig. 4D) [26]. We tested a  similar method and found the
sensitivity comparable to measuring dUrd by hydrolysis; however,
intra-sample variability was greater. Indeed, we compared DNA
samples isolated using different methods and found no variability
between DNA isolation methods when employing DNA hydrolysis,
whereas there was signiﬁcant difference using the U excision assay.
This may  result from our inability to gauge the  extent of the U  exci-
sion under these assay conditions, as well as imprecise estimation
of  the DNA concentration. In contrast, the  present DNA hydrolysis
method normalizes samples to the  amount of  dNs measured spec-
trophotometrically during the precursory HPLC step, which both
determines the extent to which DNA has undergone hydrolysis
and provides very  accurate determination of DNA concentration.
We performed hydrolysis with 5, 10, 15,  and 20  g  DNA and saw
no variation in dUrd measurements (data not shown). Moreover,
samples are minimally handled between precursory HPLC and
analytical LC/MS/MS, resulting in  better  reproducibility. Uracil exci-
sion is not necessarily inferior to DNA hydrolysis as a  DNA-uracil
quantiﬁcation method and  its shortcomings may  theoretically be
ameliorated by meticulous standardization of sample treatment,
but it is nevertheless more susceptible to  intra-lab or intra-sample
variations.
Employing DNA hydrolysis to  measure genomic dUrd has  been
reported previously [27–29]; however, the methods reported
are prone to  overestimation of  genomic dUrd content for  var-
ious reasons. DNA heat denaturation causes dCyd deamination
and therefore overestimates dUrd estimates several-fold (Fig. 4E)
[27].  The  dCyd-containing products deaminate orders of  mag-
nitude faster than double-stranded DNA during long incubation
times (6–9 h at 37 ◦C) required for complete enzymatic hydroly-
sis (Fig. 4F). We  optimized experimental conditions to only require
50 min  incubation at 37 ◦C. Decreasing this incubation time further
would potentially yield more accurate results. Finally, employment
of a  normal reverse-phase column for  precursory HPLC fraction-
ation of dNs with which dUrd elutes after dCyd results in a  risk of
dCyd contamination in  the dUrd fraction from peak tailing because
dCyd is so much more abundant than dUrd (Fig. 4G) [28]. The dCyd
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contamination is problematic both because [13C]-dCyd is isobaric
with dUrd and because dCyd may  deaminate to dUrd between
steps. To avoid that problem, we employed a  reverse-phase col-
umn  with weak acidic ion-pairing groups with which dUrd elutes
before dCyd. The precursory HPLC step may be omitted by com-
bining the  PrimeSep200 and C18 columns with  a column switcher.
A dual-column system would shorten the total analysis time and
decrease the likelihood of  dUrd contamination as  a  result of  sample
handling before LC/MS/MS analysis; however, the accuracy of the
assay would not necessarily increase. An overview of our improved
method is presented in Fig. 5.
We used the optimized conditions to measure dUrd in DNA
isolated from Ung+/+ and Ung−/− mouse embryonic ﬁbroblasts
and human lymphoblastoid cell lines derived from hyper-IgM
patients carrying UNG mutations. The  values reported for genomic
uracil here were lower than  those reported by other groups,
approximately 400–600 dUrd per human or  murine genome in
repair-proﬁcient cells [31]. Although this alone does not prove that
our method is superior to those previously published, our demon-
stration of  overestimation sources indicates that our method is
probably more reliable.
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Supplementary Figure Legends 1 
Supplementary Fig. 1. Standard curve used for genomic uracil quantification. A concentration gradient 2 
from 5 fmol to 10 nmol dU was used with 200 fmol 1313C15N2-dU as an internal standard. The R2 value 3 
was 1.000. Note that both plots represent the same data displayed with different y-axis scales. Results 4 
represent triplicate experiments ± SD. 5 
Supplementary Fig. 2. DNA hydrolysis is a more robust assay for genomic uracil than the uracil excision 6 
method. Both methods were employed to measure genomic uracil levels in DNA isolated from UNG2 7 
proficient and deficient cell lines using both a DNA extraction kit from Qiagen (DNeasy) and 8 
phenol:chloroform:isoamyl alcohol DNA isolation method (PCI). Results represent triplicate experiments ± 9 
SD. 10 
 11 
Supplementary figure 1
Su
pp
le
m
en
ta
ry
 fi
gu
re
 2

Article III

 ͳ
UNG AND SMUG1 EFFICIENTLY COMPLEMENT EACH OTHER IN REMOVING 
GENOMIC URACIL FROM MOUSE ORGANS 
 
Antonio Sarnoa#, Lene Alsøeb#, Anastasia Galashevskayaa, Laure Jobertb, Tanima SenGuptab, 
Sergio Carracedob, Nuriye Basdag Tekinb, Hans E. Krokana, Hilde Nilsenb 
 
aDepartment of Cancer Research and Molecular Medicine, Department of Medicine, 
Norwegian University of Science and Technology, Trondheim, Norway 
bInstitute of Clinical Medicine, Department of Clinical Molecular Biology, University of 
Oslo, and Akershus University Hospital, Lørenskog, Norway 
 
* Correspondence: Hilde Nilsen 
   Tel: +47-679xxxx 
   E-mail: hilde.nilsen@medisin.uio.no 
 
#These authors contributed equally to this work 
 
 
 
Key words: Uracil, 5-hydroxymethyluracil, SMUG1, UNG, Base Excision Repair, knockout 
mice, LC-MS/MS 
Running head: SMUG1 and UNG2 prevent accumulation of genomic uracil  
Character count:  
  
 ʹ
ABSTRACT 
Uracil in DNA is both a lesion and a necessary intermediate for antibody maturation. Uracil 
is primarily excised by the uracil-DNA glycosylase (UNG2) or single-strand selective 
monofunctional uracil DNA glycosylase (SMUG1), which initiate the error-free base 
excision repair pathway. The relative contributions of UNG2 and SMUG1 in limiting uracil 
accumulation have been difficult to resolve using biochemical approaches and remain an area 
of contention. Here, we used a genetic approach to clarify this issue: we generated gene 
targeted Smug1-/- mice and crossed them with the previously generated Ung-/- mice to 
generate Smug1-/-Ung-/- mice. We measured uracil excision activity and genomic uracil and 5-
hydroxymethyluracil (hmU) levels in mouse embryonic fibroblasts and organs from both 
single and double knock-out mice, as well as hmU excision activity in wild type and Smug1-/- 
MEFs and wild type organs. Expectedly, hmU excision activity was undetectable in Smug1-/- 
mice, and UNG was found to be the major contributor to uracil excision in most tissues. 
SMUG1 was the largest contributor to U:G, and more weakly to U:A excision in the brain, 
but its activity in other tissues was only apparent when UNG was inhibited. A slight 2-3-fold 
increase in genomic uracil was observed in UNG-deficient tissues, whereas genomic uracil 
levels from Smug1-/- mice were indistinguishable from isogenic wild type controls. In 
contrast, the Smug1-/-Ung-/- organs contained 3-20-fold more uracil than their wild-type 
counterparts. Our data suggests that low levels of genomic uracil are maintained by either 
UNG or SMUG1, despite their different activity levels. Thus, we postulate that physiological 
variations in glycosylase activity are not a major factor in increasing genomic uracil levels.  
 ͵
INTRODUCTION 
 Uracil is a natural intermediate in thymine biosynthesis. A small dUTP pool is 
therefore necessary, the consequence of which is occasional dUTP misincorporation in place 
of dTTP because DNA polymerases cannot distinguish between the two nucleotides 
(Friedberg et al., 1995). Genomic uracil is also generated by spontaneous and enzymatic 
cytosine deamination, generating U:G mispairs. dUMP misincorporation (generating U:A) is 
likely the larger contributor to the genomic uracil burden in proliferating cells, with an 
estimated ׽104 dUTP misincorporated per genome per division, whereas the spontaneous 
cytosine deamination rate is estimated to be 100 to 500 per cytosines per cell per day 
(Lindahl, 1993; Mosbaugh and Bennett, 1994). There is little evidence to indicate that U:A 
pairs arising from dUTP misincorporation are deleterious, though they have been shown to 
alter transcription factor binding and topoisomerase activity in vitro (Pourquier et al., 1997; 
Risse et al., 1989). In contrast, unrepaired cytosine-deamination events replicate to generate 
C:G to T:A mutations. Indeed, enzymatic deamination of cytosine by activation induced 
deaminase (AID) initiates somatic hypermutation (SHM) and class switch recombination 
(CSR) during immunoglobulin (Ig) diversification (Rada et al., 2002). Recent work has also 
shown that DNA mutational signatures associated with AID and other enzymes in the 
APOBEC-family are present in a wide variety of cancers, suggesting a role for enzymatic 
DNA cytosine deamination in tumorigenesis (Alexandrov et al., 2013; Bolli et al., 2014; 
Burns et al., 2013a, 2013b; Chen and Wang, 2014; Davis et al., 2014; Hoogstraat et al., 2014; 
Lada et al., 2012; Nik-Zainal et al., 2012). 
 Thus, understanding how uracil is processed and repaired is increasingly important. 
Uracil is primarily excised by uracil-DNA glycosylases (UDGs) that initiate the error-free 
base excision repair (BER) pathway. Mammalian cells express several (UDGs), including 
mitochondrial uracil-DNA glycosylase 1 (UNG1) and nuclear UNG2, single-strand selective 
monofunctional uracil DNA glycosylase 1 (SMUG1), G/T mismatch-specific thymine DNA 
glycosylase (TDG), and methyl-CpG-binding domain protein 4 (MBD4). All UDGs have the 
ability to excise U:G, though only UNG and SMUG1 efficiently remove U:A. The relative 
contribution of the different UDGs to uracil repair are influenced by a plethora of factors like 
sequence context, whether the DNA is single- or double-stranded, the base opposite the 
uracil, cell-cycle phase, post-translational modifications, interaction partners, and their 
localization in the genome (reviewed in (Krokan et al., 2014)). The substrate specificities of 
the UDGs and their preference for various DNA contexts partially overlap. SMUG1 also has 
 Ͷ
a particular role in removing the thymine oxidation product 5-hydroxymethyluracil (hmU) 
(Boorstein et al., 2001). 
 Ung-/- mice revealed that UNG2 has a role in U:A and U:G repair, as well as in Ig 
diversification (Nilsen et al., 2000a, 2003, 2005; Rada et al., 2002). Initial work suggested 
that SMUG1 serves as a backup for UNG2 in both uracil repair and Ig diversification 
(Dingler et al., 2014; Kemmerich et al., 2012; Nilsen et al., 2001; Rada et al., 2002); 
however, distinct intracellular localisation and interaction partners suggest that SMUG1 and 
UNG2 likely also have non-redundant functions. UNG2 interacts with RPA and PCNA and 
removes misincorporated uracil by postreplicative DNA repair (Otterlei et al., 1999). 
Divergently, SMUG1 does not localise with replicating chromatin, but is instead localised 
throughout the nucleus with some accumulation in nucleoli (Kavli et al., 2002). Furthermore, 
SMUG1 directly interacts with Dyskerin (DKC1) in Cajal bodies, and contributes to RNA 
quality control (Jobert et al., 2013). However, the distinct functions of UNG2 and SMUG1 in 
genomic-uracil repair in vivo remain poorly understood. Here, we used a genetic approach to 
clarify the relative importance of UNG2 and SMUG1 in genomic uracil repair and generated 
gene targeted Smug1-/- mice and crossed them with Ung-/- mice to generate Smug1-/-Ung-/- 
mice. 
 
 
 ͷ
MATERIALS AND METHODS 
Generation of conditionally targeted Smug1 knockout mice  
 The Smug1 gene (NM_027885) spans 14 kb and eight predicted exons of which only 
the two last exons are protein coding. Two isoforms exist that differ in their 5ƍ-UTRs. A two-
step strategy giving a final deletion of the protein coding exons 1 and 2 was used. A gene 
targeting vector containing Smug1 exon 1 and exon 2 was constructed by cloning 
genomic Smug1 fragments PCR amplified from C57Bl/6 genomic DNA using Accuprime 
Taq DNA polymerase High Fidelity (Thermo Scientific) into the pCR4-TOPO vector 
(Thermo Scientific). The long-homology arm of the targeting vector was built by TA-cloning 
of two separate PCR fragments: i) a 3371 bp fragment comprising 5´-UTR was amplified 
using forward primer 5ƍ-TAGATGTGGTGGGGATAGACTAGAACCTGG-3ƍand reverse 
primer 5ƍ-CTACAAGCTCACTTTCCTGGTAACGAAGG-3ƍ and ii) a 2464 bp fragment 
comprising the exon 1 and exon 2 regions amplified using the primers (5ƍ- 
TGACTGACAGGGTTTCTTCTGAGCCC-3ƍand 5ƍ-
GAAGGGGAAGACAGCAGGAGAGCTG-ƍ) flanked by two LoxP sites. A positive 
selection neomycine gene flanked by FRT-sites was inserted. The short homology arm was 
generated by amplification of the 3ƍuntranslated region of exon 2 (5ƍ- 
CCTTGAGCCTCTCACCCTTTTGTCTC-3ƍand 5ƍ-CTCCTATTGTTCCCAACAGTTGCC-
3ƍ). A Diphteria Toxin A (DTA) gene was used for negative selection. The absence of PCR-
generated mutations was confirmed by sequencing. The targeting vector was linearized 
with PmeI and electroporated into C57Bl/6 ES cells. ES cells were selected with 
ௗȝJPO G418. Homologous recombination events at the 5ƍand 3ƍarms were verified in 
G418 resistant ES cell clones by PCR and Southern blot analysis. Six independent clones 
were injected into C57BL/6J blastocysts. Chimeric mice were crossed with a C56BL/6 Cre-
deleter mouse strain (GenOway) to allow germline excision of the loxP-flanked region thus 
generating heterozygous constitutive Smug1 knock-out mice.  
 The generation of Ung-/- mice in a mixed 129SV-C57Bl/6J background was described 
previously and backcrossed ten generations into the C57Bl/6J background (Doseth et al., 
2011; Nilsen et al., 2000b). Smug1-/-Ung-/- double-knockout (DKO) mice were generated by 
crossing single-knockout mice born to heterozygous mothers. All strains were maintained as 
heterozygous. 
 
 ͸
Southern blotting  
 Genomic DNA was digested with PciI, blotted onto a nylon membrane and 
K\EULGL]HGZLWKDQH[WHUQDOௗESSUREHH[Wƍ probe) located downstream of the short 
homology arm of the targeting vector. The expected fragment sizes of the wild type and the 
recombined Cre-excised loci are 9.3 kb and 2.1 kb, respectively. The non-excised allele 
would give a fragment of 6.3 kb. Pre-hybridization and hybridization were performed at 
ௗ&IRUௗKLQK\EULGL]DWLRQVROXWLRQî66& SDS, 0.5% skimmed milk, 
ௗP0 EDTAௗȝJPO herring sperm DNA) followed by washing twice in 3 × SSC, 
1% SDS DWௗ&IRUௗPLQDQGWZLFHLQî66& 1% SDS DWௗ&IRUௗPLQ%DQGV
were visualised after 3 days exposure to BioMax MS films with BioMax intensifying screens. 
3ULPHUVXVHGWRJHQHUDWHWKHH[WHUQDOƍSUREHƍ-
CTCATCTGTCTCTTTAATGGTTGGTTGGATG-ƍDQGƍ-
AGCTGGCTAGGGTCACTGTGGAGGTAT-ƍ  
Genotyping  
 Mice were genotyped by multiplex PCR. The primer set for the Smug1 alleles were as 
follows: 5ƍ-GGATGAGGGTTCAGCCAGACCTACA-3ƍ (forward WT), 5ƍ-
ACTGCGAATATGACTTCAGACATCCCG-3ƍ (reverse WT), SMUG KO 5ƍ-
TGACAGGGTCACATGTCGTACATAA-3ƍ (forward KO) and SMUG KO 5ƍ-
ACTGCGAATATGACTTCAGACATCC3ƍ (reverse KO). The primer set for the Ung alleles 
were as follows: mUNG3+: 5ƍ-CACGGACCTAATCAAGCTCACG-3ƍ (forward WT), 
mUNG4-: 5ƍ-GGCCCACCCTGACAAATCCCC3ƍ (reverse WT/KO) and Neo+: 5ƍ-
CTTGGGTGGAGAGGCTATTC-3ƍ (forward KO). AccuPrime Pfx Supermix (Invitrogen) 
was used for the PCR of both Smug1 and Ung. The PCR program for Smug1 was: 1 cycle of 
95 °C for 5 min, 35 cycles of 95 °C for 15 s, 58 °C for 30 s and 68 °C for 1 min and then 1 
cycle of 68 °C for 7 min. The PCR program for Ung was equal to that of Smug1 except for 
the annealing temperature, which was 59 °C. The PCR products were run on 2% agarose gels. 
The Smug1 PCR were expected to give a wild-type band of 271 bp and a knock-out band of 
232 bp (Figure 1C). The Ung PCR gave a wild-type band of 550 bp and a knock-out band of 
850 bp (Supplementary Figure 1).  
Isolation and culture of MEFs  
 Timed matings were set up between either wild type, Smug1-/- or Ung-/- mice born to 
heterozygous parents or between Smug1-/-Ung-/- mice born from either Smug1+/-Ung-/- or 
Smug1-/-Ung+/- parents in order to obtain wild type, Smug1-/- or Smug1-/-Ung-/- MEFs. MEFs 
were established from 13.5 to ௗGSFHPEU\RVas described (Xu, 2005), and grown in 
 ͹
Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12, GlutaMAX (Invitrogen) 
supplemented with 10% fetal bovine serum (Lonza), 1x penicillin-streptomycin (Invitrogen) 
and 1x MEM non-essential amino acids (Invitrogen).  Primary MEF cell lines (Passage 1) 
and cells cultured for 23 continuous passages were used. 
Phenotypic assessment of Smug1-/- mice  
 Phenotypic assessment was performed according to the modified SHIRPA protocol 
(EMPRESS, eumorphia.org) at PhenoPro (http://www.phenopro.fr/). Briefly, 10 male wild 
type and 10 Smug1-/- mice aged 6 weeks old were housed 1 to 4 per cage and fed standard 
chow diet (D04, Safe) ad libitum. Phenotypic testing started at 11 weeks after 3 weeks 
acclimation in the phenotypic area. Starting from 13 weeks, mice were submitted to 
dysmorphology screen to assess morphological abnormalities in their general physical 
appearance (weight, length, and dysmorphology, including tail kinks, shape of ears, eyes, 
head, teeth, limbs, number and shape of digit, irregularities and variation in coat colour, hair 
distribution and development, irregularities in the genitals). Blood was collected from 14-
week-old mice by retro-orbital puncture under isoflurane anesthesia for biochemistry and 
hematologic analysis. A complete blood cell count was performed in the Advia 120 
workstation. Body composition and bone mineral content were evaluated by X-ray analysis. 
Generation of anti-SMUG1 antibodies  
 Generation of an antibody against mouse SMUG1 was carried out by BioGenes. The 
antibody was raised in rabbit against the mouse SMUG1 peptide CLTPAELPAKQREQL-
amide. The first immunisation was followed by five weekly boosts before the final bleeding 
of the rabbit. The antiserum was purified against the immunising peptide coupled to 
SulfoLink gel (Pierce). The coupling of the peptide to the SulfoLink gel and the purification 
were carried out according to the recommendations from the manufacturer. Eluted fractions 
containing the purified antibody were pooled and dialysed against 10 mM Tris HCl (pH 7.9), 
20 % glycerol, 0.5 mM EDTA, 50 mM KCl.   
Protein extraction for oligonucleotide nicking assays  
 Protein was extracted from organs and cells using two buffers. Lysis buffer I 
contained 10 mM Tris-HCl (pH 8.0) and 200 mM KCl and lysis buffer II contained 10 mM 
Tris-HCl (pH 8.0), 200 mM KCl, 40 % glycerol, and 0.5% NP-40 alternative (Merck 
Millipore). Buffers were freshly supplemented with 1 M DTT, 1X Complete Protease 
Inhibitor Cocktail (Roche), and 1X Phosphatase Inhibitor Cocktails 2 and 3 (Sigma-Aldrich). 
All steps were performed with ice-cold buffer and on ice or at 4 °C. Protein from MEFs was 
extracted by first suspending the cells in 3 l lysis buffer I per 106 cells and then adding the 
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same amount of lysis buffer II. The suspensions were then incubated for 2 h at 4 °C and 
centrifuged at 16,100 rcf. The supernatants were finally aliquoted to new tubes, snap-frozen 
in liquid nitrogen, and stored at -80 °C. Protein from organs were lysed by suspending organs 
in 1.8 l 1:1 lysis buffers I and II per mg organ and homogenization with Dounce 
homogenizers. The homogenates were then incubated, centrifuged, aliquoted, and stored 
identically to the MEFs. 
Isolation of genomic DNA  
 Organ samples were snap-frozen in liquid nitrogen and stored at -80 °C until isolation 
of genomic DNA. The genomic DNA was isolated using the DNeasy Blood & Tissue kit 
(Qiagen) according to the manufactXUHU¶VLQVWUXFWLRQV with minor modifications. Briefly, 2 ml 
CK14 homogenisation tubes containing ceramic 1.4 mm zirconium oxide beads (Precellys) 
were prepared with 400 l ice-cold lysis buffer consisting of: 360 l ATL buffer, 40 l 
Proteinase K and 0.1 g/l RNaseA. 10-25 mg tissue per tube were homogenised at 4 °C by 
bead beating for 30 s 3x with 30 s pauses between cycles. The lysates were incubated in a 
water bath for at least 1 h at 37 °C and vortexed occasionally. The lysates were recovered 
from the beads through two needle holes in the lid of the homogenisation tube as the tube was 
spin upside down inside a 15 ml tube at 250 rcf for 2 min. Each lysate was split into two spin 
columns. The final DNA elution step was performed with 200 l milli-Q water.   
Whole cell extract of MEFs for western analysis  
 Wild type and Smug1-/- primary MEFs at 80 % confluency were trypsinised with 
0.25% trypsin-EDTA (Invitrogen) and washed twice in cold PBS. The cells were resuspended 
in 300 l extraction buffer (20 mM Tris-HCl pH 7.5, 1 mM DTT, 20% glycerol, 400 mM 
KCl, 1x protease inhibitor cocktail, cOmplete Mini EDTA-free (Roche)) and incubated on ice 
for 30 min with occasional gentle mixing. The extracts were exposed to three freeze-thaw 
cycles in liquid nitrogen and spun at 16000 rcf for 20 min at 4 °C. The supernatants were 
collected and dialysed against 25 mM Tris-HCl pH 7.5, 5 mM MgCl2, 100 mM KCl, 10% 
glycerol, 1 mM DTT in a Slide-A-Lyzer Dialysis cassette 3500 MWCO (Fisher Scientific) 
overnight at 4 °C. The whole cell extracts were collected and added 1x protease inhibitor 
cocktail. Protein concentrations were determined by Bradford quantification (Bio-Rad) using 
BSA as standard. The extracts were snap-frozen in liquid nitrogen and stored at -80 °C until 
further use.      
Western blot analysis  
 100 g whole cell extract of wild type and Smug1-/- MEFs were run on a 15% Tris-
HCl Criterion gel (Bio-Rad) and transferred to a nitrocellulose membrane (Bio-Rad). The 
 ͻ
membrane was blocked in 1x PBS, 0.1% tween-20, 5% milk for 1 h at room temperature and 
incubated overnight at 4 °C in purified rabbit anti-mouse SMUG1 antibody diluted 1:500 in 
the blocking solution. The membrane was washed three times 10 min in 1x PBS, 0.1% tween-
20 and then incubated for 1 h at room temperature in goat anti-rabbit IgG-HRP (Cell 
Signaling) diluted 1:2000 in the blocking solution. The membrane was washed as above 
before it was developed with SuperSignal West Pico Chemiluminescent kit according the 
instructions from the manufacturer (Thermo Scientific). Hyperfilm ECL (GE Healthcare) was 
exposed to the membrane for various time-points. The membrane was stripped by incubation 
in 0.2 M glycine, 0.1% SDS, 0.1% tween-20 (pH 2.2) two times 20 min at 37 °C. The 
membrane was blocked as above and incubated for 1 h at room temperature with rabbit anti-
GAPDH antibody (14C10, Cell Signaling) diluted 1:2000 in blocking solution. The 
membrane was further processed as above.  
Gene expression analyses  
 Kidneys from wild type, Smug1+/-, and Smug1-/- mice had been stored in RNAlater at -
20 °C until RNA isolation. RNA was isolated using the mirVana miRNA isolation kit 
(Ambion/Life Technologies). 2 ml CK14 homogenisation tubes containing 1.4 mm ceramic 
1.4 mm zirconium oxide beads were prepared with 600 l ice-cold lysis buffer and a piece of 
tissue of 2 x 2 x 2 mm was added per tube and covered by the lysis buffer. The tissue was 
homogenised and the lysate recovered as for isolation of genomic DNA. The lysate was 
processed further according to PDQXIDFWXUHU¶Vinstructions. The RNA was eluted in 100 l 
DEPC treated milli-Q water. cDNA was synthesised from 5 g RNA using SuperScript II 
Reverse Transcriptase (Invitrogen/Life Technology) and random hexamers according to the 
instructions following the transcriptase. The Smug1 transcription was measured by 
quantitative real-time PCR using Fast SYBR Green Master Mix (Applied Biosystems) 
according to the instructions following the kit. Smug1 expression was normalised to Gapdh 
expression. 2 l cDNA was used in the qRT-PCR for both Smug1 and Gapdh. Primers for the 
qRT-PCR were Smug1 (forward) 5ƍ-TCAAGTCTTCTTCCGGCACT-3ƍ, Smug1 (reverse) 5ƍ-
ACTCCCACTACCAGACGCAC-3ƍ, Gapdh (forward) 5ƍ-AACTTTGGCATTGTGGAAGG-
3ƍ and Gapdh (reverse) 5ƍ-GGATGCAGGGATGATGTTCT-3ƍ. 
Oligonucleotide nicking assays  
 Oligonucleotide UDG assays were performed as previously described (Doseth et al., 
2011; Kavli et al., 2002). 6-carboxyfluorescein-labeled uracil- or hydroxymethyluracil-
FRQWDLQLQJROLJRQXFOHRWLGHVƍ-[6-FAM]-CATAAAGTG-U/5hmU-AAAGCCTG) were 
annealed to 1.5x of the complementary strand containing G or A opposite U/5hmU. Activity 
 ͳͲ
was measured by incubating 10 l of 20 nM substrate and 20, 2.5, or 1.25 g of (5hm)U:A, 
(5hm)U:G, or ss(5hm)U protein extracts, respectively. The reactions were buffered in 20 mM 
Tris-HCl (pH 8.0), 60 mM NaCl, and 1 mM EDTA, freshly complemented to a final 
concentration of 1 mM DTT and 0.5 mg/ml BSA. The reactions were incubated at 37 °C for 
60 min, 20 min, and 15 min for (5hm)U:A, (5hm)U:G, or ss(5hm)U protein extracts, 
respectively. UNG was inhibited by 0.4 U uracil-DNA glycosylase inhibitor (Ugi, New 
England Biolabs). The reactions were stopped on ice and abasic sites were cleaved by adding 
50 l 10 % ice-cold piperidine and subsequent incubation at 90 °C for 20 min. Next, the 
reactions were vacuum centrifuged at 60 °C for 1 h to dryness and redissolved in 30 l 60 % 
formamide loading buffer containing 0.05 % bromophenol blue. The substrate and product 
were separated by electrophoresis on a urea-PAGE gel containing 12 % acrylamide:bis-
acrylamide (19:1) and 42% urea in 0.5 x TBE and visualized using a Typhoon Trio imager 
(GE Healthcare). Analysis was performed using ImageQuant 7 TL (GE Healthcare). 
Quantification of modified bases in genomic DNA  
 Modified nucleosides were quantified as previously described (Galashevskaya et al., 
2013). Potentially co-purified deoxynucleotides in DNA were removed by incubating 15 g 
DNA with 0.2 U alkaline phosphatase from E. coli per 100 l in 100 mM NH4HCO3 (pH 7.6) 
and 10 mM MgCl2 for 30 min at 37 °C, followed by isopropanol precipitation. The DNA was 
then hydrolyzed to nucleosides by redissolving the DNA pellet in 20 l containing 10 mM 
NH4C΍HΎO΍ (pH 6.0), 10 mM MgCl2, 10 mM CaCl2, 41.65 nM 13C15N2-dUrd, 0.4 U 
nuclease P1 from P. citrinum (Sigma-Aldrich), and 2 U DNase I (Roche). The solution was 
incubated for 30 min at 37 °C, after which 5 l containing 0.5 NH4HCO3 (pH 7.6) and 0.1 U 
alkaline phosphatase were added and further incubated at 37 °C for 20 min. The reactions 
were stopped on ice and the enzymes in the reactions with 3 volumes of cold acetonitrile, 
after which the samples were centrifuged at 16,100 rcf for 30 min at 4 °C. The supernatants 
were transferred to new tubes and vacuum centrifuged at room temperature until dry. 
To separate (5hm)-dUrd from dCyd, the samples were redissolved in 100 l 90:10 
water:acetonitrile and fractionated with 3x 30 l injections on an Agilent HP1100 HPLC-UV 
system and a Primesep 200 column (2.1 mm x 150 mm, 5 m, Sielc) using a flow rate of 0.4 
ml/min and water and acetonitrile as mobile phase, each containing 0.1 % formic acid. The 
HPLC 7.5-min-long gradient was as follows: 10 % acetonitrile for 30 s, ramp to 60 % 
acetonitrile by 2 min to 2.5 min, and return to 10 % acetonitrile by 2.55 min. The (5hm)-
dUrd-containing fractions were collected from 1.3 - 1.8 min and vacuum centrifuged until 
dry. The pellets were redissolved in 25 l 95:5 water:methanol and analyzed for dUrd and 
 ͳͳ
5hm-dUrd by LC/MS/MS using a reverse phase column (2.1 mm x 150 mm, 3.5 m, Zorbax 
SB-C18, Agilent Technologies) on an LC-20AD HPLC (Shimadzu) coupled to an AB SCIEX 
5500 triple quadrupole mass spectrometer with an electrospray ion source (AB SCIEX). The 
injection volume was 20 l, the flow rate was 0.3 ml/min, and the 5-min-long HPLC gradient 
was as follows: 5 % methanol for 30 s, ramp to 30 % methanol by 1 min to 2 min, and return 
to 5 % methanol by 2.1 min. Analysis was performed in positive ionization multiple reaction 
monitoring mode, monitoring the mass transitions 228.994 Æ 113.0, 232.0 Æ 116.0, and 
259.0 Æ 143.1 for dUrd, 13C15N2-dUrd, and 5hm-dUrd, respectively. Chromatogram analysis 
was performed using Analyst 1.5 software (AB SCIEX). 
Statistical analysis  
 Data were analyzed using unpaired one-way- or repeated measures analysis of 
variance (ANOVA) with one between factor (genotype) and one within factor (time). 
Qualitative parameters (e.g. some of clinical observations) were analyzed using Ȥ2 test. The 
level of significance was set at p < 0.05. Biochemical assays were evaluated using two-way t-
test 95% confidence level. 
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RESULTS 
Smug1-/- mice display no obvious pathological phenotypes  
 Gene targeted mice deleted for both coding exons of the Smug1 gene (Figure 1A) 
were born at Mendelian ratios and are fertile. Smug1-/-mice had no residual Smug1 
expression, as measured in total RNA isolated from MEFs by qRT-PCR (Figure 1D). 
Heterozygous mice expressed Smug1 mRNA at 50% of the wild type level. An affinity 
purified peptide antibody generated against a mouse SMUG1 peptide revealed a specific band 
migrating at 29 kDa in whole cell extract prepared from wild type kidney that was absent in 
extracts prepared from Smug1-/- kidney (Figure 1E). Hence, we concluded that the Smug1-/- 
mice are true knockouts.  
 No obvious pathological abnormality was observed in the general appearance of the 
Smug1-/- mice, and they exhibited normal body shape and skeletal morphology.  No major 
changes were observed in blood-cell counts although there was a slight reduction in the mean 
number of lymphocytes in the Smug1-/- mice (5.70 ± 0.15 vs 4.57 ± 0.25, p = 0.0011).  No 
macroscopic or microscopic lesion or change was observed by histological assessment of the 
major organs. The generation and phenotypic assessment of Ung-/- mice in a mixed 129SV-
C57Bl/6J background were described previously to have no obvious morphological 
phenotype (Nilsen et al., 2000b), they present a hyper IgM phenotype resulting from 
defective processing of AID-induced uracil during CSR in the Ig loci (Rada et al., 2002). A 
high incidence of B-cell lymphoma was also observed in aging, mixed background Ung-/- 
mice (Andersen et al., 2005; Nilsen et al., 2003). Ung-/- mice (Supplementary Figure S1) were 
backcrossed ten generations into C57Bl6/J and used to generate Smug-/-Ung-/- mice. Smug1-/-
Ung-/- mice also showed no obvious morphological abnormalities. Thus, the deletion of the 
Smug1 gene and the combined loss of the two major UDGs are well tolerated in mice in the 
time period examined here.  
Smug1-/- mice lose hmU excision activity and accumulate hmU in genomic DNA 
 SMUG1 was previously characterised as the main enzyme removing 5-
hydroxymethyluracil (hmU) from DNA (Boorstein et al., 2001). To determine whether the 
Smug1-/- mice had any residual SMUG1 activity, we measured the excision capacity on an 
oligonucleotide substrate harbouring a centrally placed hmU residue. The hmU-excision 
activity from MEF and organ extracts was higher on hmU:G than hmU:A substrates, whereas 
no detectable activity was found on single-stranded substrates under our reaction conditions 
(Figure 2A/B). In contrast, there was no hmU-excision activity in extracts from isogenic 
Smug1-/- MEFs, regardless of substrate (Figure 2A). There was some variation in hmU-
 ͳ͵
excision activity between different organs, in particular on hmU:G substrate, with the highest 
activity in the brain and lowest in the liver extracts. (Figure 2B).  
 To determine whether the lack of hmU excision activity in Smug1-/- cells resulted in 
increased genomic hmU load, we measured the amount of hmU present in total genomic 
DNA by modifying our recently developed LS/MS/MS assay for measuring genomic uracil 
(Galashevskaya et al., 2013).  Primary Smug1-/- MEFs (Passage 1) contained about 20 hmU 
residues per million nucleotides, which was double the genomic hmU content of isogenic 
primary wild types MEFs (Figure 2C). The genomic hmU-levels seemed to slightly increase 
upon passage in culture, as would be expected because hmU can be formed by direct 
oxidation of thymine; however, the increase in hmU content was similar in wild type and 
Smug1-/- MEFs. Similar levels of hmU were found in genomic DNA isolated from different 
tissues (Figure 2D). The tissue variation in hmU levels was unremarkable, ranging from 
about 5 to 10 hmU per million nucleotides in wild type mice (Figure 2D, top panel). Genomic 
DNA isolated from Smug1+/- mice had about double the amount of hmU compared to wild 
types, suggesting that a single expressed copy of SMUG1 is insufficient to maintain basal 
hmU levels (Figure 2D, middle panel).  Considerably higher hmU levels were found in 
genomic DNA isolated from organs of Smug1-/- mice and most tissues exhibited 3- to 4-fold 
increased hmU levels compared to wild type organs. The largest increases relative to wild 
type were found in brain extracts where the levels increased from ~5 to 18 hmU per million 
nucleotides. Hence, we concluded that Smug1-/- mice have lost hmU excision activity and 
accumulate hmU in genomic DNA. 
Smug1-/- mice have normal uracil-excision capacity 
 SMUG1 was previously found to the predominant UDG in Ung-/- mice (Doseth et al., 
2011; Kemmerich et al., 2012; Nilsen et al., 2001).  To assess whether loss of SMUG1 
impacted uracil repair capacity, we performed standard uracil excision activity assays on 
oligonucleotide substrates containing one centrally placed uracil residue. The uracil excision 
activity varied more than the activity on hmU-containing substrates (Figure 3). High activity 
to the point of assay saturation was observed in spleen and heart extracts on U:G substrates 
(Figure 3, top panel). Wild-type mice showed less efficient uracil excision in splenic extracts 
on U:A containing substrates compared to U:G (Figure 3, middle panel). Uracil excision 
activity from single-stranded substrates resembled the U:G substrate, except that brain 
activity was reduced by 60% (Figure 3, bottom panel). SMUG1 status did not significantly 
impact uracil-excision activity from double-stranded substrates in tissues other than the brain, 
in which the activity was reduced by 40% and 60% in Smug1+/- and Smug1-/- mice, 
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respectively. Consistently, no statistically significant accumulation of genomic uracil was 
seen in Smug1-/- MEFs (Figure 4A) or any of the SMUG1-deficient organs tested (Figure 4B).  
Uracil levels also did not rise in MEFs upon culture in vitro (Figure 4A). These data are in 
agreement with previous findings that UNG is the dominating UDG in mouse cells, although 
SMUG1 contributes significantly to uracil-excision from double-stranded substrates in the 
brain. 
The combined action of SMUG1 and UNG prevents genomic uracil accumulation  
 To test whether SMUG1 activity contributes to uracil repair in the absence of UNG, 
we generated Smug1-/-Ung-/- mice. There was a complete ablation of measurable uracil 
excision activity in all Smug1-/-Ung-/- organs regardless of substrate (Figure 5A). This 
demonstrated that both UNG and SMUG1 have the ability to compensate for loss of the other 
enzyme, but that the loss of SMUG1 in an UNG-proficient background impacts relatively 
little on overall uracil excision capacity (Figure 3). In contrast, SMUG1 appears not to be 
fully able to compensate for the loss of UNG activity, as shown by partial suppression of 
uracil excision activity upon inhibition of UNG by Ugi (Figure 5A). Again, these data 
confirm that UNG and SMUG1 account for the majority of uracil excision activity in mice, 
with UNG as the larger contributor.  
 As shown above, the loss of SMUG1 did not lead to a significant increase in the 
global genome uracil content (Figure 4); however, the loss of UNG activity resulted in a 2-3-
fold increase in genomic uracil content in the tissues measured here (Figure 5B, middle 
panel). In contrast to the relatively modest increase in the UNG-deficient tissues, there was a 
dramatic increase in genomic uracil levels in the double knockout organs (Figure 5B, lower 
panel). Surprisingly, the spleen, an organ with high proliferative capacity, showed a modest 
3-fold increase from ~2 to 7 uracil per million nucleotides in wild type compared to DKO 
extracts, whereas a 6-fold uracil accumulation was seen in the essentially post-mitotic brain 
extracts. Heart, skeletal muscle, kidney, and lungs all showed between ~20 and 30 uracil per 
million nucleotides, which represent more than 10-fold increases relative to the wild type 
levels. Finally, liver extracts from DKO mice showed more than 80 uracils per million 
nucleotides, which represents a 20-fold increase relative to wild type levels. This synergistic 
increase in uracil levels demonstrates that SMUG1 efficiently, albeit not fully, compensates 
for loss of UNG activity and vice versa.  
 In summary, SMUG1 is the sole detectable hmU excision enzyme in MEFs and hmU 
accumulates in the genome of Smug1-/- mice. UNG is the major UDG in mouse cells and 
organs. The contribution of SMUG1 to uracil removal is highly tissue specific and appears to 
 ͳͷ
be either more active or abundant in brain extracts, despite the lack of uracil accumulation 
upon the SMUG1-deficient organs. There is extensive buffering between the two enzymes 
with respect to global genome uracil repair and their combined action effectively prevents 
accumulation of uracil in the mouse genome. However, the two enzymes are not entirely 
redundant as demonstrated by the synergistic increase in uracil levels in the double knockout 
mice. 
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DISCUSSION 
 In the present work we describe the generation of a gene targeted knockout mouse 
model deficient in SMUG1 and show that SMUG1 comprises the only detectable hmU-
excision activity in mouse tissues. Consequently, the absence of SMUG1 leads to genomic 
hmU accumulation. Reduced UDG activity was detected in double-stranded substrates in 
Smug-/- brain extracts, but other organs were unaffected by the loss of SMUG1; however, by 
comparing uracil accumulation in MEF and tissues extracted from Smug-/-, Ung-/-, and Smug-/-
Ung-/- mice, we demonstrate that SMUG1 and UNG effectively collaborate to limit uracil 
accumulation in genomic DNA.   
 A mouse model deficient in SMUG1 was previously generated by germline 
transmission of ES cells generated in the European Conditional Mouse Mutagenesis 
Consortium (EUCOMM, project ID 23057) in which suppression of SMUG1 expression was 
achieved by a gene trap inserted in the intron between the coding exons (Kemmerich et al., 
2012).  This mouse model has no detectable SMUG1 expression and has lost hmU-activity. 
Thus, there is no reason to suspect that this model does not represent a good Smug1-knockout 
model. We nevertheless chose to make a classical gene targeted deletion of both coding 
exons of the Smug1 gene because bioinformatic analysis performed at Genoway 
(www.genoway.com) revealed one possible splice variant from the Smug1 gene that 
harboured a cryptic ATG upstream of the gene-trap cassette coding exons (AK020817) 
giving a theoretical possibility of a splice event between the engrailed 2 gene encoded by the 
inserted gene trap  and Smug1 exon 2 giving rise to a stable mRNA. If translated, this mRNA 
would give rise to a 137 kDa protein with a partial UDG domain (39 out of 194 amino acids). 
This protein would not be predicted to have UDG activity as it would only contain 1 out of 4 
substrate binding sites, but possible hypomorphic or gain-of-function effects would, 
nevertheless, be a theoretical possibility.  
 The Smug-/- mice developed here phenocopy the previously-described model and 
showed that loss of SMUG1 does not interfere with normal development and extensive 
phenotypic screening did not reveal any obvious pathophysiological changes at 10 weeks of 
age (Kemmerich et al., 2012). The small reduction in lymphocyte numbers found in our 
model might be related to the role of SMUG1, albeit minor, in CSR (Dingler et al., 2014). 
Stimulated B-cells undergo selection in germinal centres during the immune response, so 
slightly less efficient antibody generation as a result of SMUG1-deficiency may slightly 
increase apoptosis induction or decrease proliferation in B-cells, resulting in the observed 
lowered lymphocyte levels. 
 ͳ͹
 In agreement with the previous study, we found that Smug1-/- cells and tissues had no 
detectable hmU-excision activity leading to 3-4-fold higher levels of hmU in genomic DNA 
(Kemmerich et al., 2012). The extent of hmU accumulation was similar in all tissues 
analysed. A small increase in hmU, but not uracil, levels was observed upon passage of wild 
type and Smug1-/- MEFs in culture. This is consistent with the majority of cellular hmU being 
generated from direct oxidation of thymine (Pfaffeneder et al., 2014). Surprisingly, the 
increase was similar in Smug1-/- and wild type MEFs, which might be indicative of 
compensatory changes limiting the accumulation of hmU in SMUG1-deficient cells. 
 Importantly, the work presented here offers novel insight into the long-standing 
question on the relative importance of UNG2 and SMUG1 in uracil repair. The hmU excision 
profile (i.e. the differences between organs) in wild type samples was nearly identical to that 
of uracil excision in UNG-inhibited WT samples, suggesting that SMUG1 excises the two 
nucleosides with similar efficiency. Loss of SMUG1 had no effect on UDG activity in the 
presence of functional UNG in most organs. This supports the conclusion that UNG is the 
major contributor to uracil excision in most tissues in the mouse (Doseth et al., 2011). A 
significant reduction of UDG activity in Smug1-/- tissues was found only in brain extracts on 
U:G substrate and more weakly on U:A substrate. No effect was seen on uracil excision from 
single-stranded substrates, corroborating earlier studies indicating that SMUG1 primarily 
removes uracil from double-stranded substrates under our reaction conditions (Doseth et al., 
2012). We cannot exclude the possibility that the contribution of SMUG1 to total UDG 
activity was underestimated using the present assay conditions which was optimised for UNG 
(Supplementary Figure 2) (Akbari and Krokan, 2012; Doseth et al., 2012). Indeed, the 
dramatic reduction in UDG activity in all Smug1-/-Ung-/- organs tested strongly indicates that 
SMUG1 contributes to UDG activity and that confirms that it is the major UDG in UNG-
deficient mice (Nilsen et al., 2001). Smug1-/- tissues or cells did not accumulate uracil, and 
Ung-/- tissues only showed a 2- to 3-fold increase in uracil levels. That the UDG activity 
contributed by SMUG1 is relevant in vivo is evident from the dramatic increase in uracil 
levels in the double knockout organs. Hence, both UNG2 and SMUG1 contribute to 
maintenance of baseline uracil levels.  
 As both UNG and SMUG1 efficiently remove uracil from U:A and U:G pairs, we do 
not yet know whether the main increase in uracil in the DKOs comes from misincorporation 
or deamination. The rates of spontaneous cytosine deamination are expected to be largely 
dependent on the degree of single-stranded DNA, and therefore depend on the transcription 
activity of a cell and unlikely to differ in the genetic background studied here (Lindahl, 
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1993). There are also other enzymes and pathways that can repair U:G mismatches in the 
absence of UNG and SMUG1, most notably the mismatch repair pathway and the two 
mismatch specific uracil-DNA glycosylases TDG and MBD4 (Cortázar et al., 2007; Kunz et 
al., 2009; Wong et al., 2002). For U:A the two most efficient repair enzymes are UNG2 and 
SMUG1 (Kavli et al., 2002). Uracil misincorporation will occur in replicating cells in direct 
proportion to the cellular dUTP pool, which is largely determined by the dUTPase enzyme. 
dUTPase expression is cell cycle regulated. A relatively low increase in uracil content in the 
brain, in which there is very low cellular turnover, might indicate that the bulk of genomic 
uracil in the Smug1-/-Ung-/- organs originates from uracil misincorporation. A similarly 
modest increase in uracil content in the spleen was more surprising in light of the important 
physiological function of AID induced deamination in this tissue. AID expression is low in 
mouse spleen and it can be expected that the effect of AID-dependent cytosine deamination 
will not be seen in the absence of stimulation (Nilsen et al., 2005). Furthermore, the 
importance of the mismatch repair pathway in processing AID-initiated U:G lesions is 
supported by the severe early morbidity caused by thymic lymphomas in Smug1-/-Ung-/-Msh2-
/- mice (Kemmerich et al., 2012; Kunz et al., 2009). Hence, whereas many alternatives exist 
to repair deaminated cytosine, few enzymes other than UNG and SMUG1 are known to 
effectively repair misincorporated uracil, which might suggest that the dramatic increase in 
uracil content in the Smug-/-Ung-/- mice is likely dominated by U:A pairs. The absence of a 
tumour-prone phenotype in the Smug-/-Ung-/- mice previously reported would also support this 
interpretation, but definite conclusions regarding the relative accumulation of U:A or U:G 
pairs must await assay improvements (Kemmerich et al., 2012).  
 In conclusion, there is extensive buffering between UNG and SMUG1 with respect to 
global genome uracil repair in vivo and their combined action effectively prevents 
accumulation of uracil in the mouse genome. However, the two enzymes are not entirely 
redundant as demonstrated by the synergistic increase in uracil levels in the double knockout 
mice. We therefore propose that in the absence of active uracilation by e.g. enzymatic 
deamination, physiological variations in glycosylase levels are sufficient to maintain uracil 
levels at near basal levels in vivo. 
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LEGENDS TO FIGURES 
Figure 1 - Generation of Smug1-knockout mice 
(A) Gene targeting strategy showing the endogenous Smug1 gene (top panel) with the two 
FRGLQJH[RQVVWULSHGER[HVWKH¶-UTR (blue box), and two predicted upstream exons 
(white boxes). The recombined Smug1 locus (middle panel) with the floxed neomycine 
selection marker (grey box) and LoxP VLWHVLQGLFDWHG7KHSRVLWLRQRIWKH¶H[WHUQDOSUREHLV
indicated (red box). The Smug1 locus after Cre-mediated excision (lower panel). The 
expected fragment sizes resulting from PciI digestion are indicated below each panel. (B) 
Southern blot confirming the size of the endogenous locus and in a heterozygous animal after 
Cre-mediated excision.  (C) Smug1 PCR genotyping showing both wild type (wt) and 
knockout (ko) bands of expected sizes. (D) qRT-PCR showing Smug1 mRNA expression (as 
arbitrary units AU) relative to Gapdh as mean +/- SD from triplicate measurements (E) 
Western blots of whole cell extracts prepared from mouse embryonic fibroblasts probed with 
anti-SMUG1 antibodies. GAPDH expression was used as loading control. 
 
Figure 2 - Smug1-/- mice lose hmU excision activity and accumulate genomic hmU 
(A) Smug1-/- MEFs exhibit no 5-hmU excision activity. (B) hmU excision activity is higher 
on hmU:G substrate than hmU:A substrate in all organs and undetectable on single-stranded 
substrate. (C) Smug1-/- MEFs accumulate 5-hmU in genomic DNA. (D) hmU incorporation in 
all organs is dependent on SMUG1 status. Representative gels in A and B are shown below 
each graph and error bars indicate SD of three biological replicates. 
 
Figure 3 - SMUG1 status has little impact on uracil excision activity in all organs except 
the brain 
Mice organs exhibit a wide range of uracil excision activities. The activities in brain samples 
were reduced by 40 % and 60 % on U:A and U:G substrates, respectively. SMUG1-status did 
not influence single-stranded uracil excision activity. Representative gels are shown below 
each graph and error bars indicate SD of three biological replicates. 
 
Figure 4 - Smug1-/- mice do not accumulate genomic uracil 
(A) Genomic uracil did not increase in either Smug1-/- mice or after 23 passages. (B) 
Genomic uracil did not significantly increase in any organ in either Smug1+/- or Smug1-/- 
mice. Error bars indicate SD of three biological replicates. 
 ʹͲ
Figure 5 - Ung-/-Smug1-/- mice lose all uracil excision activity and accumulate a large 
amount of genomic uracil. 
(A) U:G and U:A excision activities is decreased upon UNG inhibition by Ugi in all organ 
extracts except the brain and completely ablated in all organs in Smug1-/-Ung-/- mice. Single-
stranded uracil excision activities are ablated both in Ugi-treated extracts and in Smug1-/-Ung-
/- mice. (B) Genomic uracil increased by 2-3-fold and 3-20-fold in Ung-/- and Ung-/-Smug1-/- 
mouse organs, respectively. Representative gels in A are shown below each graph and error 
bars indicate SD of three biological replicates. 
 
Supplementary Figure 1 
Agarose gel electrophoresis image of Ung PCR genotyping showing both wild type (WT) and 
knockout (KO) bands of expected sizes. 
 
Supplementary Figure 2 - Uracil excision assay optimization using liver extracts. 
Uracil excision activity was measured over time in wild-type, Ugi-treated, and Smug1-/- livers 
on (A) U:A substrate using 20 g extract, (B) U:G substrate using 5 g extract, and (C) 
single-stranded uracil substrate using 2.5 g extract. 
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a  b s  t r  a  c  t
The most  common mutations  in  cancer are C to T  transitions, but  their origin  has  remained  elusive.
Recently,  mutational  signatures  of APOBEC-family cytosine  deaminases  were  identiﬁed  in  many com-
mon  cancers, suggesting  off-target  deamination  of cytosine  to  uracil  as a common mutagenic  mechanism.
Here  we  present evidence from  mass spectrometric  quantitation  of deoxyuridine  in  DNA that shows sig-
niﬁcantly  higher genomic  uracil  content in  B-cell lymphoma  cell lines compared  to  non-lymphoma cancer
cell  lines and normal circulating  lymphocytes.  The  genomic uracil  levels were  highly  correlated  with  AID
mRNA and  protein expression,  but not with  expression  of  other APOBECs.  Accordingly,  AID  knockdown
signiﬁcantly  reduced  genomic uracil  content.  B-cells stimulated  to express endogenous  AID  and undergo
class  switch  recombination  displayed a several-fold increase in  total genomic  uracil, indicating that  B
cells  may  undergo  widespread cytosine  deamination  after  stimulation.  In  line with  this,  we found  that
clustered  mutations  (kataegis) in  lymphoma  and  chronic  lymphocytic leukemia  predominantly  carry
AID-hotspot  mutational  signatures.  Moreover,  we  observed an inverse correlation  of  genomic uracil with
uracil excision  activity and expression  of the  uracil-DNA  glycosylases UNG and  SMUG1.  In conclusion,
AID-induced  mutagenic U:G  mismatches  in  DNA may be a fundamental  and common  cause of mutations
in B-cell malignancies.
©  2014  The  Authors.  Published by  Elsevier B.V. This  is  an open  access  article under the CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
The only sources of  uracil in DNA were previously thought
to be misincorporation of dUMP during DNA replication and
spontaneous deamination of  DNA cytosine. The discovery of
activation-induced cytidine deaminase (AID, also called AICDA) and
several other APOBEC-family enzymes as  probable DNA-cytosine
deaminases introduced a  third possible source (reviewed in  [1]).
∗ Corresponding authors. Tel.: +47 72 57 30 74/+47 72  573221;
fax:  +47 72 57  64  00.
E-mail addresses: bodil.kavli@ntnu.no (B. Kavli), hans.krokan@ntnu.no
(H.E. Krokan).
1 Present address: Science for Life Laboratory, Division of Translational Medicine
and  Chemical Biology, Department of Medical Biochemistry and  Biophysics, Karolin-
ska  Institutet, S-17121 Stockholm, Sweden.
AID was ﬁrst identiﬁed following induction of  class switch recom-
bination (CSR) in the CH12 mouse B-cell lymphoma cell line and
initially thought to  be an RNA-editing enzyme [2]. However, evi-
dence that AID was a  DNA mutator in Escherichia coli  [3]  and its
functional interaction with uracil-DNA glycosylase UNG in adaptive
immunity [4–6], indicated that AID is a  DNA-cytosine deaminase.
Later several of  the other known APOBEC-family enzymes were
also found to be DNA-cytosine deaminases in vitro [7,8].  DNA cyto-
sine deamination by APOBEC-family enzymes is a natural event in
both the  adaptive and innate immune systems, through targeted
deamination of immunoglobulin (Ig) genes by AID and deamina-
tion of  viral DNA by APOBEC enzymes, respectively [7]. Despite their
important physiological functions, these host defense mechanisms
entail a  high risk  of potentially carcinogenic off-target genomic
mutagenesis. Recent high-throughput sequencing of  large num-
bers of human cancer genomes showed that mutations at cytosine
residues, particularly C to T  transitions, are the  most prevalent
http://dx.doi.org/10.1016/j.dnarep.2014.11.006
1568-7864/© 2014 The  Authors. Published by Elsevier B.V. This is  an open access article under the  CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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mutations in human cancer, highlighting enzymatic deamination of
cytosine to uracil as a  potential source of mutagenesis [9–11]. How-
ever, the actual uracil level in normal  and various cancer genomes
has remained elusive.
Here, a sensitive LC/MS/MS-based method for quantiﬁcation
of genomic 2′-deoxyuridine (dUrd) was applied to demonstrate
that B-cell lymphoma cell lines contain several-fold increased lev-
els of  genomic uracil compared to  normal human lymphocytes
and non-lymphoma cell lines. Genomic uracil content correlated
with AID protein expression but not with other APOBEC enzymes.
In accordance with AID-generated uracil, we found that regions
of clustered mutations (kataegis)  in lymphoma and chronic lym-
phocytic leukemia (CLL) have a  distinct AID-hotspot mutational
signature. Importantly, we also show that uracil excision capac-
ity and expression of the uracil-DNA glycosylases UNG and SMUG1
correlated negatively with genomic uracil levels and to some extent
diminished the  effect of  AID. This study provides direct mechanistic
evidence for  genomic uracil accumulation due to  enzymatic DNA
cytosine deamination in  human cancers.
2. Materials and methods
2.1. Primary cells, cell  lines, cultivation, and reagents
Human cell lines HeLaS3 (ATCC  CCL-2.2TM), HEK293T (ATCC
CRL-11268TM),  and U2OS (ATCC HTB-96TM) were from ATCC. L428
(DSMZ ACC 197), DU145 (DSMZ ACC 261), KARPAS422 (DSMZ
ACC 32), T24 (DSMZ ACC 376), DOHH2 (DSMZ ACC 47), SUDHL4
(DSMZ ACC 4956), JJN3 (DSMZ ACC 541), SUDHL5 (DSMZ ACC 571),
SUDHL6 (DSMZ ACC 572 6), RAMOS (DSMZ ACC 603), RL  (DSMZ
ACC 613), DAUDI (DSMZ ACC 78 5), A431 (DSMZ ACC 91) were
from DSMZ. OCILY3 was a gift from Dr. L.M. Staudt, Metabolism
Branch, Center for Cancer Research, National Cancer Institute,
National Institutes of Health, Bethesda, MD, USA. Peripheral blood
mononuclear cells (PMBCs)  were puriﬁed from buffy coats from
three healthy blood donors using the LymphoprepTM (Progen) kit
according to the manufacturer’s protocol. Human B-lymphocytes
were puriﬁed from buffy coats from three healthy blood donors
using a  negative selection kit from StemCell Technologies accord-
ing to  the  manufacturer’s protocol. HeLaS3, HEK293T, T24, A431,
DU145, and U2OS cells were cultured in  DMEM (4500 mg/l glu-
cose) with 10% FCS, 0.03% l-glutamine, 0.1 mg/ml gentamicin and
2.3 g/ml fungizone at  37 ◦C and 5% CO2.  DAUDI, DOHH-2, KARPAS,
RAMOS, SU-DHL-4, SU-DHL-6, OCILY-3, L-428, RL, SU-DHL-5, and
JJN3 cells were cultured in RPMI-1640 with 4500 mg/l glucose,
0.03% l-glutamine, Pen-Strep (1×  ﬁnal), 0.1 mg/ml  gentamicin, and
2.3 g/ml fungizone, and 20% heat  inactivated (56 ◦C, 20 min) FCS at
37 ◦C  and 5% CO2. For  quantitative rtPCR and uracil measurements
cells were harvested at densities between 750 000  and 2 million
cells/ml.
Cell doubling times for  suspension cells were measured using
a Countess® cell counter (Invitrogen) by two parallel daily mea-
surements for three to ﬁve day periods from cell densities of
50 000–200 000 cells/ml to  one to three million cells/ml. For adher-
ent cells, doubling time was measured in  96 well plates (3–6 parallel
wells; starting density 50 000 cells/ml) for a  three day period by
daily ﬂuorescent measurement of resazurin (Sigma) metabolism
according to the manufacturer’s protocol. Doubling times were cal-
culated by exponential regression.
SUDHL5 AID knockdown and control cells were made using
Open Biosystem TransLenti Viral Packaging Mix, pTRIPZ AICDA
shRNA (RHS4741-EG57379; vectors V2THS 58282, 58283, and
58319) or pTRIPZ non-silencing control vector according to the
manufacturer’s protocol. Brieﬂy, lentiviruses were produced in
HEK293T cells, and then supernatant from three consecutive days
48 h after  HEK293T transfection were used to  infect SUDHL5 cells.
Infected SUDHL5 cells were ampliﬁed for another 48 h  and  then
selected with  2  g/ml puromycin for 30 days. Expression was
induced with 1 g/ml doxycycline.
CH12F3 AID-EYFP and EYFP stable transfectants, confo-
cal microscopy, and stimulation experiments were described
previously [12].  CH12F3 cells (2 × 106 cells/ml) were cul-
tured in RPMI medium, with 10% heat-inactivated fetal calf
serum, 0.03% l-glutamine, 50  M -mercaptoethanol, 1  mM Na-
pyruvate, 0.1 mg/ml  penicillin/streptomycin, 2.3 g/ml fungizone,
and 1.0 mg/ml  G418. CH12F3 cells were stimulated to  undergo
class switch recombination by adding 10 ng/ml mouse recom-
binant IL-4 (Peprotech), 2  g/ml anti-mouse CD40 monoclonal
antibody (BD Biosciences) and 1  ng/ml human TGF-1 (Pepro-
tech) and harvested 48 h  post stimulation for  DNA and protein
isolation. Western analysis of AID protein expression was per-
formed using mouse anti-AID monoclonal antibody no. 39-2500,
clone ZA001, 500 g/ml (Invitrogen). Nuclear extracts from  syn-
chronized HeLa cells were prepared essentially as described
[13,14].
2.2. RNA isolation and quantitative real-time PCR  (qRT-PCR)
Total RNA for  mRNA analysis was  prepared using the  mirVana
miRNA isolation kit (Ambion) according to the  manufacturer’s
instructions. RNA concentration and quality was measured on  a
NanoDrop ND-1000 UV–vis spectrophotometer. Total RNA (770 ng)
was reverse transcribed for  gene expression analysis using Taq-
Man  reverse transcription reagents (Applied Biosystems). The
following TaqMan gene expression assays (Applied Biosystems)
were used: AID (Hs00757808 m1), UNG (Hs00422172 m1),
SMUG1 (Hs04274951 m1), TDG (Hs00702322 s1), MBD4
(Hs00187498 m1), APOBEC1 (Hs00242340 m1), APOBEC2
(Hs00199012 m1), APOBEC3A (Hs00377444 m1), APOBEC3B
(Hs00358981 m1), APOBEC3C (Hs00819353 m1), APOBEC3D
(Hs00537163 m1), APOBEC3G (Hs00222415 m1), APOBEC3F
(Hs01665324 m1), APOBEC3H (Hs00419665 m1), APOBEC4
(Hs00378929 m1), and GAPDH (Hs99999905 m1). Quantitative
PCR was  carried out on  a Chromo4 (BioRad) real-time PCR detec-
tion system. Relative expression of mRNA was  calculated by the
Ct method using GAPDH as endogenous control. Regression
analyses were done using GraphPad Prism where data were ﬁtted
by linear regression (log/linear(X)  vs. log/linear(Y))  as indicated.
2.3.  Quantiﬁcation of uracil in DNA by LC/MS/MS
Genomic uracil was quantiﬁed as previously described
[15]. Brieﬂy, DNA was isolated by phenol:chloroform:isoamyl
extraction, treated with alkaline phosphatase to remove free
deoxyribonucleosides, and then  enzymatically hydrolyzed to
deoxyribonucleosides. Deoxyuridine (dU) was then separated
from deoxycytidine (dC) by HPLC fractionation using a  reverse-
phase column with embedded weak acidic ion-pairing groups
(2.1 mm × 150 mm,  5  m, Primesep 200, SIELC technologies), using
a  water/acetonitrile gradient containing 0.1% formic acid.  The dU
fraction was  ﬁnally analyzed by ESI-LC/MS/MS using a  reverse
phase column (2.1 mm  × 150 mm,  3.5 m,  Zorbax SB-C18, Agilent
Technologies), using a water/methanol gradient containing 0.1%
formic acid on  an API5000 triple quadrupole mass spectrometer
(Applied Biosystems) in  positive ionization mode. A  small frac-
tion of  the hydrolyzed deoxyribonucleosides were quantiﬁed by
LC/MS/MS in parallel and used to determine the amount of  dU  per
106 deoxyribonucleosides.
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2.4. In vitro uracil DNA excision activity and complete BER  assays
Standard UDG activity assay was performed as described [16].
Brieﬂy, 20 l reaction mixtures containing (ﬁnal) 1.8 M nick trans-
lated [3H]-dUMP-labeled calf thymus DNA (U:A substrate), 1× UDG
buffer (20 mM  Tris–HCl, pH 7.5, 60 mM  NaCl, 1 mM  DTT, 1 mM
EDTA, 0.5 mg/ml  BSA) and 1  g whole cell extract were incubated at
30 ◦C for 10 min. Acid-soluble [3H] uracil was quantiﬁed by scintil-
lation counting. Whole cell extracts was prepared as  described [17].
Oligodeoxynucleotide UDG assays were performed as described
[16]. Brieﬂy, double-stranded DNA substrates were generated by
annealing 6-FAM-labeled oligonucleotides containing a centrally
positioned uracil in an AID-hotspot (5′-CATAAAGAGUTAAGCCTGG-
3′; Eurogentec) to complementary strands containing G opposite
U. Activity was measured in  10 l assay mixtures containing (ﬁnal)
20 nM substrate, 1× UDG buffer and 0.4 g cell extract, and incu-
bated at 37 ◦C for 10  min. Reactions were stopped and AP-sites were
cleaved by addition of 50 l  10% piperidine followed by incubation
at  90 ◦C for 20 min.  Product and substrate were separated on PAGE,
scanned on Typhoon Trio imager and quantiﬁed using ImageQuant
TL software (GE healthcare).
BER assays were carried out essentially as  described [14,17].
Brieﬂy, 10 g nuclear extract was incubated with 250 ng cccDNA
(covalently closed circular DNA) substrates in ﬁnal concentra-
tions of 40  mM HEPES-KOH, 70 mM  KCl, 5 mM  MgCl2,  0.5 mM DTT,
2 mM ATP, 20  M dATP, 20 M dGTP, 20  M dTTP, 8  M dCTP,
4.4 mM phosphocreatine, 62.5 ng/l  creatine kinase and 50 nCi/l
[-32P]dCTP in a ﬁnal volume of  40 l.  Reactions were incubated
for 25 min  at 37 ◦C and stopped by addition of EDTA  (18 mM ﬁnal)
and 6 g RNaseA and incubated at 37 ◦C for  10 min  followed by
the addition of  SDS (0.5% ﬁnal) and 12  g proteinase K.  DNA was
extracted by phenol/chloroform and precipitated in ammonium
acetate/ethanol and digested with XbaI  and HincII (New England
Biolabs). Following 12% PAGE, bands were visualized and quanti-
ﬁed using ImageQuant software (Fujiﬁlm). We investigated relative
contribution of SMUG1, TDG and UNG2 to  the  initiation of  uracil
repair by pre-incubating extracts with neutralizing antibodies to
SMUG1 (0.11 g/l ﬁnal concentration), UNG (0.3 g/l ﬁnal con-
centration), and/or neutralizing anti-serum towards TDG (1:50
dilution) on ice  for 30 min  prior to the reaction.
2.5. Flow cytometric analysis of cell cycle
Cells were ﬁxed in  70% methanol, washed twice with PBS,
and then treated with 50  l RNaseA (100 g/ml in PBS) at 37 ◦C
for 30 min  prior to DNA staining with 200 l propidium iodide
(50 g/ml in  PBS) at 37 ◦C  for 30 min.  Cell  cycle analyses were per-
formed using a  FACS Canto ﬂow  cytometer (BD-Life Science).
2.6. Sample preparation and targeted mass spectrometry
Cell pellets were resuspended in 1× packed cell volume in
buffer I: 10 mM  Tris–HCl pH 8.0,  200  mM  KCl,  1× complete protease
inhibitor, and 5× phosphatase-inhibitor cocktails I and II (Sigma-
Aldrich), 10 M suberoylanilide hydroxamic acid (SAHA) (Cayman
Chemicals) and 0.05 M,  Ubiquitin Aldehyde (Biomol International
LP) followed by addition of  an equal ﬁnal volume of  buffer II: 10 mM
Tris–HCl pH  8.0, 200 mM  KCl, 10  mM EGTA, 10 mM MgCl2,  40%
glycerol, 0.5% NP40, 1 mM  DTT, 1× complete protease inhibitor,
and 5× phosphatase-inhibitor cocktails I and II (Sigma-Aldrich),
10 M suberoylanilide hydroxamic acid (SAHA) (Cayman chemi-
cals) and 0.05 M,  Ubiquitin Aldehyde (Biomol International LP)
containing an endonuclease cocktail of  200 U Omnicleave (Epicen-
ter Technologies), 2 U DNase I (Roche Inc.), 250 U Benzonase (EMD),
100–300 U micrococcal nuclease (Sigma-Aldrich), and 10 g  RNase
A (Sigma-Aldrich) per 1 ml  of  buffer II. After resuspension, the
lysates were incubated for 1.5 h at 4 ◦C  in a roller. 50 g  protein
of cell lysate pools consisting of  2–4 biological replicates from each
cell line were incubated with 5  mM  tris (2-carboxyethyl) phosphine
(TCEP) for  30 min  followed by alkylation with 1 mol/mg protein
of  iodoacetamide for 45 min  in  the dark. Proteins were precipitated
using a methanol–chloroform method as described [18],  including
another round of  reduction and alkylation prior to  overnight diges-
tion with Trypsin (Promega) at 1:40 ratio (w/w, enzyme:protein)
at 37 ◦C. Tryptic digests were dried out, resuspended in 0.1% formic
acid and analyzed on  a  Thermo Scientiﬁc QExactive mass spec-
trometer operating in  Targeted-MS2 mode coupled to an Easy-nLC
1000  UHPLC system (Thermo Scientiﬁc/Proxeon). Peptides (2 g)
were injected onto a  Acclaim PepMap100 C-18 column (75 m
i.d.  × 2 cm, C18, 5 m,  100 A˚)  (Thermo Scientiﬁc) and further sep-
arated on a  Acclaim PepMap100 C-18 analytical column (75 m
i.d.  × 50 cm,  C18, 3 m,  100 A˚)  (Thermo Scientiﬁc). A  120 min
method was used and consisted of a  300  nl/min ﬂow rate, start-
ing with 100% buffer A (0.1% Formic acid) with an increase to  5%
buffer B (100% Acetonitrile, 0.1% Formic acid) in  2 min, followed by
an increase to 35% Buffer B over 98  min  and a rapid increase to  100%
buffer B in  6 min, where it was held for  5.5 min. The solvent compo-
sition was  quickly ramped to 0%  buffer B, where it was subsequently
held  for 8  min  to allow the column to  equilibrate for the next run.
The  peptides eluting from the  column were ionized by using a
nanospray ESI ion source (Proxeon, Odense) and analyzed on the
QExactive operating in positive-ion mode using electrospray volt-
age 1.9 kV  and HCD fragmentation. Each MS/MS  scan was acquired
at a  resolution of  35 000 FWHM,  normalized collision energy (NCE)
28, automatic gain control (AGC) target value of 2 × 105, maximum
injection time of 120 ms  and isolation window 2  m/z.
All parallel reaction monitoring (PRM)-based targeted mass
spectrometry methods were designed, analyzed, and processed
using Skyline software version 2.5 [19]. In silico selection of pro-
teotypic peptides was  performed via Skyline using the Homo
sapiens reference proteome available at  www.uniprot.org to
exclude non-unique peptides. Frequently modiﬁed peptides, such
as those containing methionine, and  peptides containing contin-
uous sequences of  R and K (e.g., KR,  RK, KK or  RR) were avoided.
However, when the inclusion of non-ideal peptides was neces-
sary both unmodiﬁed and M-oxidized peptides as well as peptides
containing a  missed cleavage site were analyzed. Synthetic puri-
ﬁed peptides (JPT Peptide Technologies) and tryptic digests from
recombinant proteins were analyzed in  a  QExactive mass spec-
trometer. Information on  retention time and fragmentation pattern
of  the  top 2–6 ionizing tryptic peptides (2+ or  3+ charge states)
for each protein were used to build a scheduled method with a
retention time window of 5 min. The method was  then used for
peptide quantiﬁcation in  the cell lysate pools. A minimum of  2
peptides per protein was used for quantitative analysis except for
APOBEC3F in which  only one of the  unique peptides tested was
detectable in the  samples. The sum of  the  integrated peak areas of
the 3–5 most intense fragments was used for peptide quantiﬁca-
tion. Peptide areas for multiple peptides of the  same protein were
summed to assign relative abundance to  that protein. The error bars
represent the  standard deviation of  3 technical replicates.
2.7. Bioinformatics analysis of DNA  exome sequencing data
Kataegis regions and somatic mutations for CLL, B-Cell lym-
phoma, ALL, lung  adenocarcinoma, and breast, liver, and pancreatic
cancer were downloaded from the supplementary material of a
published study [11].  The kataegis regions within speciﬁc cancer
samples were provided as genomic coordinates into the human
reference genome version 19 (hg19); the somatic mutations were
provided as genomic coordinates in  hg19 and nucleotide alter-
ations. We used the following procedure to  create mutational
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signatures for the  kataegis regions for  each cancer type. First, for
each kataegis region, its sample ID and genomic coordinates were
used to identify the corresponding somatic mutations. Second,
for each somatic mutation, the  ﬁve nucleotides centered on  the
mutated nucleotide were retrieved from the genome sequence.
Third, if  the middle nucleotide within the retrieved sequence was  a
purine, the sequence was reverse-complemented such that all  the
mutations were represented by  pyrimidines. Fourth, for each of  the
six possible single nucleotide mutations, the relative occurrence of
each  nucleotide at  each position within the retrieved sequences
was computed. These position-speciﬁc relative occurrences were
the mutational signatures.
3. Results
3.1. High  genomic uracil levels in  B-cell lymphoma cells
To investigate whether uracil in the  genome may be an  impor-
tant factor in lymphomagenesis, we measured genomic uracil in
ten B-cell lymphoma cell lines, seven other human transformed cell
lines and in lymphocytes from three healthy human blood donors
(Fig. 1A). The origin and major characteristics of cell lines is dis-
played in Fig. 1B. We found as  much as  72-fold variation in genomic
uracil levels between the cell line with the highest uracil content
(DAUDI, 4.03 deoxyuridines (dU) per 106 deoxyribonucleosides
(nt)) and the cells with the lowest level of  genomic uracil (A431,
0.056 dU/106 nt). Strikingly, all  ten lymphoma cell lines and four of
the other transformed cell lines had signiﬁcantly (P < 0.05) elevated
genomic uracil levels compared to genomic uracil in peripheral
blood mononuclear cells (PBMC) from the mean value for three
blood donors (0.19 dU/106 nt). We  also measured genomic uracil in
B-lymphocytes isolated from buffy coats from three healthy donors,
using a  kit for negative selection. The genomic mean uracil level
in these was 0.14 dU/106 nt, with individual values of  0.07, 0.17
and 0.19 dU/106 nt, respectively. The mean value for the genomic
uracil level in B-cell lymphoma cell  lines  (2.5  dU/106 nt) was 13-fold
and 18-fold higher than in  PBMC and primary B-cells, respectively.
In addition it was signiﬁcantly higher (4.4-fold, P < 0.001) than the
mean for non-lymphoma cell lines (0.57 dU/106 nt). The B-cell lym-
phoma cell lines are likely to be exposed to  enzymatic untargeted
cytosine deamination by AID throughout the  genome, since the
total number of  genomic uracils is in the range 3000–15 000 per
haploid genome (this paper) and the density of genomic uracil in
S region of  stimulated B-cells is only ∼0.8 per kb [20]. Some of  the
non-lymphoma cancer cell  lines had intermediate genomic uracil
levels, clearly higher than  normal peripheral blood lymphocytes,
but lower than most of  the B-cell lymphoma cell lines.
3.2. AID  expression correlates with genomic uracil accumulation
AID has previously been shown to be expressed in several lym-
phoma subtypes [21–24] and AID/APOBEC family enzymes were
suggested to contribute to mutational signatures in a  number of
cancers by deaminating cytosine to uracil in DNA [11]. We  there-
fore investigated whether expression of  AID and/or other APOBECs
could explain the  observed variation in  genomic uracil levels in
the cell line  panel. We  ﬁrst measured mRNA expression of  AID
and all other APOBEC-family genes by quantitative rtPCR using
GAPDH as reference gene (Fig. 2A). AID mRNA was  detected in all 17
cell lines, although at  highly variable levels, but not in the normal
lymphocytes from blood donors. Furthermore, AID mRNA was sub-
stantially increased in lymphomas with high genomic uracil such
that AID mRNA had a  high positive correlation with genomic uracil
(R2 = 0.70, P <  0.0001). By contrast, APOBEC3B, -3D, -3F, and -3G
mRNA content did not correlate with genomic uracil level although
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Fig. 1.  Genomic uracil levels in  B-cell lymphoma-/non-lymphoma cell lines  and
on  white blood cells from peripheral blood l. (A) Quantiﬁcation of genomic uracil
levels (dU/106 nt) by LC–MS/MS in  lymphoma cell lines  (green), non-lymphoma cell
lines (yellow) and PBMCs or B-lymphocytes isolated from buffy coats from  blood
donors (red). Asterisk (*) signiﬁes measurements signiﬁcantly (P < 0.05) different
from average genomic uracil levels  in  PBMC from three healthy blood donors (Stu-
dent’s  T-test). Error bars represent mean and SD of at least two biological replicates.
Cell lines within each  group are ordered along the x-axis according to  increasing
genomic uracil levels. (B) Overview of cell  lines, PBMCs and B-lymphocytes used in
the  study and their origin. B-NHL: B-cell non-Hodgkin lymphoma. (For interpreta-
tion  of the references to  color in  this  ﬁgure legend,  the reader is referred to the web
version  of this article.)
they were expressed in all cell lines as well as in the  normal lympho-
cytes (Fig. 2A). mRNA of the other APOBECs (APOBEC1, APOBEC2,
APOBEC3A, and  APOBEC) were detected only in  some of the cell
lines and mostly at very low levels  (data  not shown).
Although mRNA expression data is useful as  a  predictor of  pro-
tein expression, it does not always correlate with the  actual protein
levels in the  cells. Thus, we quantiﬁed AID and the  APOBEC proteins
by parallel reaction monitoring using a quadrupole-Orbitrap mass
spectrometer (Fig. 2B). This is a  highly selective method allowing
quantiﬁcation of  many protein targets in a  single sample [25,26].
In agreement with mRNA data, MS  quantiﬁcation revealed higher
amounts of  AID  protein in lymphoma cells with increased genomic
uracil (Fig. 2B, upper panel). Furthermore, similar to mRNA data
(Fig. 2A, middle panel), APOBEC3B, -3D, -3F  and-3G proteins
were expressed in all cell lines (Fig. 2B, middle panel), while
APOBEC1, APOBEC2, APOBEC3A, and APOBEC4 were not detectable
or detected at very  low levels (data not shown). In  general, protein
levels for  AID and the  APOBEC proteins (normalized to GADPH pro-
tein) correlated well with mRNA levels  (Fig. 2C).  As an additional
control, we also quantiﬁed AID by western analysis, which yielded
results similar to the MS analysis (Fig. 2D).  Linear regression
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Fig. 2. Expression of AID and APOBECs, and correlation with genomic uracil. Expression of AID and APOBEC3B, 3D,  3F, and 3G mRNAs measured by  qRT-PCR (A)  or protein
by  mass spectrometric quantiﬁcation. (B) Lymphoma cell lines are shown in green,  non-lymphoma cell  lines in yellow, and PBMC in  red. Cell lines within each group  are
ordered  along the x-axis according to  increasing genomic uracil levels, as in  Fig.  1.  mRNA levels have been normalized to GAPDH mRNA, and protein levels to MS signal
counts  per total injected protein. Note  that mRNA and protein expression data are in  log-scale. Regression plots of genomic uracil (dU/106 nt) vs. AID mRNA and protein levels
are  presented in  the lower panels in Fig. 2A and B, respectively. (C) Table of correlation coefﬁcients between mRNA and protein expression for AID and other APOBECs. (D)
Western  analysis of AID protein expression with GAPDH shown  as  a loading control. (For interpretation of the references to color in  this ﬁgure legend, the reader is referred
to  the web version of this article.)
Table 1
Regression analysis of genomic uracil levels (linear)  vs. AID and APOBEC protein expression (log) normalized to total protein. Bold green indicates signiﬁcant positive
correlation  (For interpretation of the references to color in this  ﬁgure legend, the  reader is  referred to the web version of this article.).
All cell  lines including PBMC B-cell lymphoma cell  lines Non-lymphoma cell lines
R2 P-value R2 P-value R2 P-value
AID 0.65 <0.0001 0.42 0.04 0.00 0.97
APOBEC3B 0.10 0.2089 0.00 0.84 0.00 0.98
APOBEC3D 0.12 0.17  0.00 0.88 0.02 0.79
APOBEC3F  0.01 0.67  0.08  0.44 0.32 0.18
APOBEC3G 0.12 0.14  0.30  0.09 0.00 0.98
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Fig. 3. Genomic uracil levels after stimulation of endogenous AID expression, AID-YFP overexpression, and AID knockdown. (A) Genomic uracil levels in  DNA isolated
from  mouse lymphoma cells (CH12F3) stably transfected with AID-YFP or YFP, and  confocal microscopy showing subcellular distribution of AID-YFP fusion protein or YFP. (B)
Genomic  uracil levels and cell  growth of CH12F3 YFP cells and CH12F3 AID-YFP cells prior to stimulation and 48 h after being stimulated to undergo class switch recombination
using  mouse recombinant IL-4, CD40 monoclonal antibody and hTGF- (upper panel) and western blots from one representative experiment showing AID protein expression
levels  and -actin as loading control (middle panel). The lower panel shows cell growth of stimulated and unstimulated cells. Graphs represent mean and SD calculated
from  at least two  biological replicates. P-values were calculated by a two-tailed Student’s T-test. (C) Genomic uracil levels in  SUDHL5 lymphoma cells stably transfected with
AID-shRNA and control. Western blots shows AID protein expression levels  with  GAPDH as  a loading control.
analysis of  AID western signals against MS quantitation of  AID  pro-
tein revealed almost perfect correlation (R2 = 0.95). Importantly,
AID expression signiﬁcantly correlated with genomic uracil also
at the protein level (R2 = 0.65, P < 0.0001) (Fig. 2B, and Table 1),
and thereby seemed to  account for a  large part of  the  variation in
genomic uracil between the  cell lines. The correlation was  still valid
when including only the  B-cell lymphoma cell lines in the regres-
sion analysis (Table 1). No signiﬁcant correlations were observed
between the other APOBEC proteins and genomic uracil (Table 1).
Thus, AID was the  only APOBEC-family member that correlated
with genomic uracil in the  human cancer cell lines examined here.
3.3. AID  expression causes several-fold increases in  genomic
uracil
To investigate whether AID expression signiﬁcantly increases
the overall level of genomic uracil in an otherwise isogenic back-
ground, we used stable transfectants of the  mouse B-cell lymphoma
cell line CH12F3 expressing AID-YFP fusion protein, or YFP as
control [27]. AID is mostly localized in the  cytoplasm (Fig. 3A),
but is actively imported into the nucleus where it  may  access
the genome [12].  We  found that the  cells expressing AID-YFP
displayed an almost six-fold higher level of  genomic uracil com-
pared to  the YFP control (Fig. 3A). When appropriately stimulated,
CH12F3 cells increase endogenous AID  expression and have capac-
ity to undergo CSR. Thus next, we investigated whether stimulation
of these cell lines also increased the level of genomic uracil. A
clear induction of  AID and a  four-fold increase in genomic uracil
were observed in stimulated CH12F3-YFP cells already after 48 h
(Fig. 3B, upper panel). An increase in  genomic uracil was  observed
in the  stimulated AID-YFP expressing cells as well, although this
was  not signiﬁcant, probably due to the high constitutive expres-
sion AID-YFP. Importantly, the  increase in  genomic uracil observed
after stimulation could not be ascribed to increased replica-
tive  misincorporation of dUMP due to higher proliferation rate
because stimulated CH12F3 cells actually have reduced prolifer-
ation (Fig. 3B, lower panel). Finally, we examined the effect of
knocking down AID using a  lentiviral AID shRNA expressing vector.
For this experiment, we  used the human B-cell lymphoma cell line
SUDHL5, which exhibited high constitutive AID expression (Fig. 2B
and D). We  found that a  60% knockdown of AID reduced genomic
uracil level by 38% (P = 0.005; Fig. 3C). Taken together these results
strongly support the view  that enzymatic cytosine deamination is
the major source of  genomic uracil in  AID-expressing cells.
3.4. Uracil-DNA repair capacity is inversely correlated with
genomic uracil levels
Genomic uracil is predominantly repaired by base excision
repair (BER), which is mainly initiated by the uracil-DNA glycosy-
lase encoded by the  UNG gene [16]. We  have previously shown that
UNG deﬁciency in  human and mouse cells results in a  several-fold
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Fig. 4. Uracil excision activity, expression of uracil DNA glycosylases, and correlation with genomic uracil levels. Note that in  all bar graphs cell lines are  ordered
according  to increasing genomic uracil levels  in  lymphoma cell lines (green) and non-lymphoma cell lines (yellow), and Y-axes are normalized so that maximum activity
or  maximum protein abundance equals 1. Bars  and  error bars represent mean and SD of three biological replicates. (A)  Relative uracil excision activity from an AID-hotspot
sequence-oligomer containing uracil in U:G context (cleavage assay) and from a nick-translated DNA containing uracil in  U:A context (3H-uracil release assay), as indicated
by  color codes. Activity was normalized to  total protein. (B) The  corresponding correlation between genomic uracil and activity per total protein. (C) Relative uracil excision
activity  normalized to activity per cell, and  (D) the corresponding correlation with genomic uracil with activity per cell. (E) Western blot  of UNG2 and  UNG1 in  non-lymphoma
and  lymphoma cell  lines. (F) Relative abundance of MS-quantiﬁed UNG  protein per total protein; (G)  Correlation plot of average uracil excision activity vs. relative abundance
of  MS quantiﬁed UNG protein. (H) Relative abundance of MS quantiﬁed DNA glycosylases SMUG1, TDG and MBD4 and cell doubling times of cell lines; (I) Correlation plot
of  genomic uracil content vs. doubling times of non-lymphoma cell  lines and lymphoma cell lines. (J) Contribution of UNG, SMUG1  and TDG through the cell  cycle measured by
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increase in genomic uracil [15]. The  other uracil-DNA glycosylases,
i.e. SMUG1, TDG, and MBD4, are thought to be quantitatively less
important contributors, at least in proliferating cells [16,28,29].
Furthermore, the  DNA repair machinery has been shown to  protect
against AID-induced mutagenesis [30–32].  Therefore, we  measured
uracil excision activity of  cell free extracts prepared from all cell
lines against oligodeoxyribonucleotides with uracil in a U:G con-
text. In addition, we measured [3H]-uracil release from calf thymus
DNA having uracil in  a  U:A  context. The two different assays gave
similar activity proﬁles (Fig. 4A). Regression analysis of  uracil-
excision activity (relative to protein content in the cell extracts)
against genomic uracil content in the cells demonstrated a  nega-
tive correlation (Fig. 4B), which is signiﬁcant (P < 0.05), although
weak. We also calculated relative uracil excision activity per cell
since the glycosylases are predominantly nuclear enzymes and the
cells tested vary in size and nucleus-to-cytoplasm ratios (Fig. 4C).
Using these activity values, a stronger correlation with genomic
uracil level was observed (Fig. 4D).
The UNG gene encodes both nuclear UNG2 and mitochondrial
UNG1, having identical catalytic domains but speciﬁc N-terminal
domains. These isoforms are differently regulated from two pro-
moters [33,34].  Since activity assays measure total activity, we
analyzed the  isoforms by western blots. Nuclear UNG2, which is
the isoform relevant for  repair of  genomic uracil, was expressed in
all cell lines and accounted for  approximately half of  total UNG in
most cell lines (Fig. 4E).  UNG  enzymes are the  most active of the
glycosylases, at least in  vitro. However, each glycosylase with its
speciﬁc or complementary role may  exert a  signiﬁcant impact on
the total level of  genomic uracil in vivo. We  therefore quantiﬁed
all the uracil-DNA glycosylases at protein level by MS. The relative
abundance of  quantiﬁed UNG protein (UNG1 and UNG2) (Fig. 4F)
correlated strongly with total uracil excision activity (Fig. 4G), in
accordance with its presumed major role in uracil repair. Similar
to the uracil excision activity, UNG protein per cell also corre-
lated inversely with genomic uracil level when all cell lines were
included in the  regression analysis (Table 2). Furthermore, quanti-
ﬁed SMUG1 protein (Fig. 4H) correlated negatively with genomic
uracil, although more weakly. Surprisingly, however, SMUG1 was
the only glycosylase that correlated with genomic uracil when only
the B-cell lymphoma group was analyzed (Table 2). In  addition,
the AID/SMUG1 protein ratio displayed signiﬁcantly higher corre-
lation with genomic uracil in the  B-cell lymphoma group (R2 = 0.65)
compared to AID alone (R2 = 0.42). No signiﬁcant correlations were
found for TDG or MBD4 proteins and genomic uracil (Fig. 4H) when
analyzed separately (Table 2)  or in combination with AID or  other
glycosylases.
3.5. Cell doubling time, genomic uracil content and repair
capacity in  cell cycle phases
In  cells that do  not express AID, one would predict that genomic
uracil from misincorporation of  dUMP during replication should
result in  increased genomic uracil in cells with short doubling
time, as suggested previously [35]. Indeed, we observed a  signif-
icant inverse relationship between genomic uracil and doubling
time in  non-lymphoma cancer cells (R2 = 0.57; P =  0.048; Fig. 4I).
Furthermore, since AID has  been shown to  act  in  the  G1 phase of
the cell cycle [36–38],  one would expect that the lymphoma cell
lines with long doubling times might have higher genomic uracil
levels than those with shorter doubling time. However, we did not
ﬁnd a  signiﬁcant positive correlation with doubling time (R2 = 0.27;
P =  0.12), although the  curve was  apparently different from that  of
the non-lymphoma cell lines (Fig. 4I).
As mentioned above, we  found an inverse correlation between
genomic uracil and both total uracil excision capacity, and with
SMUG1 and UNG protein levels. Nuclear UNG2 expression peaks
during G1/S-phase transition and during S-phase and is expressed
at a  lower level in late S-phase, G2 and early  G1 [13,39].  In con-
trast, TDG is  mainly expressed in the  G1 phase of  the  cell cycle
[13,39].  Thus, TDG might have a role in counteracting untargeted
generation of  U:G mismatches by AID in G1, although correlation
studies did not give indications of  this. SMUG1 is not cell cycle regu-
lated [40] and may  contribute in  all cell cycle phases, but is  a rather
slow acting enzyme [16]. To explore the relative contribution of  the
uracil-DNA glycosylases in in  vitro complete BER of uracil in  differ-
ent parts of  the  cell cycle, we synchronized HeLa cells by double
thymidine block [13],  prepared nuclear extracts from the  differ-
ent cell cycle phases (monitored by ﬂow cytometry) and applied
an assay for complete BER of  U:G mismatches in  DNA [14,17,41].
To examine UNG, SMUG1 and TDG  separately, we used a  combina-
tion of  neutralizing antibodies against UNG, SMUG1 and TDG. UNG
was found to  be by far  the major contributor to initiate BER in the
G1/S transition and  in the  S  phase. Total repair capacity in G2  and
G1 was somewhat lower than in the S phase, but UNG remained a
major contributor to the  initial step in BER-process, although con-
tributing only 1.5–1.7 more than TDG. SMUG1 contributed in all cell
cycle phases, but to  a  minor degree (Fig. 4J).  Thus, a  role of  TDG and
SMUG1 in BER of  U:G mismatches in the  G1  phase, and a  smaller
role in the S-phase would seem likely from our in vitro data. The
contribution of the  different uracil-DNA glycosylases during the
cell cycle is likely to be similar in other human cell lines, includ-
ing B  cell lymphoma cell lines, although this has not been formally
demonstrated.
3.6. Lymphomas and  CLL  carry a  distinct AID-hotspot mutational
signature in  kataegis regions
Large scale genome sequencing of  cancers has produced the
novel observation that  several cancers carry localized hypermu-
tation, named kataegis,  in small regions that are also associated
with genomic rearrangements. The mutational signatures observed
in most cancer types with kataegis (acute lymphoblastic leukemia
(ALL), lung  adenocarcinomas, breast, pancreas, and liver cancer)
suggest an association with APOBEC3 enzymes, with a strong
enrichment of C to T transitions and C to G transversions at
TCA/T sequence contexts [11]. As  mentioned, these kataegis pat-
terns might be different from those found in lymphomas and CLL
[11],  though this was not explored in detail in their comprehen-
sive paper. We  therefore reanalyzed these exome sequencing data
from kataegis regions of  lymphomas and CLL and compared them  to
kataegis regions in cancers with typical APOBEC signatures (Fig. 5).
The preferred sequence for  C  to  T mutation in kataegis regions of
B-cell lymphomas and CLL  revealed a target sequence that over-
lap with the known AID hotspot motif (WRCY W = A/T, R = purine,
Y =  pyrimidine). The  general mutational pattern for C to T tran-
sitions in lymphomas and CLL  was AGCT,  rather than TCA/T  for
the other cancer  types with kataegis (Fig. 5). This strongly impli-
cates AID-induced genomic uracil formation in the  development
of localized hypermutation in  B-cell malignancies, in accordance
an in vitro assay for complete BER of a  single uracil in a deﬁned U:G  context. HeLa  cells were synchronized by double thymidine block, and harvested after 0, 3,  8,  and 14  h
representing  G1/early S-phase, mid  S-phase, G1 and G2 phase, and  G1 phase, respectively, as  shown by ﬂow cytometric conﬁrmation of cell cycle distribution in  the top row.
The  contribution of each uracil DNA glycosylase was measured by using neutralizing antibodies to  UNG, SMUG1, or TDG as indicated. Note that the column size  values in the
panels  are directly comparable since they are generated from the same gel using the same substrate. The data points represent mean of independent triplicate experiments.
(For  interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Table  2
Regression analysis of genomic uracil levels  (linear) vs.  expression of uracil-DNA repair  glycosylases (linear) normalized either  to  total protein or  to  total  protein per cell.
Bold  red indicates signiﬁcant negative correlation (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the  web version of this article.).
Per total protein
All cell  lines B-cell lymphoma cell lines Non-lymphoma cell lines
R2 P-value R2 P-value R2 P-value
UNG 0.24 0.05  0.01 0.82 0.23 0.28
SMUG1  0.28 0.03 0.41 0.04 0.13 0.43
TDG  0.05 0.35 0.02 0.69 0.13 0.41
MBD4  0.07 0.27 0.02 0.7 0.05  0.63
Per  cell
All cell  lines B-cell lymphoma cell lines Non-lymphoma cell lines
R2 P-value R2 P-value R2 P-value
UNG 0.42 0.005 0.05 0.52 0.20  0.31
SMUG1  0.28 0.03  0.16 0.24 0.06  0.6
TDG  0.22 0.06 0.14 0.27 0.32 0.17
MBD4  0.00 0.94 0.05 0.55 0.00 0.88
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Fig. 5. Sequence context of C to T transitions in  kataegis regions of lym-
phomas. Sequence analyses are based on exome sequencing data obtained from
[11]. Sequence context of C to T transitions in  kataegis regions of lymphomas (n = 21;
1102  single mutation sites) and  CLL (n =  15; 290 single  mutation sites) showing
an  AID-hotspot consensus sequence ( AGCTN ), where N  represents no signiﬁ-
cant difference between A, T, C or G. Comparative analyses of cancers with known
APOBEC signatures in  kataegis regions showing an  APOBEC consensus signature
(  NTCATN ),  from  ALL (n =  1; 153 single mutation sites), breast (n =  67;  5021 sin-
gle  mutation sites), liver (n = 15;  175 single mutation sites), lung adenocarcinoma
(n  = 20; 2024 single mutation sites), and pancreas (n = 11; 439 single mutation sites).
with our genomic uracil measurements and the  published associa-
tions between AID and lymphomas [21–24,42–44] and CLL [45,46].
Moreover, these 122 lymphoma kataegis regions mapped to 70 dis-
tinct 100 kb blocks on 16  chromosomes, further supporting that
enzymatic cytosine deamination by AID is not restricted to the S
region but occurs genome-wide.
4. Discussion
A major ﬁnding in our study is that AID expression is apparently
a predominant source of  genomic uracil in B-cell lymphoma cell
lines. The LC–MS/MS method used quantiﬁes genomic uracil as 2′-
deoxyuridine in DNA [15].  The contribution of AID in this process
was not  solely made plausible by correlations, but also demon-
strated by physiological induction of  the endogenous AID gene,
overexpression of  recombinant AID, as well as  knockdown of  AID
by shRNA. We feel that these  results provide convincing evidence
of  dC to dU  conversion in vivo by AID, which was considered miss-
ing in a  recent review [47].  Furthermore; we found that mutational
signatures in kataegis regions in human B-cell malignancies carry
a distinct AID signature, strongly supporting the  concept that AID
is a DNA cytosine deaminase that, when mistargeted cause muta-
tions and eventually B-cell malignancies. The increased genomic
uracil is in  general agreement with a  recent report on  relative
increases in  genomic uracil in B-cell lymphoma cell lines express-
ing AID, using an indirect genomic uracil-quantiﬁcation method
[48].  Evidence for  targeted generation of  uracil in Ig-genes has
been obtained using a ligation-mediated PCR approach [20,49].
AID is normally only expressed in activated germinal center B-
cells [2,50] and at low but detectable levels in early developing
B-cells in  the bone marrow [51]. This is  apparently a  risky pro-
cess because AID strongly promotes the generation of  germinal
center-derived lymphomas [22,52,53],  in which off-target activity
of AID may  contribute to point mutations and translocations during
lymphomagenesis [31,54,55].
Recently, high-throughput sequencing of  complete human
cancer genomes and exomes revealed distinct mutational signa-
tures compatible with  mutagenesis by APOBEC-family enzymes
in several common human cancers. This suggests that enzymatic
off-target deamination of DNA-cytosine to  uracil might be a major
cause of mutation in human cancers [9–11]. However, direct evi-
dence from measurements of  uracil in the cancer genomes has
largely been missing. Importantly, we  found that endogenous
AID-induction in  CH12F3 mouse B-cells increases genomic uracil
four-fold, from  approximately 750 to 3000 uracils per genome
already after 48 h. It is unlikely that this substantial increase can be
conﬁned to  target regions in the  Ig genes. Therefore, the increase in
genomic uracil levels following endogenous AID expression indi-
cates that even transiently induced AID expression during CSR
causes widespread cytosine deamination. This is also in accor-
dance with the  mutational AID signatures found at  many regions
in human B-cell malignancy genomes. We  did not observe corre-
lation of  genomic uracil with expression of  other APOBEC-family
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members.  This does not rule out these as signiﬁcant mutators
in cancer cells, particularly since we only examined seven non-
lymphoma cell lines. Low levels of enzymatic cytosine deamination
may be overshadowed by dUMP misincorporation and sponta-
neous cytosine deamination. In addition, the  strong effect of  AID
in B-cell lymphomas may  obscure contribution of other APOBEC
enzymes. A  contribution from APOBECs may  become signiﬁcant
over time and help drive transformation from normal cell to  cancer
cell, as indicated by mutational signatures [11,56].
Although AID expression levels correlated with  variation in
genomic uracil in the  cells we tested, our results indicate that
additional factors may  modulate genomic uracil levels. The  most
obvious factor would be uracil repair capacity, which varies con-
siderably between cell lines, and dUMP incorporation. We have
previously shown that UNG is a  rate-limiting factor in complete
in vitro BER of genomic uracil [14] although UNG  and SMUG1 may
have complementary roles in uracil repair [16,29,57] and in the
prevention of mutagenesis [58]. Studies on UNG−/− cells have doc-
umented an important function for UNG in  keeping genomic uracil
levels low [15]. However, the complete absence of  any BER fac-
tor is a  dramatic and rare event, whereas several-fold variation is
rather common, at least  in transformed cells. Earlier work demon-
strated that AID-induced mutagenesis was counteracted by  UNG,
which initiates U:G DNA repair [31]. Our data showed that UNG
and SMUG1 protein levels both correlated inversely with genomic
uracil, with UNG showing the  strongest correlation across all  cells,
while only SMUG1 correlates signiﬁcantly in the  lymphoma cell
lines. Consequently, these results indicate that BER protein lev-
els do affect genomic uracil. These results do not in themselves,
however, necessarily reveal the relative importance of individual
glycosylases for  in vivo BER. We therefore made an effort to  ana-
lyze the role of  the glycosylases independently, using an assay for
complete BER based on nuclear extracts from synchronized HeLa
cells and a  plasmid containing a  single uracil. The results indicated
that overall, UNG is the  main contributor in  initiating BER of  uracil,
at  least in  HeLa cells.  However, SMUG1 and TDG may  contribute sig-
niﬁcantly in G1 (and G2),  which is also the time when AID is most
active.
It  is thought that U:G mismatches arising from AID in Ig genes
and U:G from spontaneous deamination are processed by different
mechanisms. Indeed, in order for SHM and CSR to  be successfully
carried out, canonical uracil DNA repair may  be locally suppressed.
One factor contributing to this may  be transcription factor E2A,
which induces AID [59,60], but represses both  UNG-expression and
its binding to relevant regions in  the Ig  genes [60]. Furthermore,
p53 is actively reduced in germinal center B cells, presumably to
allow mutagenic processing required for  antibody maturation [61].
Although complex, the  evidence that AID may drive carcinogenesis
is well supported. In  mice, AID expression was shown to be required
for translocations between Ig  loci and proto-oncogenes, a  hallmark
of several human B-cell lymphomas [62]. In contrast, AID knockout
mice have fewer translocations [63] and accumulate fewer muta-
tions in genes linked to B cell tumorigenesis [31].  AID expression
has also been shown to confer a  mutator phenotype in established
lymphomas [42–44],  but the role of  AID in cancer progression
remains unsettled [23,64,65]. Interestingly, AID expression has
been reported in numerous cancers of non-B-cell origin, including
breast, prostate, stomach, liver, and lung [66]. It  would be inter-
esting to  investigate whether aberrant AID expression also confers
high genomic uracil levels in these cancers. Interestingly, Ung−/−
mice have roughly a  20-fold higher frequency of  B-cell lymphoma
compared with wild-type mice, but no apparent increase in other
cancer types [67,68].  A straightforward explanation for this obser-
vation would be that  SMUG1 and TDG together with MMR may
compensate for UNG-deﬁciency in most tissues, but not in B-cells
expressing AID, due to their increased genomic uracil levels.
A central role for  AID-induced mutagenesis in  lymphomas is
also indicated by the AID-hotspot signature in the kataegis regions
of a  random selection of  all lymphomas and CLLs  (Fig. 5).  We
ﬁnd that the  kataegis AID-hotspot signature is not limited to lym-
phomas, but is also present in  CLL, which overlaps with the  category
small lymphocytic lymphoma. Indeed, AID expression as cause
of an ongoing mutator phenotype has been suggested for both
lymphomas [42–44] and CLL [45,46].  Interestingly, progression of
established cancers through expression of AID was also demon-
strated in other blood cell cancers, such as  ALL [69] and chronic
myelogenous leukemia (CML), in which AID expression may lead
to fatal lymphoblastoid crisis [70].  Thus, AID may  be involved in
development and progression of B-cell malignancies, and possibly
only in late stage progression of other blood cell malignancies. This
would be in agreement with the  lack of  an  overall AID signature in
ALL, as observed in  our study.
In conclusion, we  have provided strong evidence that AID is  a
DNA-cytosine deaminase that due to persistent expression causes
accumulation of genomic uracil in  B-cell lymphoma cell lines, as
well as AID mutational signatures in human B-cell malignancies.
Other factors, including expression levels for uracil-DNA glycosyl-
ases and cell doubling time, may  modulate genomic uracil levels,
but AID levels remain the  strongest predictor.
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